Pathogenic role of (S)IgA in IgA nephropathy by Oortwijn, B.D.








de graad van Doctor aan de Universiteit Leiden,
op gezag van de Rector Magnificus Dr. D.D. Breimer,
hoogleraar in de faculteit der Wiskunde en
Natuurwetenschappen en die der Geneeskunde,
volgens besluit van het College voor Promoties




geboren te Purmerend in 1979
PROMOTIECOMMISSIE
Promoter Prof. Dr. M.R. Daha
Copromoter Dr. C. van Kooten
Referent Prof. Dr. J.J. Weening (Academisch Medisch Centrum, Amsterdam)
Overige Leden Prof. Dr. A.M. Deelder
Dr. M. van Egmond (Vrije Universiteit Medisch Centrum, Amsterdam)
Dr. A. Gorter
Prof. Dr. P.S. Hiemstra
Prof. Dr. G.J. Navis (Universitair Medisch Centrum Groningen, Groningen)
The research described in the present thesis was performed at the Department of
Nephrology of the Leiden Unversity Medical Centre and was financed by a grant from the
Dutch Kidney foundation (C99.1822)
Financial support for printing of this thesis from 3A-out foundation, the Dutch Kidney
Foundation and the Jurriaanse stichting is gratefully acknowledged
Used by permission: Chapter 2 - © 2007 Elsevier, Chapter 4& 5 - © 2006 Lippincott
Williams & Wilkins, Chapter 6 - © 2006 Nature Publishing Group 
ISBN: 90-9021342-2, 978-90-9021342-2
Coverdesign: Beatrijs D. Oortwijn 
Origin of the picture: Maria Pia Rastaldi
Printed by: Gildeprint Drukkerijen B.V., Enschede, The Netherlands.
© 2007 Beatrijs D. Oortwijn




Chapter 1 General Introduction 9
Chapter 2: Monomeric and polymeric IgA show a similar association         27
with the myeloid FcαRI/CD89. 
Mol. Immunol. 44:966-973, 2007
Chapter 3: Comparable binding of monomeric and polymeric IgA 41
to the novel IgA Fc receptor, Fcα/µR.
Chapter 4: Glomerular activation of the lectin pathway of complement in    55
IgA nephropathy is associated with more severe renal disease
J. Am. Soc. Nephrol. Jun;17(6):1724-1734, 2006
Chapter 5: Differential glycosylation of polymeric and monomeric IgA:       73
a possible role in glomerular inflammation in IgA nephropathy
J. Am. Soc. Nephrol. in press
Chapter 6: A pathogenic role for secretory IgA in IgA nephropathy 93
Kidney Int. 69:1131-1138, 2006
Chapter 7: Demonstration of secretory IgA in kidneys of patients with      109
IgA nephropathy
Submitted









BSA bovine serum albumin
CHO chinese hamster ovary





ELISA enzyme-linked immunosorbent assay
FACS fluorescence-activated cell sorter
FCS fetal calf serum





KLH keyhole limpet hemocyanin 
mAb monoclonal antibody
MAC membrane attack complex
MASP MBL-associated serine protease
MBL mannose-binding lectin
MCP-1 monocyte chemoattractant protein-1
MFI mean fluorescence intensity
MIF macrophage migration inhibitory factor
mIgA monomeric IgA
NHMC normal human mesangial cells
NHS normal human serum 
pIgA polymeric IgA
pIgR polymeric Ig receptor
RT-PCR reverse transcriptase polymerase chain reaction
SC secretory component
SDS-PAGE sodium dodecyl sulphate- poly acrylamide gel eletrophoresis
SIgA secretory IgA
SNP single nucleotide polymorphism
SPR surface plasmon resonance
TGF transforming growth factor









Clinical presentation of IgA nephropathy
Primary IgA nephropathy (IgAN) is the most common form of primary glomeru-
lonephritis. The disease shows a broad spectrum of clinical presentations, leading
to progressive renal failure in a substantial proportion of patients. The hallmark of
this disease is deposition of IgA1 in the glomerular mesangium (1-3). In the
glomeruli of patients with IgAN mostly high molecular weight IgA1 is detected,
sometimes together with IgM and/or C3 (4,5). After renal transplantation recurrent
mesangial IgA deposition is observed in 50 % of the patients (6). Case reports have
shown that IgA deposits disappear after transplantation of a kidney with IgA deposits
into a non-IgAN patient (7). These results strongly suggest that IgAN is not only a
disease of the kidney, but also dependent on systemic factors.
Interestingly, patients with IgAN often present macroscopic hematuria following
upper respiratory tract infections. Mucosal immune challenge leads to an increased
production of IgA in the systemic compartment, probably based on the migration of
B cells (the mucosa-bone marrow axis) (8). This mucosa-bone marrow traffic has
been confirmed by challenging healthy individuals intranasally with the neoantigen
cholera toxin subunit B (CTB) (9). In patients with IgAN a mucosal IgA hypo-
response to mucosal immunization with this neoantigen was observed (9).  
Since differences in circulating IgA together with IgA binding to mesangial cells
have been proposed to play an important role in the pathogenesis of IgA nephropa-
thy, detailed analysis of circulating IgA and its interactions with cellular receptors is
important.
Histopathology of IgA nephropathy
The most common histological lesion seen in renal biopsies from patients with
IgAN are focal or diffuse mesangial proliferative glomerulonephritis (10). The initial
phase of IgAN is characterized by increase in mesangial matrix but no segmental
sclerosis. Focal proliferative lesions comprise the largest subgroup of IgA nephropa-
thy. The histologic changes range from focal and segmental mesangial proliferative
glomerulonephritis to focal glomerulonephritis with segmental endocapillary cell pro-
liferation, with or without crescent formation. Associated with these variable expres-
sions of glomerular pathology are variable degrees of tubular atrophy, interstitial
fibrosis, and interstitial inflammation comprised of lymphocytes,
monocytes/macrophages, and plasma cells. The number of macrophages in the
glomeruli correlates with the presence of crescents and proteinuria (11).
Furthermore, more monocytes and T-cells were found in biopsies of patients with
active disease as compared to those without disease activity (12).
Immunohistochemistry has revealed that IgA deposits mainly consist of the IgA1
subclass (13,14), and commonly occur with co-deposits of C3, IgG, and, less com-
mon, IgM (15). The predominance of IgA1 deposits and the specific hinge region of
IgA1 with potential O-linked glycosylation sites have initiated a directed search for
alterations in glycosylation. Indeed, in the eluate of renal deposits, a specific reduc-
tion of O-linked galactosylation has been observed (16,17). Furthermore, with size
fractionation of eluted proteins from kidney sections, it was shown that deposited
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IgA is mostly high molecular weight of nature (18). Additional evidence for the dep-
osition of high molecular weight IgA was obtained from immunohistochemical analy-
sis of renal tissue (14,19,20). 
Composition of IgA
IgA is the most abundant class of immunoglobulin synthesized in humans, with
66 mg of IgA/kg of body weight produced daily compared to 34 mg of IgG and 8 mg
of IgM. The half life of IgA in the circulation is 6 days. Almost all circulating IgA (2
mg/ml) is produced in the bone marrow and the liver is involved in the catabolism of
the circulating IgA. Only negligible amounts (1 mg/ kg bodyweight/ day) of the total
IgA produced in the bone marrow, spleen and lymph nodes (20 mg/ kg bodyweigth/
day) reach the external secretions (21). The other part of the IgA (46 mg/ kg body-
weight/ day) is produced at the mucosal sites and is secreted efficiently as secreto-
ry IgA (SIgA).
General composition
Human IgA exists as two isotypes, IgA1 and IgA2, with IgA2 having two allotyp-
ic variants: IgA2m(1) and IgA2m(2). The human IgA subclasses differ at 14 amino
acid (aa) positions in the α-chain sequence. α-Chains have three constant region
domains Cα1 to Cα3 (Figure 1A). IgA2 of the A2m(2) allotype differs from A2m(1)
and IgA1 in 6 positions; 2 in Cα1 and 4 in Cα3. The Cα3 domain is the same for
IgA1 and IgA2m(1). The Cα2 domain is the same for both A2 allotypes and differs
from IgA1.
A major difference between IgA1 and IgA2 occurs in the hinge region. IgA2 mol-
ecules lack a 13-aa segment found in the hinge region of IgA1 molecules, which
contain 5 potential O-linked carbohydrate sites.
Serum IgA
Human IgA in serum exists with an IgA1: IgA2 ratio of about 9:1 (22,23) and is
found in different molecular forms: monomeric IgA (mIgA), composed of two heavy
and two light chains; dimeric IgA (dIgA), consists of two IgA molecules linked with a
joining (J-) chain. Finally, in serum also additional high molecular weight forms of IgA
can be recognized, generally described as polymeric IgA (pIgA). The composition of
human serum polymeric IgA is diverse and may include CD89/IgA complexes, IgA
immune complexes and IgA-fibronectin complexes (24). In humans, circulating IgA
primarily consists of monomeric IgA (mIgA), and only 10-20% of the IgA is found in
high molecular weight IgA (dIgA and pIgA) forms. In contrast, in rodents IgA is most-
ly present in a high molecular weight form (25). 
Secretory IgA
Secretory IgA (SIgA) is the major immunoglobulin responsible for protecting the
mucosal surfaces. To generate SIgA, dimeric IgA with the attached J-chain is pro-
duced in plasma cells close to the epithelium. The epithelial cells express on the
basolateral side the polymeric Ig receptor (pIgR) that binds to dIgA; this complex is
translocated through the epithelial cell (transcytosis). During transcytosis the extra-
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cellular part of the pIgR, the secretory component (SC), is covalently linked to dIgA.
At the mucosal surface the secretory component is cleaved from the pIgR and
secretory IgA is secreted. Besides the presence of SIgA in the mucosa, low levels
(10 µg/ ml) of SIgA can be detected in serum (Figure 1B) (26,27).
Chapter 1
12
Figure 1: proposed domain structure of human monomeric IgA
A) The α heavy chain contains 3 constant domains Cα1, Cα2 and Cα3 and 1 variable
domain VH. The light chain contains 1 constant domain CL and 1 variable domain
VL. Positions of disulfide bonds (S), N- (N) and O-(O) linked glycosylation sites are
































































Glycosylation of serum IgA
Glycans contribute 6 to 7 % of the total molecular mass of IgA1 and 8 to 10% of
the total mass of IgA2 proteins. The higher carbohydrate content in IgA2 proteins is
the result of additional N-linked oligosaccharide side chains (28). Human IgA1 con-
tains two conserved N-glycosylation sites in each α-chain (Asn263 and Asn459),
while the IgA2 subclass contains an additional two (IgA2m(1)) or three (IgA2m(2))
conserved N-glycans (29). The number, the type and the terminal sugar residues
vary between proteins of IgA subclasses but also within one subclass (Figure 2)
(30). Serum IgA contains complex type N-linked carbohydrate moieties. Biantennary
structures accounted for 86 % of the N-linked glycans on IgA whereas 14 % of the
oligosaccharides were multiantennary or extended (31). 
IgA1 is one of the few serum proteins and unique among circulating immunoglob-
ulins in having O-glycosylation as well as N-glycosylation sites. These O-glycosyla-
tion sites are restricted to the hinge region of IgA1, which contains four to five short
chains. The O-glycans are relatively simple sugars in which N-acetylgalactosamine
(GalNAc) is O-linked to a serine or threonine residue. The glycan is completed with
a terminal galactose (Gal) with or without additional sialic acid residues (NeuNAc)
(Figure 2).
Glycosylation of SIgA
The glycosylation of SIgA is different compared to that of serum IgA in several
aspects (Figure 2). Modelling of SIgA suggests that the N-glycans on the heavy
chain can be masked by the SC (32). This may also result in a different exposure of
the O-glycans. Moreover, specific analysis of the glycosylation of the IgA heavy
chain present in SIgA, demonstrated different N-glycan structures compared to that
of serum IgA. Specifically, terminal GlcNAc residues are present on the majority of
the N-glycans of SIgA (32). The O-glycans on the hinge region of the heavy chain
of SIgA1 presented a wide range of glycan structures, of which the major part is now
characterized (32). Finally, also SC itself is heavily glycosylated. 
The J chain (16 kDa) contains a single carbohydrate side chain linked to
asparagine. This N-linked glycan is approximately 8 % of the molecular mass of J
chain. This chain consists of fucose, mannose, galactose, N-acetylglucosamine and
sialic acid. The N-glycan appears to be critical to polymer formation between J chain
and IgA monomer subunits (Figure 2) (33). 
Free secretory component (SC) was isolated from mucosal secretions as well as
associated with SIgA. SC (70 kDa) consists of five immunoglobulin-like domains
with approximately 22 % of the total molecular mass of SC contributed by carbohy-
drates. The 5 to 7 site chains contain N-acetylglucosamine, fucose, mannose,




Effector functions of IgA
IgA plays an important role in providing protection at mucosal surfaces. Passive
protection by SIgA, secreted by the mucosal immune system, plays a central role in
the protection of mucosal surfaces in general. Mechanisms of protection by SIgA at
mucosal surfaces are: inhibition of adherence (SIgA appears to surround a microbe
and other particulate antigens with a hydrophilic shell that repels attachment to a
mucosal surface), agglutination, mucus trapping (SIgA diffuses freely through
mucus (35)), neutralization of enzymes and toxins, and interaction with innate
antimicrobial factors. On the other site there is increasing evidence that serum IgA
is able to trigger effector functions that have the potential to destroy micro-organ-
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Figure 2: prototype structures of O- and N-linked
carbohydrates identified on the heavy chain of
serum and secretory IgA, the J chain and
secretory component (30,32). ± indicates that some
chains terminate at the site of the preceding sugar










































































isms, including: interaction with the complement pathway (although the level of acti-
vation differs between isotypes), interaction with Fc receptors on leukocytes, and
epithelial cells (Figure 3).
Complement activation
The complement system is a key component of our innate immune system and
is comprised of a complex of at least 30 proteins and regulators. The liver is the
main source of complement synthesis. The complement molecules constitute
approximately 5 % of the total serum proteins. Three principle pathways are
involved in complement activation, the classical pathway, the alternative pathway
and the lectin pathway, each with their own recognition mechanism. These path-
ways converge at the central component of the complement system, C3. The final
common pathway leads to the formation of a protein complex on a complement-acti-
vating surface, named the membrane attack complex (MAC) (Figure 4). IgA can acti-
vate complement via the alternative pathway and the lectin pathway (36,37). The
lectin pathway can be activated via the recognition molecules mannose-binding
lectin (MBL), H-ficolin and L-ficolin. IgA can interact with MBL and thereby activate
the lectin pathway as demonstrated by activation and deposition of C4 (37), where-
as for the ficolins no IgA binding data are available yet. 
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Figure 3: Biological consequences of the interaction of IgA with various cell
types (adapted from (30)).
Cells of the myeloid lineage (neutrophils, eosinophils, monocytes, and macrophages) express CD89
through which these cells can be activated by IgA. B cells produce IgA, whereas T cells are
important for the regulation of the IgA production. The interaction of IgA with Natural Killer (NK) cells
may be mediated by lectin-like receptors for carbohydrate determinants. Epithelial cells transport
dIgA to the apical surface where it release SIgA. Hepatocytes are important in the clearance of IgA
from the circulation.
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IgA receptors 
Different IgA receptors are described in literature (Table 1). These receptors
belong to two major families of receptors, namely the Ig superfamily and the lectin
family. The known receptors for IgA in the Ig superfamily are the FcαRI (CD89), the
Fcα/µR and the polymeric Ig receptor. The polymeric Ig receptor is present on
epithelial cells and is important for the transcytosis of IgA to the mucosal surfaces
(38). The known receptors for IgA in the lectin family are the asialoglycoprotein
receptor (ASGPR) and the mannose receptor. The ASGPR is present on hepato-
cytes and is important for clearance of IgA (39). The ligand specificity for ASGPR is
terminal galactose. The other IgA receptor in the lectin family, the mannose recep-
tor, is present on dendritic cells and macrophages, and can bind and internalize
SIgA without inducing maturation in dendritic cells (40). This binding of SIgA to the
mannose receptor is sugar dependent and can be blocked with mannose, fucose
and N-acetylglucosamine.
FcαRI (CD89)
FcαRI (CD89) is an IgA receptor, which is constitutively expressed on polymor-
phonuclear leukocytes (PMN), monocytes, eosinophils, and selected macrophages
(41). CD89 is also expressed on Kupffer cells in the liver. It was suggested that
CD89 on Kupffer cells provides a second line of defence in mucosal immunity (42).
Initially it has been suggested that CD89 might be an IgA receptor at the surface of
mesangial cells (43), however it is now widely accepted that CD89 is not expressed
by mesangial cells (44-47). CD89 consists of two extracellular Ig-like domains with
potential N- and O-linked glycosylation sites, followed by a stretch of hydrophobic
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Figure 4: The three
complement pathways of
complement activation
(MAC: membrane attack complex)
amino acids representing the predicted transmembrane domain, with a positively
charged arginine which is essential for association of CD89 with the FcR γ-chain
homodimer-signalling subunit (48), and a short cytoplasmic tail devoid of recognition
signalling motifs (Figure 5). The protein core of CD89 has a predicted molecular
mass of 30 kDa with differential glycosylation at six potential N-linked sites, and the
probability of additional O-glycosylation contributing to the variable size observed for
the mature receptor, 55-75 kDa on monocytes and neutrophils, 70-100 kDa on
eosinophils. The site of interaction between CD89 and IgA was identified in the first
extracellular domain of CD89 (49,50) and in the Cα2/Cα3 junction of IgA (51,52). 
CD89 participates in different aspects in host defence. CD89 induces phagocy-
tosis of IgA complexed antigens (53), initiates antibody-dependent cellular cytotoxi-
ty (54) and CD89 is important for the clearance of IgA from the circulation (48). Upon
activation, a soluble form of CD89 is released from the surface of monocytes and
monocytic cell lines (55). These soluble CD89 molecules circulate in a complex,
covalently linked with IgA, in the high molecular weight fractions of serum IgA (56).
Binding studies with different molecular forms of IgA have shown that pIgA binds
better to CD89 than mIgA (54,57,58). Furthermore one study suggested that SIgA
can only interact with CD89 if MAC-1 (CD11b/ CD18) is present (59).
To study the role of the IgA-CD89 interaction mouse models were used. Although
CD89 is described on human myeloid cells, no murine homolog has yet been
defined. Therefore transgenic mouse models have been created, including a model
in which the CD11b promoter was used (60). In this model human CD89 was high-
ly expressed on macrophages/ monocytes. These transgenic mice develop sponta-
neously massive mesangial IgA deposits after 12 weeks, suggesting a role for CD89
in IgA nephropathy (60).
Fcα/µR
The Fcα/µR, located on chromosome 1, is a newly identified receptor for IgA.
Transcription of the receptor is demonstrated in several tissues including thymus,
spleen (B cells and macrophages, but not on granulocytes, T cells or NK cells), liver,
kidney, small and large intestines, testis and placenta (61,62). Furthermore, tran-
scription of the Fcα/µR was described on mesangial cells and was upregulated after
stimulation of mesangial cells with IL-1 (63).
The Fcα/µR is a type 1 transmembrane protein with a 32-aa leader sequence, a
Introduction
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Table 1: Receptors with IgA binding capacities 
  
  Receptor Ligand Cellular distribution 
Ig 
family FcαRI (CD89) 
pIgA> 
mIgA Myeloid cells 
 Fcα/µR IgA/ IgM B cells,Macrophages,Mesangial cells 
 pIgR dIgA Epithelial cells 
C-type ASGPR IgA Hepatocytes 
lectins Mannose receptor (CD205) SIgA Macrophages,Dendritic cells 
 Transferrin receptor (CD71) IgA1 Mesangial cells 
 
423-aa extracellular domain, a 20-aa transmembrane domain and a 60-aa cytoplas-
mic region. The extracellular domain has four potential sites for NH2-linked glycosy-
lation (61), leading to a mature protein of 60- 70 kDa. In the extracellular domain of
the receptor cysteine residues are identified and it is flanked by the consensus
sequence for immunoglobulin-like domains, indicating that this molecule is a mem-
ber of the immunoglobulin super family. The Fcα/µR shows no significant homology
with other proteins. However, in the immunoglobulin like domain there is a motif that
is conserved in the first immunoglobulin like domain of the polymeric Ig receptor
(Figure 5) (61). 
The Fcα/µR mediates endocytosis of immune complex composed of
Staphylococcus aureus and IgM anti-S. aureus antibody by primary B lymphocytes
(61). The underlying mechanism of this internalization is not yet known. However,
experiments with Fcα/µR mutants suggest that the di-leucine motif is important in
this process (61). Furthermore, the Fcα/µR acquires the ability to bind IgM and IgA
antibodies after stimulation of B cells.
IgA receptors and mesangial cells 
The binding of high molecular weight IgA is better to mesangial cells than that of
monomeric IgA. However the specific mechanism for the binding and retention of
IgA1 remains uncertain. Several findings point to an IgA-specific receptor(s) on
mesangial cells (41,64). However none of the known IgA receptors (CD89, ASGPR,
pIgR) is expressed on mesangial cells (45,47). Two other receptors have recently
emerged as candidate receptors for binding IgA; CD71 (transferrin receptor) and the
Fcα/µR (63,65,66).  CD71 expression is enhanced in the glomeruli of IgA nephropa-
thy patients and co-localizes with IgA1 deposits. Mesangial cells bind both IgA sub-
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Figure 5: structure of Fcα /µR and of CD89 with the γ-chain.
The extracellular, membrane and cytoplasmic domains of the Fcα/µR and

































classes, whereas CD71 binds only IgA1, suggesting involvement of an additional
receptor. Theoretically, it may be the Fcα/µR that can be transcribed by mesangial
cells in vitro (63). In contrast, another group found that polymeric IgA1 from IgA
nephropathy patients induces macrophage migration inhibitory factor (MIF) and
TNF-α in mesangial cells. This induction is probably through an unidentified IgA
receptor, as shown by failure to suppress IgA-induced MIF synthesis by blocking IgA
receptors with specific antibodies or various ligands to IgA receptors (67). 
IgA in IgA nephropathy 
Several studies using lectin interactions (Table 2) and fluorophore-assisted car-
bohydrate electrophoresis (FACE) focused on the analysis of IgA glycosylation,
showing aberrant O-glycosylation in circulating IgA from IgAN patients, resulting in
increased Tn antigen (GalNAcβ1-Ser/Thr) residues (68-71). This undergalactosylat-
ed IgA1 may lead to recognition by IgG antibodies and generation of circulating IgG-
IgA1 complexes (72). Furthermore, altered interaction with mesangial cells has
been described (73). This aberrantly O-glycosylated IgA is suggested to be depend-
ent on a hampered function of the β1-3 galactosyltransferase (74). Furthermore, it
is suggested that downregulation of the β1-3 galactosyltransferase chaperone
(Cosmc) is important for the aberrant O-glycosylation in patients with IgAN (75). 
Levels of plasma IgA1 are elevated in about half of the patients with IgAN (76-
78), which appears to be the result of an increased production of this isotype by the
bone marrow (79-82) and by a low elimination rate by the liver. Mucosal pIgA plas-
ma cell numbers are normal or even reduced in IgAN (83,84), whereas pIgA anti-
body levels in mucosal secretions are not elevated and are sometimes lower than
controls (9). Furthermore, systemic antigen challenge results in increased titers of
circulating pIgA1 antibodies (85,86) with normal levels in mucosal secretions (87).
IgA and mesangial cells 
Functional studies with purified IgA from IgAN patients showed that IgA from
IgAN patients binds better to mesangial cells than IgA healthy individuals (73),
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Table 2: Reactivity of lectins used for analysis of IgA glycosylation  
 
Name Abbreviation Sugar specificity 
Artocarpus integrifolia Jacalin Galβ1-3GalNAc 
Helix aspersa HAA GalNAc 
Vicia villosa VV GalNAc 
Helix pomatia HPO GalNAc 
Erythrina crystagalli ECL Galβ1-4GlcNAc 
Ricinus communis RCA βGal 
Sambucus nigra SNA NeuNAc 
Peanut agglutinin PNA Galβ1-3GalNAc 
 
although this is still controversial (88). The binding of polymeric and aggregated IgA
to mesangial cells was stronger as compared to monomeric IgA. Moreover, polymer-
ic IgA with the highest net negative charge is superior in binding to mesangial cells
(73). In IgAN circulating aberrantly glycosylated IgA1 has been described. To mimic
this IgA, IgA1 was purified with Jacalin and in vitro degalactosylated. The removal
of galactose residues from IgA1 isolated with Jacalin increases binding to mesan-
gial cells in vitro (89). 
The activation of mesangial cells by IgA1 immune complexes is considered the
initiating event in the pathogenesis of IgA nephropathy. Mesangial cell activation
was observed in vitro in many instances (90-93). Exposure of mesangial cells to IgA
is capable of initiating a proinflammatory cascade involving mesangial cell secretion
of IL-1β, TNF-α , IL-6, TGF-β and MIF and the release of the chemokines  MCP-1
(CCL2), IL-8, and IP-10 (91,94-97). After stimulation of mesangial cells with
degalactosylated IgA the production of these factors is higher as compared to con-
trol IgA. In vivo, urinary IL-6 (98), the tubular and interstitial expression of intercellu-
lar adhesion molecule type 1 (99), and the intrarenal expression of proinflammato-
ry cytokines and chemokines (100) correlated with renal injury and may have prog-
nostic value. 
IgA is also capable of altering mesangial cell-matrix interactions by modulating
integrin expression, and this could have an important role in remodeling of the
mesangium following glomerular injury (101). There is also evidence that activation
of mesangial cells by co-deposited IgG could synergistically contribute to the devel-
opment of a proinflammatory mesangial cell phenotype and thereby influence the
degree of glomerular injury (102). It is not yet clear which specific physicochemical
properties of mesangial IgA affect mesangial cell activation; however, there is some
in vitro evidence that undergalactosylated IgA glycoforms from patients with IgAN
reduce proliferation, increase nitric oxide synthesis and the rate of apoptosis, and
enhance integrin synthesis in cultured mesangial cells (101,103). This, together with
the overrepresentation of aberrantly glycosylated IgA1 in mesangial IgA, suggests
that IgA1 O-glycosylation plays a role in both the deposition of IgA and the subse-
quent injury.
Scope of this thesis 
For a better understanding of the role of IgA and mesangial cells in IgA nephropa-
thy, we focused on different questions in the course of the disease. In chapter 2 and
3 we focused on the possible receptor mechanisms underlying mesangial IgA dep-
osition. Therefore we studied the interaction of IgA with CD89 in different binding
assays. We showed a similar association to CD89 for monomeric and polymeric IgA
(chapter 2). CD89 is described not to be present on mesangial cells, whereas the
recently identified Fcα/µR is suggested to be expressed by mesangial cells. To
investigate the role of the Fcα/µR in IgA nephropathy we produced fusion proteins
of this receptor and used these fusion proteins for IgA binding studies (chapter 3). 
Because it is suggested that IgAN is not only a disease of the kidney, but also
dependent on systemic factors we investigated in chapter 4 to chapter 8 which
changes in IgA lead to the deposition of IgA in the glomeruli. Therefore, we investi-
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gated in chapter 4 the activation of the lectin pathway of complement via IgA in
glomeruli of IgAN patients. We show that activation of the lectin pathway of comple-
ment in the glomeruli of patients with IgAN is associated with more severe renal dis-
ease. In chapter 5 we isolated IgA from patients and controls and separated this IgA
in monomeric and polymeric IgA. With these IgA preparations we investigated the
differences between monomeric and polymeric IgA between patients and controls
including the interaction with lectins and mesangial cells. In this study we observed
clear differences between monomeric and polymeric IgA for lectin and mesangial
cell interactions, but there were no differences between patients and controls.
However, the concentration of SIgA in the polymeric IgA preparations was signifi-
cantly higher in patients as compared to controls. This suggests that only a minor
part of the IgA from patients might be different from controls. Finally, we demonstrat-
ed that SIgA is able to bind stronger to mesangial cells than serum IgA, and that
SIgA is present in glomerular IgA deposits (chapter 6). To confirm the presence of
SIgA in the glomerular IgA deposits we studied the presence of SIgA in biopsies
from IgAN patients. We showed in chapter 7 that in 15 % of the cases SIgA is
detectable in the glomerular IgA deposits. Finally, chapter 8 summarizes the studies
described in this thesis and discusses the relevance of these new findings.
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Summary
IgA is found in both mucosal secretions and serum and is the dominant
immunoglobulin isotype produced in humans. It exists in different molecular
forms, namely monomeric IgA, dimeric IgA, polymeric IgA and secretory IgA,
all exhibiting interactions with FcaRI/CD89 to some extent. CD89 is an acti-
vating, γ-chain associated, Fc receptor for IgA expressed on myeloid cells.
Here, we investigated the interaction of monomeric and polymeric IgA purified
from human serum with CD89 using surface plasmon resonance. The results
demonstrate a similar association for monomeric and polymeric IgA with
CD89. In contrast, monomeric IgA dissociated more rapidly from CD89 than
polymeric IgA. Removal of N-glycans from mIgA resulted is an increased
association with CD89, whereas the dissociation was more rapid, resulting in
binding comparable to that of untreated monomeric IgA. We conclude that
the initial interaction of monomeric and polymeric IgA with CD89 is similar,
whereas monomeric IgA dissociates more rapidly from CD89. In view of the
large excess of monomeric IgA in serum, monomeric IgA will compete for
CD89 interaction with polymeric IgA, thereby preventing cell activation initiat-
ed by receptor aggregation contributing to the anti-inflammatory role of IgA.










Immunoglobulin A (IgA) is the predominant immunoglobulin isotype, and plays a
critical role in protecting the host against environmental pathogens and antigens
encountered at mucosal surfaces (1). In secretions, secretory IgA (SIgA) is generat-
ed during transcytosis of dimeric IgA (dIgA) by epithelial cells, ultimately leading to
its association with the extracellular part of the polymeric Ig receptor (secretory com-
ponent) (2). In humans, IgA in the circulation primarily consists of monomeric IgA
(mIgA), but about 10-20% of the IgA is found in dimeric or polymeric IgA (pIgA)
forms, while in rodents IgA is mostly present in a polymeric form (3). Furthermore,
IgA consists of two subclasses namely IgA1 and IgA2. IgA1 contains ten potential
O-glycosylation sites and two N-glycosylation sites and IgA2 does not contain O-gly-
cosylation sites but contains two or three additional N-glycosylation sites. In vitro
deglycosylation of IgA leads to self-aggregation, suggesting that underglycosylation
of IgA may contribute to generation of high molecular weight IgA (4). 
The transmembrane molecule FcαRI (CD89) has been identified as receptor for
the Fc portion of human IgA (5). This receptor is constitutively expressed on poly-
morphonuclear leukocytes (PMN), monocytes, eosinophils, dendritic cells and a
subset of macrophages (5-7), as well as on Kupffer cells in the liver, where it has
been suggested to provide a second line of defence (8). CD89 consists of two extra-
cellular Ig-like domains followed by a stretch of hydrophobic amino acids represent-
ing the predicted transmembrane domain, with a positively charged arginine which
is essential for association of CD89 with the FcR γ-chain homodimeric signalling
subunit (9), and a short cytoplasmic tail devoid of recognition signalling motifs. The
protein core of CD89 has a predicted molecular mass of 30 kDa with differential gly-
cosylation at six potential N-linked sites, and the probability of additional O-glycosy-
lation contributing to the variable size observed for the mature receptor (55-110 kDa)
(10). CD89 has been reported to bind both IgA1 and IgA2 with similar affinity (Ka
~106 M-1). The site of interaction between CD89 and IgA was identified in the first
extracellular domain of CD89 (11,12) and in the Cα2/Cα3 junction of IgA (13,14). 
CD89 participates in different aspects in host defence. CD89 induce phagocyto-
sis of IgA complexed antigens (15), initiates antibody dependent cellular cytotoxity
(16) and CD89 is important for the clearance of IgA from the circulation (9). Binding
studies with different molecular forms of IgA have shown that pIgA binds stronger to
CD89 than mIgA (16-18).
Furthermore, one study suggested that secretory IgA (SIgA) can only interact
with CD89 if MAC-1 is present (19). For most of these binding studies total IgA was
purified from serum as a source for mIgA followed by production of pIgA by an arti-
ficial aggregation process (17). Alternatively, mIgA was generated from SIgA via a
chemical treatment (16). 
The purpose of present study was to study the interaction of mIgA and pIgA in
their physiological conformation with CD89 in a quantitative manner. Therefore,
these two biological forms of IgA were directly isolated from serum and their inter-
action with CD89 was studied by ELISA and surface plasmon resonance.
Furthermore, we studied a potential role for IgA glycosylation in the differential inter-
action of the molecular forms of IgA with CD89. The results indicate that the initial
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interaction of mIgA and pIgA with CD89 is comparable, but since mIgA dissociates
more rapidly from CD89, the final outcome is that pIgA remains associated with
CD89 for an extended time, thereby potentially increasing its signalling potency.
MATERIAL AND METHODS
IgA purification
Serum from 6 individuals was used for IgA purification, according to methods described
before (20). In brief, serum was applied to an anti-IgA (HisA 43, kindly provided by dr J. van
den Born, Free University Medical Center, Amsterdam) affinity column. The column was
washed with 0.5 x PBS and 0.3 M NaCl, and subsequently IgA was eluted with 0.1 M glycine/
0.3 M NaCl (pH 2.8). Directly after elution the fractions were neutralized with 1 M Tris pH 8.0.
The eluted protein fractions that contained IgA, as assessed by ELISA (21), were pooled and
dialysed against PBS containing 2 mM EDTA.    
Isolated IgA was size-separated with a HiLoadTM 16/60 HR200 Superdex prep grade
gelfiltration column (120 ml, Amersham Pharmacia, Roosendaal, The Netherlands) into poly-
meric IgA and monomeric IgA. These pools were analysed for total IgA content using ELISA
(21).
Secretory IgA that was used in some experiments was obtained from Sigma.
ELISA
Binding of IgA to Fc-(CD89)2 was analysed by coating ninety-six well Nunc Maxisorb
microtitre plates (Gibco/Invitrogen, Carlsbad, CA) with Fc-(CD89)2 (2 µg/ml) in carbonate
buffer (pH 9.6) (100 µl/well) overnight at room temperature. After coating, the plates were
washed with PBS/ 0.05 % Tween. Plates were incubated with different concentrations of IgA
in PBS/ 1 % BSA/ 0.05 % Tween for one hour at 37 ºC. After washing, bound IgA was detect-
ed using mouse anti-human IgA (4E8), followed by HRP-conjugated goat anti-mouse IgG
(Dako, Heverlee, Belgium), both diluted in PBS/ 1 % BSA/ 0.05 % Tween and incubated for
1 hour at 37 ºC. Enzyme activity of HRP was developed using ABTS (2, 2'-azino-bis (3-ethyl
benzathioline-6-sulphonic acid)) (Sigma, St. Louis, MO). The O.D. at 415 nm was measured
using a microplate biokinetics reader (EL312e, Biotek Instruments, Winooski, Vermont, USA). 
Surface plasmon resonance analysis
Surface plasmon resonance (SPR) analysis was carried out using a BIAcore instrument
(Biacore AB, Uppsala, Sweden). A CM5 sensor chip (BIAcore AB) was coupled with recom-
binant CD89 (10000 response units (RU)), chimeric Fc-(CD89)2 (10000 RU), and BSA
(10000 RU), following manufacturers' instructions. Binding assays were performed at flow
rates of 5 µl/min using HBS EP buffer (0.01 M HEPES, pH 7.4, 0.15 M NaCl, 3 mM EDTA and
0.005% (v/v) surfactant P20). A 10 µl aliquot of analytes was injected and subsequently
allowed to dissociate for 10 minutes. Subsequently, the surfaces were regenerated with 0.1
M glycine/ 0.3 M NaCl, pH 2.8. Early binding was defined as the response units at 450 sec-
onds, and late binding was defined as the response units at 1100 seconds. 
Another CM5 sensor chip was coupled with BSA (200 RU) and chimeric Fc-(CD89)2 (250
RU). Kinetic assays were performed at flow rate of 30 µl/min and 180 µl IgA was injected.
Data collected for each experiment were analyzed in a bivalent model using biaevaluation
software (mIgA 180 kDa and pIgA 360 kDa). 
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Glycosidase treatment of IgA
Monomeric IgA (800 µg) was first digested with N-glycosidase F (PNGase F), cloned from
flavobacterium meningosepticum and expressed in E. coli (6 U/ 200 µg IgA, Roche) in 0.02
M sodium phosphate buffer pH 7.2 with 2 mM EDTA. The first sample, to be used as control,
was IgA with incubation buffer (mock IgA); the second sample was IgA with enzymes (treat-
ed IgA). After 72 hours of incubation at 37ºC this IgA was further digested with Neuraminidase
from Arthrobacter ureafaciens (6 mU/200 µg IgA, Roche, Mannheim, Germany),β (1-3,4,6)
galactosidase isolated from a cloned gene expressed in E. coli (7 mU/ 200 µg IgA, Prozyme),
or combinations of the enzymes. This deglycosylation step was performed in 50 mM sodium
acetate pH 5.6 for 72 hours at 37ºC. After treatment, samples (10 µg) were analysed by load-
ing on a 10 % reduced SDS-PAGE gel and Coomassie stained.
HAA ELISA
To confirm deglycosylation, the deglycosylated IgA was assessed for binding to biotinylat-
ed Helix Aspersa (HAA, Sigma) lectin, known to recognize terminal GalNAc, was performed.
Ninety-six well NUNC Maxisorp microtitre plates were coated with 2 µg/ml IgA in carbonate
buffer (pH 9.6) (100 µl/well), overnight at room temperature. After washing with PBS/ 0.05 %
Tween and blocking for one hour 37 ºC with PBS/ 1 % BSA, the plate was incubated with 5
µg/ml biotinylated HAA in PBS/ 1 % BSA/ 0.05 % Tween. Binding of HAA to IgA was detect-
ed with HRP-conjugated streptavidin (Zymed). Enzyme activity of HRP was developed using
ABTS (Sigma). The O.D. was measured at 415 nm.
Western blot analysis
IgA preparations (3 µg) were subjected to 10 % SDS-PAGE under reducing conditions,
followed by semi-dry blotting to PVDF (immobilin-P, Millipore, Bedford, MA). Blots were
blocked for 2 hours in PBS/ 0.1 % Tween/ 5 % BSA. Blots were subsequently incubated with
2 µg/ml biotinylated HAA in PBS/ 0.1 % Tween/ 2.5 % BSA overnight at 4ºC. After washing
with PBS/ 0.1 % Tween, blots were incubated with HRP-conjugated streptavidin (Zymed) for
2 hours at room temperature. After extensive washing bands were visualized with
Supersignal (Pierce Chemical Co., Rockford, IL) and exposure to HyperfilmTM films
(Amersham Pharmacia).
Statistical analysis
Statistical analysis was performed using the Wilcoxon signed rank test. Differences were
considered statistically significant when p values were less than 0.05. 
RESULTS 
Dose dependent binding of IgA to Fc-(CD89)2 in ELISA
To investigate the interaction of different molecular forms of IgA with CD89, IgA
was purified from serum using a monoclonal anti-IgA affinity column and the eluate
was size fractionated by gel filtration (Figure 1A). Pools containing mIgA or pIgA
were obtained and assessed for the binding to Fc-(CD89)2 in ELISA (Figure 1B).
The binding of IgA was dose-dependent over a wide range of concentrations.
Binding of pIgA to CD89 was much stronger than that of mIgA, the latter requiring a
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50-fold higher concentration to reach the same level of binding. We have reported
earlier that in serum low concentrations of SIgA are present (22). Therefore we also
tested the binding of SIgA to CD89. The binding of SIgA to CD89 was similar to that
of pIgA, whereas it was much stronger than the binding of mIgA.
Using the same procedure, mIgA and pIgA were isolated from serum of 6 differ-
ent individuals and tested for binding to Fc-(CD89)2 in ELISA at a fixed concentra-
tion (Figure 1C). In all cases, pIgA bound stronger to Fc-(CD89)2 compared to mIgA.
Difference in IgA binding is determined by dissociation from immobilized
CD89 and not by association
The interaction of mIgA or pIgA with CD89 was evaluated using a biosensor. Two
channels of a CM-5 sensor chip were coupled with recombinant CD89 and chimeric
Fc-(CD89)2. A third control channel was coupled with BSA.  Monomeric IgA and
polymeric IgA exhibited strong binding to both CD89 (not shown) and Fc-(CD89)2
Similar association of mIgA and pIgA with CD89
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Figure 1: Binding of pIgA and SIgA to CD89 in ELISA is stronger
than that of mIgA.
A) IgA was affinity purified and size-fractionated on a HiLoadTM 16/60 HR200
Superdex prep grade gelfiltration column. All fractions were measured for total
protein and the presence of total IgA by ELISA. B) Isolated IgA was pooled in pIgA
fraction (39-47.5ml) and mIgA fraction (47.5-57ml). Binding of mIgA, pIgA and
SIgA to immobilized Fc-(CD89)2 was measured in ELISA. C) From 6 individuals,
IgA was purified and size fractionated as above. The binding of IgA (10 µg/ml) to
Fc-(CD89)2 was measured in ELISA.
(Figure 2). The association of pIgA and mIgA to Fc-(CD89)2, was similar while the
dissociation was more rapid for mIgA compared to pIgA which led to a higher late
binding level for pIgA (Figure 2A).  SIgA binding was assessed as well and it was
found that the association of SIgA to CD89 was lower compared with mIgA and
pIgA. The binding of SIgA remained stable, comparable to that of pIgA (Figure 2A).
Similar results were obtained from IgA preparations from 6 different individuals
(Figure 2B). The profiles of the binding of IgA isolated from 6 different individuals to
Fc-(CD89)2 were also analysed for the early (450 s) and late binding (1100 s).
Monomeric and polymeric IgA, applied at identical concentrations, showed similar
early binding to Fc-(CD89)2 (Figure 2B, C). The late binding assessed by SPR, in
agreement with the measurements in ELISA, showed a stronger binding of pIgA to
CD89 compared to mIgA (Figure 2B, C). 
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Figure 2: Real time binding of IgA to CD89.
A) Binding profile of mIgA (200 µg/ml), pIgA (200 µg/ml), isolated from serum, and SIgA (200 µg/ml)
to Fc-(CD89)2 measured with SPR. From 6 individuals, IgA was purified and size fractionated as
above. The binding of mIgA B); (200 µg/ml) and pIgA C); (200 µg/ml) to Fc-(CD89)2 was measured
with SPR at two different time points (early (450 s) and late (1100 s) binding). Results represent
response units of binding to Fc-(CD89)2 after subtraction of response units obtained with BSA.
To determine the binding constants of the interaction of IgA with CD89, another
CM-5 sensor chip was coupled with a low concentration of Fc-(CD89)2 and BSA,
and the binding of different concentrations of mIgA and pIgA was measured. To
investigate the dissociation constants (kd) for mIgA and pIgA we made use of a biva-
lent model with a molecular mass of 180 kDa for mIgA and 360 kDa for pIgA. As pre-
sented above the dissociation of mIgA was more rapid compared with pIgA. Kinetic
analysis showed a lower affinity for mIgA (kd = 3.9x10-4) compared to pIgA (kd =
2.6x10-4). These dissociation constants explain why pIgA ultimately remains asso-
ciated with CD89 for a longer period, and also provide a rationale for the higher bind-
ing of pIgA as compared to mIgA to CD89 in ELISA.
Binding of deglycosylated IgA to CD89 is not changed while association is
increased 
Results presented above demonstrate that the interaction between pIgA and
CD89 is more stable than the interaction between mIgA and CD89. Since previous-
ly published results suggest that underglycosylation promotes the production of
polymeric IgA (4), and since the glycosylation of IgA has been implicated in its inter-
action with CD89 (23), we postulated that the glycosylation differences between
monomeric and polymeric IgA could account for their differential interaction with
CD89. Furthermore, underglycosylated IgA has been shown in serum of IgA
nephropathy patients (24,25). This patient-derived IgA shows enhanced exposure of
terminal GalNAc on O-linked glycans, which can be recognized by a GalNAc-spe-
cific lectin, Helix Aspersa (HAA). Previously, it has been reported that HAA might
specifically bind to high molecular weight proteins in human serum (26), but interac-
tion with pIgA has not been studied. The binding of HAA lectin to immobilized high-
ly purified monomeric and polymeric IgA was studied by ELISA. We observed a
dose-dependent binding of both mIgA and pIgA with HAA, with mIgA exhibiting sig-
nificantly less binding to HAA as compared to pIgA (Figure 3A). These results sug-
gest that pIgA, compared with mIgA, has smaller O-linked glycans with increased
exposure of GalNAc.
To investigate whether exposure of terminal O-linked GalNAc might lead to an
increased interaction of IgA with CD89, we treated mIgA with neuraminidase and
galactosidase. Furthermore, to evaluate a possible role of N-glycans in the binding
of IgA to CD89, mIgA was treated with PNGase F to remove N-linked sugars. These
enzymatic treatments resulted in a clearly reduced MW of the IgA heavy chain as
shown by SDS-PAGE, without affecting the light chain which is known to be non-gly-
cosylated (Figure 3B). Increased exposure of terminal GalNAc after treatment of
mIgA with neuraminidase and galactosidase was confirmed by a lectin-blot using
biotinylated HAA (Figure 3B, C) and by using an ELISA system (Figure 3D). As
expected, removal of N-glycans with PNGase F did not result in increased exposure
of GalNAc (Figure 3B-D). Interestingly we observed that treatment of mIgA with neu-
raminidase alone already increased HAA reactivity, suggesting the presence of
undergalactosylated O-linked glycans on mIgA. 
To investigate whether exposure of terminal GalNAc or removal of N-glycans
might enhance the interaction between IgA and CD89, we tested these well charac-










































































Figure 3: Binding of HAA to
enzymatically treated mIgA.
A) Purified and size-fractionated IgA
from 6 individuals was coated (2
µg/ml) and HAA binding was
detected. The horizontal dashed line
represents the detection limit. B) IgA
was loaded on a 10 % reduced
SDS-PAGE gel and was Coomassie
stained or after Western blotting
HAA binding was detected. C)
Quantification of HAA binding on
Western blot. Intensity of bands on
Western blot divided by intensity on
SDS-PAGE gel (Neur:
neuraminidase, Gal: galactosidase)
D) IgA (2 µg/ml) treated with different
enzyme combinations were coated
on an ELISA plate and HAA reactivity
was detected. Shown is the mean ±
SD of 3 experiments. The horizontal
dashed line represents the detection
limit.
terized deglycosylated IgA preparations for binding to Fc-(CD89)2 using ELISA and
SPR. Treatment of mIgA with combinations of neuraminidase, galactosidase and/or
PNGase F did not change the binding of IgA to CD89 in ELISA (Figure 4A) and this
was confirmed by showing a similar level of binding to CD89 in the late phase of
SPR (Figure 4B, C). However, the early binding of mIgA after removing the N-gly-
cans was increased compared to mock treated IgA or IgA treated with other
enzymes (Figure 4B, D). These results suggest that N-glycans negatively affects the
interaction of IgA with CD89.








































































































Figure 4: Interaction of
deglycosylated IgA with CD89.
A) Dose-dependent binding of enzyme
treated IgA to Fc-(CD89)2 detected with
ELISA. B) Binding profile of mock-treated
mIgA (200 µg/ml), and PNGase F and
neuraminidase-treated mIgA (200 µg/ml)
measured with SPR. Results represent
response units of binding to Fc-(CD89)2
after subtraction of values obtained with
BSA. C) Late binding of enzyme-digested
IgA (200 µg/ml) to Fc-(CD89)2 measured
with SPR. Depicted is the percentage of
early binding compared with mock-treated
IgA of a representative experiment of 3
experiments. D) Early binding of
enzyme-digested IgA (200 µg/ml) to
Fc-(CD89)2 measured with SPR. Depicted is
the percentage of early binding compared
with mock-treated IgA of a representative
experiment of 3 experiments.
DISCUSSION  
The present study provides evidence that the initial binding of mIgA and pIgA to
CD89 by SPR were similar. However the dissociation of mIgA is more rapid than that
of pIgA leading to a more sustained binding of the latter to CD89. Furthermore we
show that SIgA is able to bind to CD89 without the presence of accessory mole-
cules. It seems that N-glycans are important for the initial interaction of mIgA to
CD89 because removal of the N-glycans by enzymatic treatment of mIgA resulted
in enhanced association of IgA with CD89, whereas the final binding level remained
the same as that for mock treated IgA. Taken together, these data provide more
insight in the interaction of different molecular forms of IgA with CD89.
Binding studies with IgA and CD89 using mutagenesis and chemical modification
showed that R82 and H85 in the FG loop of the first domain of CD89 are essential
for the binding activity of CD89 (11). In a model (27), based on the KIR structure, it
was suggested that the ligand binding site of CD89 is located in the first domain and
not in the second domain, as described for other Fc receptors. The crystal structure
of the IgA/CD89 recently confirmed these findings (28). The binding site for CD89
on IgA seems to overlap with that of bacterial IgA-binding proteins, suggesting
involvement of the Cα2/Cα3 interdomain regions (29). Furthermore, using recombi-
nant IgA molecules it has been shown that the presence of certain regions in both
the Cα2 and Cα3 domains of IgA are required for efficient interaction with CD89 and
for triggering of this receptor (14). Such a model (27) is consistent with a study that
revealed a 2:1 stoichiometry for the CD89-IgAFc interaction (30,31). Furthermore,
the crystal structure of the IgA1Fc-CD89 complex also showed that IgA could be in
complex with two CD89 molecules (30). Our data indicate that mIgA molecules are
able to interact similar with CD89 as pIgA, in contradiction with earlier suggestions
(16,17). 
In the circulation a large excess of mIgA is present and therefore CD89 might be
permanently occupied with mIgA, thereby competing for CD89 binding by pIgA and
prevents cell activation.  The interaction of mIgA with CD89 might also be sufficient
for internalization of mIgA via CD89, thereby creating intracellular CD89-IgA com-
plexes which then can be secreted in the circulation (20). 
In IgA nephropathy (IgAN), the most common primary glomerulonephritis with
IgA deposits in the glomeruli, an altered O-glycosylation of the IgA1 molecule is
described (24,32-34). Patient IgA1 contains smaller O-linked glycans with more ter-
minal GalNAc and this could play a role in the deposition of IgA1 in the mesangial
area of these patients (24,25,35). IgA treated with neuraminidase and galactosidase
resembles the underglycosylated IgA as described in IgA nephropathy (24). In our
studies we did not find a difference in binding of IgA treated with neuraminidase and
galactosidase to CD89 as compared to control IgA. However after treatment of IgA
with PNGase F, to remove the N-glycans, the initial interaction of mIgA with CD89
was enhanced, suggesting an important role for the N-glycans on IgA in the initial
interaction with CD89. Several different N-glycans are described to be present on
IgA, among which high mannose type N-linked glycan chains (36). These high man-
nose N-glycans may be likely candidates for the interaction of IgA with MBL (37).
Recent studies have suggested the presence of MBL in association with IgA in the
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mesangial area of patients with IgAN (38,39). 
In literature it is still controversial whether N-glycans present on IgA do influence
the interaction with CD89. One study showed that IgA with a mutation in ASN-263
in IgA, which lacks the Cα2 N-glycan, led to loss of binding to CD89 (23). However,
another study showed a normal binding of the IgA1 mutant N263A to CD89 (32). In
the first study mutant IgA was expressed in insect cells. This could lead to differ-
ences in the glycan structure (23). In the present study we show that deglycosyla-
tion of IgA could lead to an increase in early binding and therefore more interaction
in the circulation, however this will not lead to an increase in late binding, which is
in agreement with the data observed with mutant N263A. In the crystal structure of
the IgA-CD89 complex (28), the observed N-glycans on IgA approach within 8 Å, but
do not directly contact, the receptor (28). In CD89, a mutation in an amino acid that
is not directly in contact with IgA resulted in an 11-fold loss of affinity (28). Because
of the presence of the N-glycans on IgA close to these binding sites it could be that
the N-glycans hamper the IgA/ CD89 interaction, but more research is needed to
confirm this. 
In summary we have shown that mIgA is able to interact with CD89 in a similar
way as pIgA but that the interaction is more stable for pIgA than for mIgA.
Furthermore we show that the N-glycans of IgA are important for the initial interac-
tion with CD89. This binding of mIgA to CD89 could explain the observed presence
of IgA-CD89 complexes in serum.
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Summary
Aberrant interaction between IgA and IgA-receptors has been implicated as an
important pathogenic factor in IgA nephropathy (IgAN). Several IgA receptors
have been characterized but most of these receptors are not present on
mesangial cells. Recently a novel Fc receptor for IgA (Fcα/µR) has been iden-
tified in B cells and macrophages. It has been shown that Fcα/µR is abundant-
ly expressed in the kidney. In this study we produced recombinant human
Fcα/µR proteins and investigated their interaction with human IgA and IgM.
Using RT-PCR we showed that human renal mesangial cells express Fcα/µR
and that the expression is upregulated following IL-1 stimulation of the mesan-
gial cells. Human Fcα/µR chimeric proteins (Fcα/µRIg), consisting of the extra-
cellular domain of Fcα/µR and the human IgG1 Fc-tail, were generated and
produced in CHO cells. The interaction of Fcα/µRIg with IgA was tested with
two different assays. First the binding of different forms of IgA and IgM to
Fcα/µRIg was measured directly by ELISA. In a second assay the competition
with binding of labelled mIgA to Fcα/µRIg by different forms of IgA and IgM
were investigated. All forms of IgA and IgM showed a dose dependent binding
to Fcα/µRIg. The binding of monomeric and polymeric IgA to Fcα/µRIg were
comparable. Enzymatically deglycosylated IgA obtained by PNGase F and
neuraminidase treatment showed a reduced interaction with the Fcα/µRIg. In
conclusion, using recombinant chimeric proteins, we showed that IgA binds to
Fcα/µR and that the interaction of IgA with Fcα/µR is partially dependent on











Receptors for the Fc portion of immunoglobulins are present on different cell
types of the immune system and play important roles in a wide array of immune
responses, like antibody dependent cellular cytotoxity and phagocytosis. IgA is the
predominant isotype produced and it plays a critical role in the protection of the host
against environmental pathogens at mucosal surfaces (1). 
IgA nephropathy (IgAN) is the most common type of primary glomerulonephritis
worldwide. The disease presents a spectrum of clinical symptoms, leading to pro-
gressive renal failure in a substantial proportion of patients. The hallmark of the dis-
ease is deposition of IgA in the glomerular mesangium (2-4). In glomeruli of patients
with IgAN mostly high molecular weight IgA1 is detected, sometimes together with
IgM and/or C3 (5-7). The deposition of IgA in the mesangium is associated with
renal inflammation, however extensive studies still have not revealed a specific
mechanism of deposition.
Binding of IgA to mesangial cells has been studied before (8,9) and has revealed
that the binding of polymeric IgA to mesangial cells is stronger than that of
monomeric IgA. Moreover, recently our group showed that secretory IgA, present in
low concentrations in the circulation, has the best binding to mesangial cells in vitro
as compared to serum IgA (10). Several studies have shown that aberrant O-glyco-
sylation of circulating IgA from IgAN patients, may result in increased Tn antigen
(GalNAcβ1-Ser/Thr) expression (11-13) and that binding of IgA from patients with
IgAN to mesangial cells is better as compared to that of IgA from healthy individu-
als (9). However, this finding is still controversial (14).
Several IgA receptors have been described in literature. The best-known recep-
tors, the polymeric Ig receptor (pIgR), the asialoglycoprotein receptor and CD89
have already been described to be absent on mesangial cells (15-17). Recently a
novel IgA receptor, Fcα/µR, located on chromosome 1, has been identified.
Expression of transcripts of this receptor has been demonstrated in several tissues
including kidney, small intestine, lymph node and appendix (18,19). Furthermore,
transcription of the Fcα/µR was demonstrated in mesangial cells, and shown to be
upregulated by IL-1, a cytokine implicated in the pathogenesis of IgAN (20). Studies
in mice have shown surface expression of Fcα/µR in mature but not in immature B
lymphocytes. Furthermore, stimulated B lymphocytes were able to bind IgA and IgM
(19). Of interest is the finding that rat IgA and both human and rat IgM binds to
mouse Fcα/µR (18). However, the interaction of human Fcα/µR with human IgA and
IgM has not been reported until now. 
Therefore, the aim of the present study was to analyse the interaction of human
IgA and IgM to recombinant human Fcα/µR. We show that two different recombinant
Fcα/µRs react with IgM and with different molecular forms of IgA in ELISA and that
monomeric IgA has similar binding as polymeric IgA to Fcα/µR. Furthermore, the
binding of monomeric IgA to Fcα/µR is affected by its glycosylation.
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MATERIAL AND METHODS 
Production of Fcα/µRIg
Two forms of Fcα/µRIg fusion protein were produced following cloning of the complete
extracellular part of the receptor into the pME-Neo Fc vector (long Fcα/µRIg) (21) or of the N-
terminal Ig domain without the long stalk (short Fcα/µRIg). The XHO-1 restriction site in the
linker between the fusion product and the human IgG1 Fc tail and Eco-RI at the beginning of
the extracellular part of the receptor were used. PCR was used to amplify the extracellular
part of the Fcα/µR using a pcDNA3.1/ His/ TOPO vector containing the whole receptor (20)
(Table 1) and PWO polymerase (5U/µl, Roche). The purified product obtained after agarose
gel electrophoresis was subcloned in the pME-Neo Fc vector previously used for the produc-
tion of Fc-(CD89)2 (21) and the identity and orientation were confirmed by sequencing and
restriction digestion. The vector was subsequently introduced into Chinese hamster ovary
(CHO) cells using electroporation and selected for neomycin resistance with G418 (400
µg/ml, Gibco). Single clones with stable expression were obtained, and clones with the high-
est production as determined by ELISA were selected (long Fcα/µRIg: 4 µg/ml, short
Fcα/µRIg 1.7 µg/ml). Supernatants of CHO cells producing long or short Fcα/µRIg were
applied to a prot G or HiTrap Mabselect SuRe columns and after washing the column with
PBS, bound proteins were eluted with 0.1M citric acid pH 3.0. Fractions were neutralized
immediately with 1M Tris-HCl pH 10, and tested for human IgG content by ELISA. 
Cytospin preparations
Cells were harvested by trypsin digestion and subsequently incubated with 1 %
paraformaldehyde for 30 min at 4 ºC. After washing with PBS, the cells were centrifuged onto
glass slides and air dried. After blocking with PBS/ 1 % BSA for 1 hour RT, the cytospin prepa-
rations were incubated with 10 µg/ml monoclonal anti human IgG (HB43, ATCC) for 1 hour
RT. Binding of HB43 was visualized with Oregon Green conjugated goat anti mouse IgG
(Molecular probes, Leiden, The Netherlands).
IgG ELISA
In order to determine the chimeric protein concentrations we used an IgG ELISA as
described before (22). Plates were coated with rabbit anti human IgG (Jackson, West Grove,
PA, USA) in carbonate buffer (pH 9.6) (100 µl/ well) overnight at RT. Subsequently, the plates
were washed with PBS/ 0.05 % Tween. Plates were incubated with chimeric protein or IgG in
PBS/ 1 % BSA/ 0.05 % Tween for one hour at 37 ºC. After washing, bound IgG was detect-
ed with goat anti human IgG biotin, followed by streptavidin conjugated to HRP (Zymed).
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Table 1: Primer sequences 
    Sequence (5’-3’) 
Long Fcα/µRIg Forward CTT CGA ATT CAT GCC CCT CTT CCT CAT ACT GTG CC 
  Reverse TCA ACT CGA GCC GAG AGC TGC TTT CAT CTT CTG G 
Short Fcα/µRIg Forward CTT CGA ATT CAT GCC CCT CTT CCT CAT ACT GTG CC 
  Reverse ATT ACC TCG AGC CCA GCA GCT GGA GTG GCT GT  
Fcα/µR Forward GAC AAC TAC CAA GGC TGA TAG G 
  Reverse TCT GTC CCT CAG GGT CCT GGA T 
 
Enzyme activity of HRP was developed using ABTS (Sigma). The O.D. at 415 nm was meas-
ured. 
RNA extraction and RT-PCR 
Total RNA was extracted from mesangial cells using RNeasy mini kit (Qiagen, Valencia,
CA). OD260/280 ratio was measured to determine the quantity and purity of RNA prepara-
tions. Fixed amounts of total cellular RNA (1 µg) were reverse transcribed into cDNA by
oligo(dT) priming, using M-MLV reverse transcriptase (Gibco/Life Technologies, Breda, The
Netherlands). PCR to detect the human Fcα/µR was performed with specific primers (Table
1) using AmpliTaq DNA polymerase (Applied Biosystems, Roche, Mannheim, Germany). The
PCR reaction was performed as described before (20). The cDNA samples were also sub-
jected to PCR for GAPDH as an internal control (23). PCR products were resolved on 1 %
agarose gels and bands were visualized by ethidium bromide staining.
Purification of IgA, IgG and IgM 
Serum was used as a starting source for IgA purification, using methods described before
(24). In brief, serum was applied to an anti-IgA (clone HisA 43, kindly provided by dr J. van
den Born, Free University Medical Center, Amsterdam) affinity column. The column was
washed sequential with 0.5 x PBS and 1 M NaCl, and subsequently bound IgA was eluted
with 0.1 M glycine/ 0.3 M NaCl (pH 2.8). Directly after elution the fractions were neutralized
with 1 M Tris pH 8.0. The eluted protein fractions that contained IgA, as assessed by ELISA
(25), were pooled and dialysed against PBS containing 2 mM EDTA.    
Purified IgA was size-separated into monomeric IgA (mIgA) and polymeric IgA (pIgA)
using a HiLoadTM 16/60 HR200 Superdex prep grade gelfiltration column (120 ml,
Amersham Pharmacia, Roosendaal, The Netherlands). Pools of monomeric and polymeric
IgA were made and analysed for total IgA content using ELISA (25).
Secretory IgA (SIgA) was obtained from Sigma. Human IgG and IgM, free of IgA, were
isolated as described before (26).
Assessment of immunoglobulin binding to Fcα/µRIg
Binding of IgA and IgM to Fcα/µRIg constructs was analysed by ELISA. Ninety-six well
Nunc Maxisorb microtitre plates (Gibco/Invitrogen, Carlsbad, CA) were coated overnight with
long Fcα/µRIg (5 µg/ml) in carbonate buffer (pH 9.6) (100 µl/well) at room temperature.
Subsequently, the plates were washed with PBS/ 0.05 % Tween and incubated with different
concentrations of IgA or IgM in PBS/ 1 % BSA/ 0.05 % Tween for one hour at 37 ºC. After
washing, bound IgA was detected with biotin labelled monoclonal anti human IgA (4E8),
bound IgM with biotin labelled monoclonal anti human IgM (HB57). After incubation of one
hour the plates were washed and bound conjugates were detected with streptavidin conjugat-
ed to HRP. Enzyme activity of HRP was developed using ABTS (2, 2'-azino-bis (3-ethyl ben-
zathioline-6-sulphonic acid)) (Sigma, St. Louis, MO). The O.D. at 415 nm was measured
using a microplate biokinetics reader (EL312e, Biotek Instruments, Winooski, Vermont, USA). 
In order to compare the interaction of different immunoglobulins to the Fcα/µRIg con-
structs we set up a competition ELISA. For this purpose, the dose dependent binding of dig
labelled mIgA was tested to immobilized long and short Fcα/µRIg. Subsequently, plates were
coated with long Fcα/µRIg (5 µg/ml) in carbonate buffer (pH 9.6) (100 µl/well) overnight at
room temperature and after extensive washing with PBS/ 0.05 % Tween, incubated with IgA,
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IgM or IgG in PBS/ 1 % BSA/ 0.05 % Tween for one hour at 37 ºC. After one hour, dig-conju-
gated mIgA (final concentration 1 µg/ml) was added to the plate. The amount of mIgA-dig
bound was detected subsequently using F(ab)2 anti-Dig Abs conjugated to HRP.
Glycosidase treatment of IgA
In order to investigate whether the IgA glycosylation is important for the interaction with
Fcα/µR, mIgA was enzymatically deglycosylated. Therefore, monomeric IgA (800 µg) was
first digested with N-glycosidase F (PNGase F), cloned from flavobacterium meningosep-
ticum and expressed in E. coli (6 U/ 200 µg IgA, Roche) in 0.02 M sodium phosphate buffer
pH 7.2 with 2 mM EDTA. The first sample, to be used as control, was IgA with incubation
buffer (mock IgA (800 µg)); the second sample was IgA with enzymes (treated IgA (800 µg)).
After 72 hours of incubation at 37 ºC this IgA was further digested with neuraminidase from
Arthrobacter ureafaciens (6 mU/200 µg IgA, Roche, Mannheim, Germany), β (1-3,4,6) galac-
tosidase isolated from a cloned gene expressed in E. coli (7 mU/ 200 µg IgA, Prozyme), or
combinations of the enzymes. This deglycosylation step was performed in 50 mM sodium
acetate pH 5.6 for 72 hours at 37 ºC. After treatment, samples (10 µg) were analysed by load-
ing on a 10 % reduced SDS-PAGE gel and Coomassie stained.
Flow cytometry
NHMC (normal human mesangial cells, Cambrex, USA) were expanded according to the
protocol provided by the manufacturer. Experiments with NHMC were performed in RPMI with
10 % FCS, 1 % non-essential amino acids, 0.5 % transferrin/insulin/selenium, 1 % sodium
pyruvate, 1 % L-glutamine (all purchased at Gibco/ life Technologies, Paisley, Scotland). Cells
were harvested by trypsinization (0.02 % (w/v) EDTA/ 0.05 % (w/v) trypsin in PBS from Sigma
(St. Louis, MO)), and washed with FACS buffer (0.5 x PBS containing 1 % BSA/ 2.8 % glu-
cose/ 0.01% NaN3) and incubated with monomeric and polymeric serum IgA, and SIgA
(Sigma). Following incubation for 1 hour at 4 ºC, cells were washed and incubated for one
hour at 4 ºC with monoclonal anti-IgA Ab 4E8 (IgG1) (25). IgA binding was visualized using
PE-conjugated goat anti-mouse IgG1 (Southern Biotechnology, Birmingham, AL) and
assessed for fluorescence intensity by flow cytometry (FACSCalibur, Cell quest software; BD
Biosciences). Dead cells, identified by propidium iodide uptake, were excluded from analysis.
Binding of IgA to mesangial cells was also determined following activation of mesan-
gial cells for 48 hours with IL-1 (10 ng/ml).
RESULTS  
Construction of chimeric forms of Fcα/µR
In order to investigate the interaction of different molecular forms of IgA with
Fcα/µR, two different Fcα/µRIg fusion proteins were generated. Long Fcα/µRIg was
generated by fusion of the complete extracellular part of the receptor with the human
IgG1 Fc tail, whereas short Fcα/µRIg was generated by fusion of the extracellular
part containing the Immunoglobulin-like domain with the human IgG1 Fc tail (Figure
1A). Recombinant soluble long and short Fcα/µRIg were produced in CHO cells.
Because no specific reagents were available for detection of human Fcα/µR, we
tested the cells (Figure 1B) and supernatants for the presence of the IgG Fc-tail.
Untransfected cells were negative for the human IgG1 Fc tail, whereas both fusion
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proteins were produced by a number of cell lines. 
Supernatants of the two transfected cell lines were applied to protein G columns
and after acid elution one peak each was collected and tested in the human IgG




















Figure 1: Fcα /µRIg fusion
proteins.
A) Schematic representation of
the long and short Fcα/µRIg. B)
IgG staining of transfected cells
after cytospin centrifugation. C)
IgG ELISA to detect the fusion
proteins.
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Dose dependent binding of IgA and IgM to Fcα/µR in ELISA
To investigate the interaction of different molecular forms of IgA with Fcα/µR,
long Fcα/µRIg was coated in ELISA plates and binding of IgA and IgM was
assessed. The binding of IgA was dose-dependent over a wide range of concentra-
tions (Figure 2A). Binding of monomeric and polymeric IgA to Fcα/µR were similar.
We have reported earlier that in serum low concentrations of SIgA are present (10).
Therefore we also tested the binding of SIgA to Fcα/µR. Binding of purified serum
IgA to Fcα/µR was stronger than that of SIgA. Also IgM exhibited a dose dependent
binding to Fcα/µR (Figure 2B).   
Inhibition of binding of mIgA-Dig to Fcα/µR by monomeric and polymeric IgA
Results presented above demonstrated that several forms of IgA and IgM bind to
Fcα/µR. However, the detection antibody for binding of IgA and IgM were different
and therefore it was not possible to compare the relative amounts of binding of IgA
and IgM to Fcα/µR. To obtain more quantitative comparison of the binding of IgA and
IgM to Fcα/µR, a competition ELISA was set up. First, the dose dependent binding
of mIgA-Dig to Fcα/µR was tested (Figure 3A). Binding of mIgA-Dig to Fcα/µR was
dose dependent and the binding of mIgA-Dig to Fcα/µR was similar for long
Fcα/µRIg and short Fcα/µRIg. Short Fcα/µRIg contains the immunoglobulin domain
of the Fcα/µR without the long extracellular stalk, whereas long Fcα/µRIg consists
of the whole extracellular part of the Fcα/µR. The similar binding of mIgA-dig to long
Fcα/µRIg and short Fcα/µRIg, suggests the involvement of the immunoglobulin like
domain of Fcα/µR for binding to mIgA.
Based on the results, we then selected a dose of 1 µg/ml mIgA-Dig for subse-
quent competition experiments with different forms of IgA and IgM (Figure 3B). The
binding of mIgA-Dig to Fcα/µR was inhibited with mIgA and pIgA in a dose depend-
ent manner, while IgG was unable to influence the binding of mIgA-Dig to Fcα/µR.
Furthermore, SIgA showed a reduced capacity to inhibit mIgA-Dig binding to
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Figure 2: Binding of IgA and IgM to Fcα /µR in ELISA.
A) Dose dependent binding of IgA to immobilized long Fcα/µRIg (5 µg/ml). IgA binding was
detected with a monoclonal anti-human IgA antibody B) Dose dependent binding of IgM to
immobilized long Fcα/µRIg (5 µg/ml). IgM binding was detected with a monoclonal anti-human
IgM antibody. Dotted line represents the negative control.
Fcα/µR. Using IgM as a competitor; we did find some inhibition even at relatively low
concentrations. However, IgM inhibited the mIgA-Dig binding with a maximum of 30
%, indicating that SIgA and IgM have a much lower affinity for Fcα/µR than mIgA or
pIgA. 
Deglycosylation of mIgA is associated with reduced binding to Fcα/µR
Since previously published results suggest that glycosylation of IgA can be
important for the interaction with its receptors (27,28), we investigated whether gly-
cosylation differences of IgA affect its interaction with Fcα/µR. Therefore, IgA was
treated with neuraminidase, galactosidase, PNGase F or with combinations of these
enzymes (28), and tested this treated IgA for binding to Fcα/µR (Figure 4).
Treatment of mIgA with a combination of galactosidase and neuraminidase did not
alter the binding of IgA to Fcα/µR (Figure 4). Removal of the N-glycans of IgA by
treatment of IgA with PNGase F resulted in reduced inhibition of the binding of mIgA-
Dig to Fcα/µR. This reduction in binding of IgA to Fcα/µR was even more pro-
nounced after treatment of IgA with a combination of PNGase F and neuraminidase.
These results suggest that N-glycans and sialic acids positively affect the interaction
of IgA with Fcα/µR. 
No difference in interaction of IgA with stimulated mesangial cells
We hypothesized that after IL-1 stimulation the IgA binding to mesangial cells
was increased. Therefore, we first analyzed the IgA binding to mesangial cells with-
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Figure 3: Inhibition of mIgA-Dig
binding to Fcα /µRIg by mIgA.
A) Dose dependent binding of mIgA-Dig to
immobilized long and short Fcα/µRIg (5
µg/ml) B/C) After preincubation of
immobilized long Fcα/µRIg with different
concentration of IgA, IgM or IgG mIgA-Dig
binding (2 µg/ml) was examined. Depicted
is the percentage of mIgA-Dig binding.
A
CB
out stimulation of the mesangial cells (Figure 5A). After incubation of different molec-
ular forms of IgA with mesangial cells the binding was examined by FACS. Binding
of mIgA to mesangial cells was very low. In contrast, pIgA and SIgA showed a clear
binding to mesangial cells. 
The results presented above indicate IgA binding to mesangial cells. It has been
suggested that Fcα/µR is present on mesangial cells, and thereby could play a role
in IgAN (20). Therefore, we investigated whether Fcα/µR was detectable in mesan-
gial cells (Figure 5B). The Fcα/µR transcript was present in mesangial cells and was
up-regulated after stimulation of mesangial cells with IL-1, as described before (20). 
The binding of IgA to mesangial cells was examined after mesangial cell stimu-
lation with IL-1. Although the transcript of Fcα/µR is up-regulated in mesangial cells
after IL-1 stimulation, there was no increase in IgA binding after stimulation of
mesangial cells (Figure 5C). This was observed with all different molecular forms of
IgA.
DISCUSSION 
To our knowledge this is the first time that the interaction of human IgA and
human IgM to human Fcα/µR was studied directly. In literature it has been suggest-
ed that the binding of mouse IgM to mouse Fcα/µR was stronger as compared to
the binding of mouse IgA (18). In the present study we cannot confirm the mouse
study in the human situation, in that the interaction of human IgA and human IgM
with human Fcα/µR was strongest for IgA. Furthermore, this interaction of IgA with
Fcα/µR was affected by the glycosylation of IgA. The binding of IgA and IgM was
similar for both fusion proteins investigated, suggesting an important role for the
immunoglobulin-like domain of the receptor in the interaction with IgA and IgM. 
The mouse Fcα/µR is homologous to the human Fcα/µR (18). Strong binding of
rodent IgM and IgA to mouse Fcα/µR was observed, but in contrast to rodents in
humans 90 % of circulating IgA is monomeric (29). In this study we found that the
interaction of human Fcα/µR was similar for monomeric and polymeric IgA. This




























Figure 4: Interaction of
deglycosylated IgA with Fcα /µR.
A) Inhibition of mIgA-Dig binding (2
µg/ml) with mock treated IgA (10 µg/ml)
or deglycosylated IgA (10 µg/ml) to
immobilized long Fcα/µRIg, depicted is
the percentage of mIgA-Dig inhibition B)
mIgA-Dig binding after preincubation of
immobilized long Fcα/µRIg with different
concentration mock treated or PNGase
F and neuraminidase treated IgA.
Depicted is the percentage of mIgA-Dig
binding.
interaction of IgA with Fcα/µR is different as compared to the interaction of IgA with
another IgA receptor of the Ig superfamily, the FcαRI/CD89 (28,30-32).
Fcα/µR has been described to be present on mesangial cells and was suggest-
ed to play a role in IgAN. With size fractionation of eluted proteins from kidney sec-
tions, it was shown that deposited IgA was mostly of high molecular weight nature
(5). Furthermore, elution of deposits from glomeruli from a patient with IgA
nephropathy, revealed a high accumulation of SIgA in the IgA deposits (10).
Moreover, in vitro binding studies showed that high molecular weight IgA bound bet-
ter to mesangial cells than monomeric IgA. In the present study we show that the
Fcα/µR interacts similar with monomeric and polymeric IgA. Furthermore we
showed an up-regulation of Fcα/µR transcript in mesangial cells after IL-1 stimula-
tion. However, high molecular weight IgA binds better to mesangial cells as com-
pared to monomeric IgA and we could not detect differences in IgA binding to IL-1
stimulated mesangial cells. Altogether this suggests an additional receptor on
mesangial cells. 
In IgAN an aberrantly O-glycosylated IgA1 molecule has been described. With
enzymatic treatment of IgA we investigated whether the interaction of IgA with
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Figure 5: Interaction of IgA with stimulated mesangial cells.
A) mesangial cells were incubated with different molecular forms of IgA (200µg/ml) and assessed
for IgA binding by flow cytometry. Filled histograms represent the binding of IgA, the open
histograms represent the control staining with secondary antibodies B) mRNA expression of
Fcα/µR in mesangial cells with and without IL-1 stimulation. Kidney was used as positive control
and H2O as negative control. C) FACS analysis with IL-1 stimulated mesangial cells and different
molecular forms of IgA. Depicted is the mean fluorescence intensity (MFI).
Fcα/µR was glycosylation dependent. After treatment of IgA with neuraminidase and
galactosidase, to generate a glycan structure as described to be present on IgA from
IgAN patients, no difference in the interaction of IgA with Fcα/µR was observed.
However, after removal of the sialic acid and N-glycan residues a clear reduction in
binding of IgA to Fcα/µR was observed, suggesting that the charge of the sialic acid
residues together with the N-glycan structure is important for the IgA- Fcα/µR inter-
action. However, it is not clear whether the carbohydrates itself or the possible
change in confirmation as a result of the treatment play a role in this process.
Mouse Fcα/µR can mediate endocytosis of immune-complexes composed of
IgM and S. aureus (18). The underlying mechanism of this internalization is not
known yet, but with receptor mutants it is suggested that the di-leucine motif is
important in this process (18). For human Fcα/µR it is not known whether the recep-
tor is able to internalize immune-complexes with IgA or IgM and if so then which
mechanism could be of importance for this process. Therefore it would be very inter-
esting to investigate, whether human Fcα/µR is also able to mediate endocytosis of
IgA immune-complexes. 
The Fcα/µR immunoglobulin like domain has the same motif as the first extracel-
lular immunoglobulin like domain of the polymeric Ig receptor (pIgR) (18). IgA and
IgM are also able to bind to pIgR, and this binding is described to be on the first
extracellular domain of the pIgR (33). The binding of IgA and IgM to pIgR is restrict-
ed to IgA (dimeric IgA (dIgA)) and IgM containing the J chain (34). The binding of
IgA and IgM was similar for the long Fcα/µRIg and the short Fcα/µRIg, suggesting
an important role for the immunoglobulin like domain of the Fcα/µR for the interac-
tion with IgA and IgM. As mentioned before the binding of IgA to the pIgR is restrict-
ed to dIgA (34), whereas monomeric IgA has the best interaction with Fcα/µR, sug-
gesting another role for the Fcα/µR as compared to the role of pIgR. 
In conclusion, we showed that IgA and IgM are able to interact with Fcα/µR. A
similar binding of monomeric and polymeric IgA to Fcα/µR was observed.
Furthermore, we showed that this interaction is affected by the glycosylation of the
IgA molecule. The mechanism of interaction of IgA with Fcα/µR is still not clear how-
ever our data suggest an important role for the immunoglobulin like domain of the
extracellular part of the Fcα/µR. This study provides more insights in the interaction
of IgA with Fcα/µR.
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Summary
IgA nephropathy (IgAN) is characterized by glomerular co-deposition of IgA
and complement components. Earlier studies have shown that IgA activates
the alternative pathway of complement, whereas more recent data also indi-
cate activation of the lectin pathway. The lectin pathway can be activated by
binding of mannose-binding lectin (MBL) and ficolins to carbohydrate ligands,
followed by activation of MBL-associated serine proteases (MASPs) and C4.
We studied the potential role of the lectin pathway in IgAN.
Renal biopsies of IgAN patients (N = 60) showed mesangial deposition of
IgA1 but not IgA2. Glomerular deposition of MBL was observed in 15 out of
60 cases with IgAN (25 %) and showed a mesangial pattern. All MBL-positive
cases, but none of the MBL-negative cases, showed glomerular co-deposition
of L-ficolin, MASPs and C4d. Glomerular deposition of MBL and L-ficolin was
associated with more pronounced histological damage, as evidenced by
increased mesangial proliferation, extracapillary proliferation, glomerular scle-
rosis and interstitial infiltration, as well as with significantly more proteinuria.
IgAN patients with or without glomerular MBL deposition did not show signifi-
cant differences in serum levels of MBL, L-ficolin or IgA, nor in the size distri-
bution of circulating IgA. Furthermore, in vitro experiments showed clear bind-
ing of MBL to polymeric but not monomeric patient IgA, without a significant
difference between both groups. 
Together, these findings strongly point to a role for the lectin pathway of com-
plement in glomerular complement activation in IgAN, and suggest a contribu-
tion for both MBL and L-ficolin in the progression of the disease. 










IgA nephropathy (IgAN) is a common renal disease primarily characterized by
mesangial deposition of IgA (reviewed in (1,2)). Mesangial IgA deposition induces
an inflammatory process, involving mesangial proliferation, interstitial damage and
proteinuria, which slowly progresses to sclerosis and end-stage renal failure in
about one third of cases. Several effector mechanisms are likely to be involved in
the induction of renal inflammation and damage, including direct interactions
between IgA and mesangial cells (3-5) and IgA-mediated complement activation
(1,6,7).
IgA deposition in IgAN is commonly associated with deposition of complement
factors, most often C3, the terminal complex C5b-9, and properdin (8,9).
Furthermore, increased levels of soluble split products of activated C3 have been
observed in the circulation of IgAN patients (10-12). These findings suggest involve-
ment of the alternative pathway. Indeed, in vitro studies with IgA from humans and
rodents, as well as in vivo studies in rats, have indicated that IgA can directly acti-
vate the alternative pathway of complement (6,13-15). 
The complement system can be activated via three pathways, the classical path-
way, the alternative pathway, and the lectin pathway. These pathways converge at
the cleavage of C3, followed by activation of the common terminal pathway and for-
mation of C5b-9. The classical pathway involves binding of C1q to e.g. immune
complexes, leading to generation of the C3 convertase C4b2a. The more recently
discovered lectin pathway of complement is activated following an interaction of the
plasma lectins mannose-binding lectin (MBL), L-ficolin or H-ficolin with their carbo-
hydrate ligands (16-19). This leads to activation of MASPs  (MBL-associated serine
proteases) present in a pro-enzymatic complex with these lectins. Activated MASP-
2 generates C4b2a, followed by C3 cleavage. In contrast to the classical pathway
and the lectin pathway, the alternative pathway leads to activation of C3 in a C4-
independent way, involving factors B and D and properdin. 
Until now, the mechanism of complement activation in IgAN is still incompletely
defined. Next to the presence of factors indicative for alternative pathway activation,
several studies have shown glomerular deposition of C4, as well as circulating C4
activation products in a subpopulation of IgAN patients (10,20). Since in vitro stud-
ies indicated that IgA can not activate the classical complement pathway, and evi-
dence for C4 activation in IgAN was observed in the absence of C1q deposition,
activation of the lectin pathway of complement was hypothesized. Deposition of
MBL in association with IgA, as a marker for lectin pathway activation, was report-
ed in a subpopulation of IgAN patients by several authors (21-23), but these findings
were questioned by others (24). Furthermore, the relation of glomerular MBL posi-
tivity with parameters of renal damage and complement activation via the lectin
pathway was inconsistent between the different studies.
Recently, we reported that human polymeric serum IgA can bind to human MBL
(25). This interaction involves the lectin domain of MBL, and results into activation
of C4 and C3. Therefore, we hypothesize that C4 activation in IgAN may result from
binding of serum MBL-MASP-2 complexes to IgA deposited in the renal mesangium.
In the present study we have analyzed the possible contribution of the lectin path-
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way of complement to activation of C4 and induction of renal damage in a well-
defined set of renal biopsies of IgAN patients. Next to MBL, also deposition of the
functionally related molecule L-ficolin was studied. The results indicate activation of
the lectin pathway, involving both MBL and L-ficolin, in a subpopulation of IgAN
patients, which is strongly associated with markers of disease progression. 
MATERIAL AND METHODS
Patients and biopsies
Renal biopsies were selected from patients with IgA nephropathy of whom a renal biopsy
was taken between January 2001 and December 2003. Patients were selected if adequate
tissue was obtained for diagnostics (at least 8 glomeruli in light microscopy sections; com-
plete immunohistology and electron microscopy examination), and if sufficient frozen materi-
al was available for additional staining after immunodiagnosis (at least 6 glomeruli in at least
15 (5  m thick) tissue sections). Cases with Henoch-Schönlein purpura, systemic lupus ery-
thematosus, liver cirrhosis or other systemic diseases were excluded. In total, 60 biopsies
were selected for evaluation. 
Among selected patients, 69 % were males and 31 % females. Serum creatinine levels
ranged from 44 to 972 µmol/l at the time of renal biopsy. Creatinine clearance was calculat-
ed according to the Cockroft formula (range 10-160 ml/min). Presentation at time of renal
biopsy was as following: 58 % urinary abnormalities, 32 % chronic renal failure, and 10 %
acute renal failure. Chronic renal failure was defined as serum creatinine value >124 µmol/l
or creatinine clearance <80 ml/min in at least three determinations prior to renal biopsy and
further confirmed during hospitalization. Acute renal failure was defined as an abrupt decline
in glomerular filtration rate detected at patient admission, without previous altered examina-
tions and without ultrasonographic signs of chronic renal injury. 
Urine samples (24 hour collection) and serum samples were obtained at time of renal
biopsy. 
For additional immune fluorescence studies, a more recent series of renal biopsies was
collected from IgAN patients (N = 25) using the same selection criteria as described above.
From these patients, detailed clinical and histological information has not been collected. 
Serological analysis
Serum IgA concentration was measured by standard nephelometric immunoassay. MBL
complex activity was assessed by ELISA using coated mannan as a ligand and detecting the
activation of purified C4, as described before (26) with some modifications (27). MBL com-
plex activity was expressed in arbitrary units per ml based on the activity of a normal human
pool serum. MBL concentrations were assessed by sandwich ELISA as described previously
(25). Concentrations of L-ficolin were assessed using a similar protocol. In brief, plates
(Maxisorb, Nunc, Roskilde, Denmark) were coated with mAb GN5 (5 µg/ml; mouse mAb
against human L-ficolin) or mAb 3E7 (5 µg/ml; mouse IgG1 anti-human MBL) in coating buffer
(100 mM Na2CO3/ NaHCO3, pH 9.6). After each step, plates were washed with PBS contain-
ing 0.05 % Tween 20. Residual binding sites were blocked by incubation with PBS contain-
ing 1 % BSA. Serum samples and subsequent detection antibodies were diluted in PBS con-
taining 1 % BSA and 0.05 % Tween 20, and incubated for one hour at 37 °C. Primary anti-
bodies were mAb 3E7 and mAb GN5, respectively, conjugated to digoxygenin (dig) (from
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Roche Diagnostics, Almere, The Netherlands). Binding of mAb was detected using HRP-con-
jugated sheep anti-dig antibodies (Fab fragments, from Roche). Concentrations of MBL and
L-ficolin were calculated using serial dilutions of a standard serum with a known concentra-
tion of MBL (kindly provided by Dr. P. Garred, Kopenhagen, Denmark) or L-ficolin (kindly pro-
vided by Dr. D.C. Kilpatrick, Edinburgh, UK), respectively.
Purification of serum IgA and assessment of MBL binding to IgA
IgA was purified starting from 350 µl of patient serum (N = 12). The serum was directly
applied to an IgA affinity column (Sepharose beads conjugated to mAb HisA43 anti-human
IgA, kindly provided by Dr. J. van den Born, Amsterdam, the Netherlands), using Veronal-
buffered saline containing 2 mM EDTA as a running buffer. IgA was eluted using 0.1 M Glycin
/ 0.3 M NaCl (pH 2.8) and fractions were immediately neutralized by 1 M Tris pH 8.0.
Fractions were assessed for IgA content and the IgA peak was pooled and concentrated until
approximately 350 µl. These samples were further purified on a Sephadex 200 gel filtration
column (25 ml, from GE Healthcare, Munich, Germany), using the same running buffer.
Fractions of 0.3 ml were collected. 
On basis of the protein profile, fractions were selected that contain polymeric, dimeric and
monomeric IgA, respectively. IgA concentration in these fractions was quantified by IgA sand-
wich ELISA. Increasing concentrations of IgA were coated on ELISA plates and binding of
purified human MBL was assessed as described previously (25) using dig-conjugated mAb
3E7 for detection. In parallel, the amount of immobilized IgA was detected using biotinylated
goat anti-human IgA (Dako, Glostrup, Denmark), followed by HRP-conjugated streptavidin
(Zymed, Invitrogen, Breda, The Netherlands). 
The relative amounts of polymeric, dimeric, and monomeric serum IgA were quantified on
basis of the protein profile obtained following gel filtration of purified IgA, using calculation of
the area under the curve. 
Immunohistology and immunofluorescence
For immunofluorescence and immunoperoxidase stainings, the unfixed renal tissue was
embedded in OCT compound (Sakura Tissue-tek, Bayer, Leverkusen, Germany), snap-
frozen in a mixture of isopentane and dry-ice and stored at -80 °C. Subsequently, 5 µm sec-
tions were placed on slides and stored at -20 °C until immunostaining. 
We used mouse monoclonal antibodies directed against the following molecules: MBL
(mAb 3E7 (28), mAb 1C10 and mAb 2A9 (29)), L-ficolin (mAb GN4, mAb GN5 (30)), MASP-
1/3 heavy chain (mAb 1E2 and mAb 4C2 (31,32)), C4 binding protein (mAb from Quidel, San
Diego, CA, USA), C5b-9 (aE11, from Abcam, Cambridge, UK), IgA1 (mAb  NI69-11 from
Nordic Tilburg, The Netherlands (33)) and IgA2 (mAb 14-3-26 from Becton Dickinson,
Erembodegem, Belgium and mAb NI512 from Nordic  (33)). Rabbit polyclonal antibodies
were applied for detection of C3 (FITC-labeled anti-human C3c, from Dako), C4d (from
Biomedica, Vienna, Austria (34)) and MASP-2 (a MASP-2-specific antibody generated in the
laboratory of Nephrology using the recombinant protease domain of MASP-2 ( (35,36)) kind-
ly provided by Dr. P. Gal, Institute of Enzymology, Budapest, Hungary; to be described else-
where).
For indirect immunofluorescence, after fixation in cold acetone, tissues were incubated
sequentially with the primary antibody and the proper fluorescently labeled secondary anti-
body (Alexa Fluor 488-conjugated goat anti-mouse Ig or goat anti-rabbit Ig, Molecular
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Probes). Slides were finally mounted with an anti-fading aqueous mounting medium
(Fluorsave, Calbiochem).  
Immunoperoxidase staining of MBL was performed as previously described (37). Briefly,
after incubation with 0.5 % avidin (Sigma Chimica, Milan, Italy) and 0.01 % biotin (Sigma), to
suppress endogenous avidin-binding activity, tissue sections were fixed in a methanol-H2O2
solution to block endogenous peroxidase. After washing, sections were incubated with pri-
mary antibody, followed by biotinylated anti-mouse antibody (Zymed), and peroxidase-
labeled streptavidin (Zymed). Peroxidase activity was detected with 3,5-diaminobenzidine
(DAB, from Sigma), sections were counterstained with Harry's hematoxylin, dehydrated, and
mounted in Permount. 
In both immunofluorescence and immunoperoxidase methods, specificity of antibody
labeling was demonstrated concurrently using proper control immunoglobulins (Zymed).
Evaluation of renal tissue 
Evaluation of renal tissue was performed blindly by two independent observers. For
immunostaining, tissues were scored as negative (0) or positive (1), according to the detec-
tion of staining in the majority of glomeruli, in at least 3 tubular cross-sections per field, and
in vessel endothelium.
For histology, sections were stained using standard periodic-acid Schiff (PAS), periodic-
acid-silver methenamine (PASM), and/or Trichrome techniques. Mesangial proliferation was
scored as 1+ when mild-moderate (i.e. between 4 and 6 cells per mesangial area) and 2+
when intense (more than 6 cells per mesangial area). Extracapillary proliferation, global scle-
rosis, and segmental sclerosis were calculated as percentage of the total number of
glomeruli. Interstitial infiltration and fibrosis were scored 0 when absent, 1+ when mild (involv-
ing < 30 % of the interstitium), 2+ when moderate (30-60 % of the interstitium involved), or 3+
when intense (when present in > 60 % of the renal interstitium). Hyalinosis of the vessel wall
was indicated when absent (0) or present (1). 
Statistical analysis
Data were compared between IgAN patients showing positive and negative glomerular
staining for MBL, respectively. Frequency analysis was performed using Chi-square test.
Other comparisons were evaluated using the Mann Whitney U test. The Spearman Rank cor-
relation coefficient was used to analyze correlation. Differences were considered statistically
significant when P was below 0.05. 
RESULTS
Evidence for glomerular lectin pathway activation in IgA nephropathy
The presence of MBL was examined in 60 renal biopsies from IgAN patients.
Glomerular staining for MBL was observed in a predominantly mesangial pattern in
15 biopsies (25 %, Figure 1A, C) whereas glomeruli in 45 IgAN biopsies stained
negative for MBL (Figure 1D). A similar positive staining was observed using three
different mAb directed against MBL, whereas staining with an isotype control mAb
was completely negative (Figure 1B). 
Next we examined the presence of other molecules involved in the lectin path-
way of complement. All renal biopsies with positive glomerular staining for MBL also
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showed glomerular staining for L-ficolin, as shown by two different mAb, whereas
glomerular L-ficolin staining was negative in all MBL-negative cases (Table 1, Figure
2). Similarly, all cases positive for MBL and L-ficolin, but none of the negative cases,
showed positive mesangial staining for the common heavy chain of MASP-1 and
MASP-3, using two mAb, and for C4d and C4 binding protein (Table 1, Figure 2).
The majority of biopsies in both MBL-negative and MBL-positive groups showed
deposition of C3, whereas C1q was negative (Table 1). 
All IgAN biopsies showed a typical mesangial deposition of IgA1 (Table 1, Figure
2). In contrast, we were unable to show a positive staining for IgA2, using two differ-
ent IgA2-specific mAb (Table 1, Figure 2), although these antibodies showed clear
positive staining on renal biopsies from lupus nephritis patients (data not shown). 
In order to further extend the analysis of complement activation in IgAN, deposi-
tion of MASP-2, being the C4-cleaving enzyme of the lectin pathway, and C5b-9, as
the final product of the terminal pathway of complement, was evaluated. Due to a
shortage of renal tissue, an additional series of 25 renal biopsies was used for these
studies. From these biopsies, 6 showed positive glomerular staining for MBL (24 %),
confirming the results presented above in an independent study. All MBL-positive
biopsies showed positive glomerular staining for MASP-2 (Figure 2), whereas
MASP-2 was negative in all other biopsies. Staining for C5b-9 was clearly positive
in a mesangial pattern in all IgAN biopsies. However, in MBL-positive biopsies,
staining was observed with a high intensity (Figure 2), whereas intensity showed a
marked variation in MBL-negative biopsies (not shown). 
Glomerular lectin pathway activation in IgA nephropathy is associated with
markers of disease progression
Data indicated above show that IgAN patients can be divided in two groups, with
(25 %) and without (75 %) evidence for glomerular activation of the lectin pathway




MBL deposition in IgAN
patients. Biopsies from
patients with IgAN were
stained with mAb 1C10 (A),
mAb 3E7 (C, D) or an isotype
control mAb (B). Figures A, C,
and D are derived from
different patients who showed
positive (A, C) or negative (D)
staining for MBL. Figures A
and B are from the same
patient. Please note tubular
and vascular staining for MBL
in C, in addition to glomerular
staining.
MBL-positive and negative cases had a similar male/female distribution and a
similar age at the time of the renal biopsy (Table 2). However, patients with glomeru-
lar MBL-positivity presented twice as often with renal failure at the time of renal biop-
sy, mostly chronic renal failure (P < 0.0001, Table 2). Furthermore, MBL-positive
cases showed significantly more proteinuria than MBL-negative IgAN patients,
whereas, in contrast, less MBL-positive IgAN patients suffered from episodes of
macroscopic hematuria (Table 2, Figure 3A, B). In our IgAN patient population,
macroscopic hematuria seems to be associated with a more benign disease course,
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Figure 2. Lectin pathway activation in IgAN.
Renal tissue from IgAN patients was stained for the presence of MBL (mAb 3E7), L-ficolin (mAb GN4),
MASP-1/3 (mAb 1E2), MASP-2, C4d, C4 binding protein, C5b-9, IgA1 and IgA2 (mAb NI512), as
indicated. Representative images are shown.
Table 1. Molecular composition of glomerular deposition in IgA nephropathy* 
MBL staining 
L-
ficolin MASP-1/3 C4d 
C4 binding 
protein C1q C3 IgA1 IgA2 
Neg ( N = 45) 0% 0% 0% 0% 0% 82% 100% 0% 
Pos (N = 15) 100% 100% 100% 100% 0% 60% 100% 0% 
 
*The data indicates the percentage of biopsies with positive staining for a certain marker. 
Positive staining means clear positivity in the majority of glomeruli. Neg: negative, Pos: 
positive 
 
since patients with macroscopic hematuria showed significantly less proteinuria than
patients without macroscopic hematuria, also when MBL-negative cases were
analysed only (P = 0.04, not shown). MBL-positive cases also showed a higher
serum creatinine level than MBL-negative IgAN patients, although the creatinine
clearance was not significantly different (Table 2). However, the latter parameter
could be analyzed for only part of the patients in our study. 
Data presented above suggest that glomerular MBL-positivity in IgAN is associ-
ated with a more severe disease. This is strongly supported by semi-quantitative
histological evaluation of renal damage, demonstrating that biopsies from IgAN
patients with positive glomerular staining for MBL had more intense mesangial pro-
liferation as well as significantly more extracapillary proliferation, global sclerosis
and interstitial infiltration than MBL-negative cases (Figure 3C-F, Table 3). Increased
glomerular and tubulointerstitial damage in MBL-positive cases, as compared to
MBL-negative cases, is illustrated in Figure 4. 
No difference between the two groups was found for the presence of vascular
lesions. Glomerular staining for MBL was significantly associated with staining for
MBL in vessels and tubuli (Table 3 and Figure 1C). However, tubular and vascular
staining for MBL was only weakly associated with mesangial proliferation (P = 0.03),
and no association was found with proteinuria or other parameters of disease activ-
ity. Furthermore, tubulointerstitial staining for MBL was not clearly associated with
markers of complement activation (not shown). 
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positive N P 
Age at renal biopsy (yr;median) 35 36 27 12 0.28 
Female gender (%) 36 36 17 12 0.21 
Renal failure  (% chronic) 33 (73 % 
chronic) 45 
67 (80 % 
chronic) 15 <0.0001 
Proteinuria (gram/24 hr;median) 0.7 45 2.5 15 0.004 
Macroscopic hematuria present (%) 46 39 13 15 0.025 
Serum creatinine (µmol/l;median) 97 45 133 15 0.042 
Creatinine clearance (ml/min;median) 92 25 61 10 0.43 
Serum MBL (ng/ml;median) 1299 28 873 12 0.8 
MBL complex activity (U/ml;median) 738 29 865 12 0.27 
Serum L-ficolin (µg/ml;median) 2.6 28 1.82 12 0.15 
Serum IgA (mg/ml;median) 2.54 36 2.28 15 0.37 
Monomeric serum IgA (%;median) 73 6 73 6 0.7 
Dimeric serum IgA (%;median) 23 6 20 6 0.39 
Polymeric serum IgA (%;median) 4 6 5.4 6 0.09 
MBL-negative cases and MBL-positive cases are defined on basis of glomerular 
staining. The size distribution of purified serum IgA is expressed as % of total IgA. All 
data were obtained at the time of the renal biopsy.  
 
































































































































































Figure 3. MBL positivity is associated with markers of renal damage.
IgAN patients were divided in two groups on basis of glomerular positivity for MBL. Clinical (A, B)
and histological data (C-F) presented are scored as explained in Materials and Methods. Horizontal
lines in B, D, and F represent the median. Statistical analysis was performed as described in Tables
2 and 3.
Table 3. Histological data from IgA nephropathy patients  
Parameter MBL-neg MBL-pos P 
  (N = 45) (N = 15)   
Intense mesangial proliferation (% of cases) 20 60 0.003 
Extracapillary proliferation present (% of cases) 31 60 0.046 
Global sclerosis (% of glomeruli;median) 10 25 0.031 
Segmental sclerosis (% of glomeruli;median) 0 8 0.069 
Interstitial infiltration (0-3 scale scoring;median) 1 2 0.017 
Interstitial fibrosis (0-3 scale scoring;median) 1 2 0.12 
Vessel lesions present  (% of cases) 33 40 0.64 
Vascular MBL staining positive (% of cases) 36 73 0.01 
Tubular MBL staining positive (% of cases) 22 80 0.0001 
MBL-negative cases and MBL-positive cases are defined on basis of glomerular 
staining 
 
Characterization of circulating MBL, L-ficolin and IgA
We further examined whether the observed dichotomy in IgAN patients with
respect to glomerular lectin pathway activation could be associated with certain
properties of the lectin pathway of complement and /or the IgA in the circulation. 
Serum levels of MBL are genetically determined and highly variable in the human
population (27). A similar variability was observed for IgAN patients in our study,
without a significant difference between cases showing positive and negative stain-
ing for MBL (Figure 5A and Table 2). Serum levels of L-ficolin showed less variabil-
ity, and also did not distinguish between both groups (Figure 5B and Table 2). As a
functional parameter, we assessed MBL complex activity, being a measure of the
ability of the MBL-MASP-2 complex to activate C4. MBL complex activity showed a
similar distribution in both groups (Figure 5C and Table 2), and was strongly corre-
lated to MBL serum concentration (Figure 5D). As expected, three patients with clear
MBL deficiency (Figure 5D) showed negative glomerular staining for MBL. 
Since these data exclude the simple explanation that lectin pathway deficiency
explains the lack of glomerular lectin pathway activation in most IgAN patients, we
further studied whether properties of serum IgA may explain the observed dichoto-
my. The concentration of serum IgA was not significantly different between both
groups (Figure 5E and Table 2). To address the question more in depth, serum IgA
was purified from serum from IgAN patients. From patients with and without
glomerular MBL deposition, we selected 6 patients in each group. Patients with a
(possible) MBL deficiency were excluded. IgA was purified from serum and subject-
ed to gel filtration. The protein profile clearly reveals the presence of polymeric,
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Figure 4. Renal histological damage in IgAN patients.
Renal histology from three patients w ithout glomerular MBL deposition (A-C) show s glomeruli affected
by mild mesangial proliferation and mild mesangial matrix expansion. No major tubulo-interstitial lesions
are visible. Images D-F represent patients w ith glomerular MBL deposition (N = 3). Glomerular injury is
characterized by intense mesangial proliferation and mesangial matrix expansion (D), segmental and
global sclerosis (E), and extracapillary proliferation (F), w hereas tubular dilations, interstitial inf iltration
and f ibrosis are evident in the interstitium (D-F).  Sections w ere stained w ith PAS (A, B), PASM (C, F)
or trichrome (D, E) techniques.
dimeric and monomeric IgA (Figure 6A). The size distribution of serum IgA in IgAN
patients with and without glomerular MBL deposition showed a low variability with-
out any significant differences (Figure 6B and Table 2).  
Subsequently, we studied the binding of purified MBL to patient IgA of different
sizes. Therefore, increasing concentrations of monomeric, dimeric, and polymeric
IgA were coated on ELISA plates, and binding of MBL was assessed. The results
showed a high variability in the MBL binding properties of IgA from different donors,
although similar amounts of IgA were immobilized on the ELISA plates (Figure 7A).
Monomeric IgA did not show MBL binding, whereas strong but donor-dependent
MBL binding could be observed to polymeric IgA (Figure 7B). MBL binding to dimer-
ic IgA was significantly less than that to polymeric IgA (P < 0.01). Quantification of
the binding of MBL per unit immobilized IgA did not reveal a significant difference
between patients with and without glomerular MBL positivity, respectively (Figure
7B). However, two patients whose IgA showed strong MBL binding both showed
positive deposition of MBL in the glomerulus.  




























































































Figure 5. Circulating MBL, L-ficolin, and IgA in IgAN patients. Concentrations of MBL
(A), L-ficolin (B) and IgA (E), as well as MBL complex activity (C) were quantified in serum of IgAN
patients as described in Materials and Methods. IgAN patients were divided in two groups on basis of
glomerular positivity for MBL. Horizontal solid lines represent the median, and dashed lines indicate
the detection limit. Correlation between MBL concentration and MBL complex activity is shown in D.
DISCUSSION
Data from the present study indicate that IgAN patients can be divided in two
groups on the basis of the pattern of complement activation. About 75 % of IgAN
patients show negative glomerular staining for MBL, L-ficolin, MASP, C4d and C4-
binding protein, indicating that C3 and C5b-9 activation in these patients most like-
ly occurs via the alternative pathway. In contrast, 25 % of IgAN patients show
glomerular deposition of MBL, L-ficolin, MASP, C4d but not C1q, which is strongly
indicative of activation of complement via the lectin pathway of complement.
Importantly, the clinical and histological data clearly indicate that activation of the
lectin pathway of complement is associated with more severe renal damage. 
Using a well-defined polyclonal antibody to C4d, which is now frequently used in
the diagnostic evaluation of renal transplant rejection (34), we observed deposition
of glomerular C4d in IgAN exclusively in association with molecules of the lectin
pathway. An identical pattern was observed for deposition of C4-binding protein, a
regulatory protein that was also previously reported as a sensitive marker for the
presence of C4 (20). Activated C4 is most likely generated by MASP-2, the key com-
plement-activating enzyme of the lectin pathway, which was shown to be present in
the mesangial area in association with MBL. 
Next to strongly suggesting activation of C4 via the lectin pathway in a subpop-
ulation of IgAN patients, our data indicate glomerular activation of C3 and C5b-9 via
the alternative pathway in the majority of IgAN patients, independently of C4. The
latter aspect is in agreement with a number of in vitro studies showing alternative
pathway activation by IgA from human and rodent species (6,13,15). 
We assume that mesangial MBL and L-ficolin are derived from the circulation as
preformed complexes with MASPs, although local production of molecules of the
lectin pathway can not be excluded (38). Our previous in vitro studies showed that
MBL is able to interact via its lectin domain with purified polymeric serum IgA (25).
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Figure 6. Size distribution of circulating IgA. A. Typical example of a protein profile
obtained after gel filtration of purified IgA. Position of polymeric, dimeric and monomeric IgA is
indicated. B. Quantification of IgA size distribution of IgA from 12 IgAN patients showing
positive or negative glomerular staining for MBL.
Further support for an interaction between MBL and IgA is provided by studies in
Henoch Schönlein Purpura nephritis (39,40). In the present study, we show that
MBL binds to polymeric IgA from IgAN patients. It is possible that MBL binds to gly-
cans present on the IgA heavy chains. IgA consists of two subclasses, IgA1 and
IgA2, of which the former dominates in the circulation (90 % IgA1). However, mucos-
al IgA may contain up to 65 % IgA2 (7). Interestingly, circulating IgA1 from IgAN
patients was reported to have aberrant glycosylation of O-linked glycans, potential-
ly involved in recognition by lectins (41). 
Although it is generally believed that IgA deposits in IgAN consist almost exclu-
sively of IgA1 (1,2,7,33,42,43), biopsies from IgAN patients may also contain IgA2
(44). A recent study in this field by Hisano et al. (23) showed that about 50 % of a


















































































































Figure 7. Binding of MBL to
polymeric circulating IgA from
IgAN patients. A. IgA of different
sizes was coated, followed by
assessment of MBL binding and, in
parallel, detection of immobilized IgA, as
indicated. Two representative examples
are shown for IgA samples that show a
high or low binding of MBL. B.
Quantification of MBL-binding properties
of patient IgA of different sizes, on basis
of a calibration line and corrected for the
amount of immobilized IgA.
Japanese population of IgAN patients showed deposition of IgA2 next to IgA1,
whereas glomerular MBL deposition was exclusively observed in these IgA2-posi-
tive patients. Similar results were recently reported in Henoch-Schönlein purpura
nephritis (40). Stimulated by these striking observations, we investigated the
glomerular presence of IgA2 in our patient population, using two different IgA2-spe-
cific mAb, including mAb 14-3-26 that was also used by Hisano et al. (23). However,
we were not able to detect any glomerular positivity for IgA2 in IgAN biopsies. This
difference might be due to ethnical differences between patient populations.
Furthermore, although we tried several amplification methods to acquire a signal for
IgA2, it could still be that IgA2 is present in tiny amounts and/or masked by other
molecules, thereby hampering detection.
IgA deposited in the renal mesangium of IgAN patients is classically accepted as
being polymeric IgA (45). Polymeric IgA contains several other molecular compo-
nents, which are currently only partially identified (45,46). It can not be excluded that
MBL binds to a glycosylated molecule associated with polymeric IgA and present in
the mesangial deposits of IgAN patients. An alternative explanation would be that
MBL binds to injured tissue in the glomerulus, which is in line with the binding of
MBL to apoptotic and necrotic cells (47). 
To our best knowledge, data from the present study are the first indication for a
role of L-ficolin in disease. In vitro data indicate that ligand specificities of MBL and
L-ficolin do only partially overlap (16,17,48). However, recent experiments in our
group indicate that L-ficolin also binds to polymeric IgA (Roos et al. manuscript in
preparation). MBL and ficolins have an important role in innate immune defense.
However, evidence is increasing that MBL and the lectin pathway of complement
can also be harmful for the host as mediators of inflammation. In this respect, MBL
has been proposed to be involved in ischemia/reperfusion injury (49), diabetic
nephropathy (50) and ulcerative colitis (51). In the present study, we observed that
IgAN patients with glomerular MBL deposition and lectin pathway activation showed
significantly more renal damage, as evidenced by increased mesangial proliferation,
extracapillary proliferation, glomerular sclerosis, interstitial infiltration, and protein-
uria. An association of glomerular MBL positivity with decreased renal function and
increased mesangial proliferation and proteinuria was also reported by Matsuda et
al. (21) but could not be confirmed by studies from Endo et al. (22) and Hisano et
al. (23). In Henoch-Schönlein purpura nephritis, MBL deposition was associated
with increased progression of renal disease (40). Increased disease progression in
association with glomerular lectin pathway activation may possibly be ascribed to
pro-inflammatory activation products of the complement system, including C5a and
C5b-9, and potentially also to a direct effect of MBL. 
Similar to several other studies (21-23), we observed lectin pathway activation
only in a subpopulation of IgAN patients. The majority of IgAN patients without
mesangial MBL deposition did not show any evidence for deficiency of MBL or L-
ficolin. Interestingly, serum concentrations of MBL in this population of IgAN patients
(N= 41, median = 1213 ng/ml) were significantly higher than those in a population
of Caucasian healthy controls (N = 190; median = 677 ng/ml, P = 0.002, data not
shown). This difference could be explained by genetic differences and/or by condi-
tions associated with renal disease. 
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We hypothesize that the difference between IgAN patients with and without
mesangial MBL deposition is based on differential availability of the ligand, poten-
tially related to differences in IgA glycosylation. In order to further examine this
hypothesis, we investigated the binding of purified MBL to polymeric, dimeric and
monomeric IgA from IgAN patients being either positive or negative for glomerular
MBL deposition. This analysis revealed binding of MBL to polymeric serum IgA with
a large inter-individual variation, but the degree of MBL binding could not be direct-
ly related to glomerular lectin pathway activation. However, mesangial IgA is not
necessarily similar to serum IgA, and furthermore, it could be that glomerular IgA is
differentially accessible in IgAN patients. We assume that the observed dichotomy
in IgAN patients is due to several factors acting in combination. 
In conclusion, the current study shows that MBL and the lectin pathway of com-
plement are involved in complement activation in a subpopulation of patients with
IgAN, which is highly likely to play an adverse role in the disease. In vitro data point
to a role for polymeric IgA in lectin pathway activation. Precise identification of the
ligand for MBL and L-ficolin in the mesangium, which is presumably present and/or
accessible in only part of the patients with IgAN, will provide novel insight in the
pathogenesis of IgAN and may provide novel therapeutic options to treat disease
progression.
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Summary
IgA nephropathy (IgAN) is characterized by mesangial deposition of polymer-
ic IgA1 and complement. Complement activation via MBL and the lectin path-
way is associated with disease progression. Furthermore, recent studies have
indicated a possible role for secretory IgA. IgAN is associated with abnormal-
ities in circulating IgA, including aberrant O-linked glycosylation. The present
study characterized and compared functional properties and N-linked glycosy-
lation of highly purified monomeric and polymeric IgA from IgAN patients and
controls. Total serum IgA was affinity-purified from patients (n= 11) and con-
trols (n= 11) followed by size-separation. Polymeric but not monomeric IgA
contained secretory IgA, and its concentration was significantly higher in IgAN
patients than in controls. Both in IgAN patients and in controls, IgA binding to
the GalNAc-specific lectin HAA and to MBL was much stronger for polymeric
than for monomeric IgA. Furthermore, binding of IgA to mesangial cells was
largely restricted to polymeric IgA. Binding of polymeric IgA to mesangial cells
resulted in increased production of IL-8, predominantly with IgA from IgAN
patients. Quantitative analysis of N-linked glycosylation of IgA heavy chains
showed significant differences in glycan composition between monomeric and
polymeric IgA, including the presence of oligomannose exclusively on poly-
meric IgA. In conclusion, binding and activation of mesangial cells, as well as
lectin pathway activation is a predominant characteristic of polymeric IgA as
opposed to monomeric IgA. Furthermore, polymeric IgA has different N-gly-
cans, which may recruit lectins of the inflammatory pathway. These results
underscore the role of polymeric IgA in glomerular inflammation in IgAN.










Primary IgA nephropathy (IgAN) is the most common form of primary glomeru-
lonephritis. The disease leads to progressive renal failure in a substantial proportion
of patients. The hallmark of this disease is deposition of IgA in the glomerular
mesangium, together with markers of complement activation (1,2). It is generally
thought that this mesangial IgA mainly consists of IgA1 and is mostly polymeric (3).
The composition of polymeric forms of IgA in serum is diverse and may include
dimeric IgA, secretory IgA (SIgA), CD89 (FcαRI) /IgA complexes, IgA immune com-
plexes and IgA-fibronectin complexes (4-6). Serum dimeric IgA consists of two IgA
molecules linked with J chain, whereas SIgA in addition contains secretory compo-
nent, derived from the mucosal epithelium. 
Deposition of circulating IgA in the mesangium leads to renal inflammation,
potentially involving direct interactions of IgA with resident and infiltrating cells in the
glomerulus, as well as complement activation. The inflammatory process results in
renal injury. Although the mechanism of IgA deposition in the renal mesangium of
IgAN patients has been a subject of intensive research during the last decades, the
pathogenesis of IgAN is still incompletely characterized. A number of studies provid-
ed evidence for a mesangial IgA receptor, which is involved in mesangial cell acti-
vation by IgA in vitro (7-9). 
Glomerular IgA deposition is associated with activation of the complement sys-
tem (5), involving the alternative pathway and the lectin pathway of complement
(10). Recent studies indicate deposition of MBL, a major recognition molecule of the
lectin pathway of complement, in a subpopulation of patients in association with a
more severe renal injury (10,11), whereas in vitro studies demonstrated binding of
MBL to polymeric serum IgA (12). Glomerular complement activation can enhance
renal injury via the pro-inflammatory effects of the complement activation cascade. 
Studies in IgAN patients who received a renal transplant showed recurrence of
mesangial IgA deposition in a high number of cases (13). Vice versa, the accidental
transplantation of a kidney with mesangial IgA deposition into a recipient without
IgAN resulted in spontaneous disappearance of IgA deposits following transplanta-
tion (14). These studies strongly suggest that IgAN is a systemic disease rather than
a disease of the kidney. 
On basis of these data, abnormalities in IgA are hypothesized to be involved in
the pathogenesis of IgAN. Therefore, circulating IgA from IgAN patients has been
extensively studied. Serum from IgAN patients contains higher concentrations of IgA
(15,16).  Recently, our group showed low concentrations of circulating secretory IgA
in IgAN patients and controls, whereas IgAN patients with a high serum concentra-
tion of SIgA showed more hematuria (17). Furthermore, SIgA accumulated in
glomerular IgA deposits, suggesting a pathogenic role for SIgA in IgAN (17). Several
studies also focused on IgA glycosylation, showing aberrant O-glycosylation on cir-
culating IgA from IgAN patients, resulting in increased Tn antigen (GalNAcα1-
Ser/Thr) residues (18,19). This undergalactosylated IgA1 may lead generation of
circulating IgG-IgA1 complexes (20). O-linked glycans are present on IgA1 but not
IgA2, whereas IgA1 and IgA2 heavy chains both contain several N-glycosylation
sites (21). The galactosylation of the N-glycans is not different between IgAN
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patients and controls (22). However, the complete structure of N-linked glycans on
IgA has not been studied in IgAN. 
Functional studies with purified IgA from IgAN patients suggested an increased
interaction of IgA from IgAN patients with mesangial cells as compared to IgA from
healthy individuals (23), although this is still controversial (24). Furthermore, after
stimulation of mesangial cells with IgA from IgAN patients, the production of proin-
flammatory cytokines and chemokines was shown to be increased (25), possibly
involving (26,27) undergalactosylation of IgAN IgA (28). 
The aim of the present study was to characterize and compare the molecular
composition and functional properties of monomeric and polymeric serum IgA from
IgAN patients and controls. Therefore, we analysed highly purified total serum IgA
from patients and controls in a number of aspects that are potentially important in
the pathogenesis of IgA nephropathy, including interaction with lectins and mesan-
gial cells. The results show clear functional differences between naturally occurring
polymeric and monomeric serum IgA both for patients and controls. The most obvi-
ous difference that was noted between IgA isolated from IgAN patients and from
controls was an increased fraction of SIgA in polymeric IgA from IgAN patients.
Furthermore, we demonstrate that polymeric IgA differs from monomeric IgA in its
composition of N-linked glycans. 
MATERIAL AND METHODS
Human subjects
In the present study, we obtained serum from 11 healthy volunteers and 11 patients with
primary IgAN (Table 1). All patients had biopsy-proven IgA nephropathy. None of these
patients had clinical or laboratory evidence of Henoch Schönlein purpura, systemic lupus ery-
thematosus or liver disease, or received immunosuppressive therapy. A healthy control group
was selected and matched for gender. The mean age of the controls was somewhat lower;
however we had no indications that this affects the biochemical properties of IgA. Renal func-
tion was non stable in 5 of the 11 patients with serum creatinine ranging from 203 to 366
µmol/L. The study was approved by the ethical committee of the Leiden University Medical
Center. All individuals gave informed consent. 
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Table 1 Clinical characteristics of the patients with IgA nephropathy and 
control persons 
 IgAN patients controls 
Number 11 11 
Male/ female 8/3 9/2 
Mean age (years) 
 
48 33 
Mean serum creatinine (µmol/L; range) 190 (82-366) ND 
Proteinuria (0 to 3+; median) 1+ ND 
Erythrocyturia (0 to 5+; median) 1+ ND 
IgA purification 
IgA was precipitated from serum using (NH4)2SO4 at 50 % saturation, followed by affini-
ty chromatography using HisA43 (mAb against human IgA, kindly provided by dr J. van den
Born, Free University Medical Center, Amsterdam) coupled to CNBR-activated Sepharose
4FF (Amersham). A column of 15 ml was loaded with gamma globulin precipitate correspon-
ding to 10 ml serum, using 0.5 x PBS as a running buffer, followed by washing with 90 ml 0.5
x PBS. Fractions of 3 ml were collected. To remove non-specifically bound proteins, the col-
umn was washed with 70 ml 1 M NaCl. Finally, bound IgA was eluted with 100 ml 0.1 M
glycine/ 0.3 M NaCl (pH 2.8). Fractions were neutralized with 1 M Tris (pH 8.0). Fractions that
contained IgA, as assessed by ELISA (29), were pooled, dialysed against PBS containing 2
mM EDTA, and applied to a mixture of protein G/ anti-human IgM (HB57)-Biogel A5 to remove
residual contaminating IgG and IgM, followed by concentration and size-separation with a
HiLoadTM 16/60 HR200 Superdex prep grade gel filtration column (120 ml, Amersham
Pharmacia, Roosendaal, The Netherlands), run in 50 mM NH4HCO3. Fractions were
assessed for the presence of IgA and total protein. On basis of the protein profile, IgA-con-
taining fractions were pooled into polymeric IgA (eluted at 44-50 ml) and monomeric IgA (elut-
ed at 50-60 ml). These pools were analysed for total IgA, IgA1 and IgA2 content using ELISA
(29). The percentage of polymeric IgA was quantified using calculation of the area under the
curve on basis of the gel filtration profile. 
MBL binding ELISA
MBL was purified from pooled plasma obtained from healthy human donors, as described
before (12), resulting in a preparation of MBL in complex with its associated serine proteas-
es (MASPs). MBL binding was studied by ELISA, in which 5 µg/ml IgA, or  human serum albu-
min (HSA) as a control, was coated , followed by  blocking with PBS/BSA, incubation with
MBL (2 µg/ml) and detection of MBL binding as described (12). For inhibition experiments,
MBL was pre-incubated with MgEGTA (10 mM), D-mannose or L-mannose (100 mM, from
Sigma). 
Activation of C4 via the lectin pathway
Activation of C4 by MBL-MASP complexes was measured as described before (12). In
brief, incubation of MBL-MASP-complexes on coated IgA was followed by incubation with
purified C4 and detection of C4 binding.
HAA binding
IgA was assessed for binding to biotinylated Helix Aspersa (HAA, Sigma) lectin, known to
recognize terminal GalNAc. NUNC Maxisorp plates were coated with 5 µg/ml IgA or HSA as
a control, in carbonate buffer (pH 9.6), overnight at room temperature. After washing with
PBS/ Tween and blocking for one hour with PBS/ 1 % BSA, wells were incubated with 5 µg/ml
biotinylated HAA in PBS/ 1 % BSA/ 0.05 % Tween. Binding of HAA was detected with HRP-
conjugated streptavidin (Zymed). Enzyme activity of HRP was developed using ABTS
(Sigma). The O.D. at 415 nm was measured.
SIgA ELISA
In order to quantify SIgA levels in isolated IgA, a sandwich ELISA specific for SIgA was
used as described before (17). Briefly, plates were coated with a mAb against secretory com-
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ponent (NI194-4), followed by incubation with IgA and detection of IgA binding. 
Glycosidase treatment of IgA
Detection of undergalactosylated IgA with lectins could be hampered by the presence of
sialic acids. To get a clear and full picture of the galactosylation, we treated IgA with neu-
raminidase and checked for binding to HAA and MBL.  IgA (5 µg/ml) and HSA were coated,
followed by blocking, and subsequent incubation with 100 mM sodium acetate pH 5.0, with
or without 10 mU/ml Neuraminidase from Arthrobacter ureafaciens (Roche, Mannheim,
Germany), for 3 hours at 37 ºC. Subsequently HAA and MBL binding were assessed as
described above.
Cell culture 
Normal human mesangial cells (NHMC, Cambrex, USA) were expanded according to the
protocol provided by the manufacturer in mesangial cell basal medium with supplements
(Cambrex, USA). Experiments with NHMC were performed in RPMI with 10 % FCS, 1 % non-
essential amino acids, 0.5 % transferrin/insulin/selenium, 1 % sodium pyruvate, and 1 % L-
glutamine (all purchased at Gibco/ life Technologies, Paisley, Scotland). AMC11, a sponta-
neously growing mesangial cell line of adult human origin (kindly provided by Prof. Holthofer,
Helsinki), was cultured in DMEM with 10 % FCS. Cells were harvested by trypsinization.
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Figure 1. Purification of
monomeric and polymeric IgA.
A) Affinity purification of IgA with an anti-IgA
column. First peak is flow through (protein,
no IgA), the second peak is after washing
with 0.5 M NaCl (protein, no IgA), and the
third peak is after acid elution. This peak
contains IgA as detected with ELISA. B)
Size-fractionation of IgA on a HiLoadTM
16/60 HR 200 Superdex prep grade
gelfiltration column. All fractions were
measured for total protein and the presence
of total IgA by ELISA. IgA was pooled in
pIgA (44-50 ml) and mIgA (50-60 ml) as
indicated.
Flow cytometry
Cells were washed with FACS buffer (0.5 x PBS containing 1 % BSA/ 2.8 % glucose/ 0.01
% NaN3) and incubated with monomeric and polymeric IgA. Following incubation for 1 hour
at 4 º C, cells were washed and incubated for one hour at 4 º C with monoclonal anti-IgA mAb
4E8 (IgG1) (29). IgA binding was visualized using PE-conjugated goat anti-mouse IgG1
(Southern Biotechnology, Birmingham, AL) and fluorescence intensity was assessed by flow
cytometry (FACSCalibur, Cell quest software; BD Biosciences). Dead cells, identified by pro-
pidium iodide uptake, were excluded from analysis.
Cytokine analysis
Production of IL-8 and MCP-1 was measured in supernatants of cultured mesangial cells.
Prior to stimulation, cells were transferred to 96-wells plates (Costar, Corning, NY) at a den-
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Figure 2. Increased binding and stimulation of mesangial cells with polymeric IgA.
A) Normal human mesangial cells w ere incubated w ith different molecular forms of IgA (200 µg/ml) from
IgAN patients and controls, and assessed for IgA binding by flow cytometry. Depicted is the mean
fluorescence intensity after subtracting the isotype control. B) Human mesangial cells (15 x 103
cells/well) were stimulated with different molecular forms of IgA (200 µg/ml). After 72 hours supernatants
were harvested and tested for IL-8. Horizontal lines indicate the median, the dotted line represents the
detection limit. IL-8 was undetectable in cultures without IgA. Polymeric IgA versus monomeric IgA (A,
B): P < 0.01. C) Correlation between production of IL-8 after stimulation of mesangial cells with IgA and
the binding of IgA to mesangial cells.
sity of 15 x 103 cells per well and cultured overnight in culture medium with 0.5 % serum.
Cells were cultured in the presence or absence of monomeric and polymeric IgA for 72 hours,
in concentrations as indicated. The concentration of IL-8 and MCP-1 in culture supernatants
was measured by ELISA as described (30,31). 
N-glycan analysis
The IgA heavy chains were isolated on SDS-PAGE under reducing conditions and visu-
alised by Coomassie staining. The N-Glycans were released from these excised gel bands
by PNGase F, labelled with the fluorophore 2-aminobenzamide and analysed by normal
phase (NP) HPLC with exoglycosidase sequencing as described (32). 
Identification of Gel Bands by Mass Spectrometry.
The Coomassie-stained IgA heavy chain bands from an SDS-PAGE gel were excised and
in-gel digested with trypsin (sequencing grade; Roche) as described (32). 
Statistical analysis
Statistical analysis was performed using the Mann-Whitney test and the Wilcoxon signed
rank test. The Spearman Rank correlation coefficient was used to analyze correlations.
Differences in N-glycan composition were evaluated using the Student's T-test. Differences
were considered statistically significant when p values were less than 0.05.
RESULTS
Polymeric IgA binds better to mesangial cells and induces more cytokine
production after activation of mesangial cells
Human IgA was purified with an anti-IgA affinity column (Figure 1A). In the flow
through no IgA was detectable whereas IgA was eluted by acid elution. The fractions
containing IgA were pooled. Purified IgA was applied to a gel filtration column
(Figure 1B), and fractions containing polymeric IgA (pIgA) and monomeric IgA
(mIgA) were pooled as indicated. 
To examine possible functional differences between monomeric and polymeric
IgA from IgAN patients and controls, we investigated the binding of IgA to mesan-
gial cells, as well as the cytokine response following stimulation. Polymeric IgA
showed a 5.9-fold higher binding to mesangial cells than mIgA (P = 0.0003), but
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Figure 3. HAA binding to monomeric
and polymeric IgA.
Monomeric IgA and polymeric IgA of IgAN
patients and controls were coated in
ELISA plates (5 µg/ml), followed by
incubation with biotin-labeled HAA.
Horizontal lines indicate the median, the
dotted line represents binding to HSA.
Polymeric IgA versus monomeric IgA: P =
0.0003.
there was no difference between IgAN patients and controls (Figure 2A). 
Supernatants of the cells stimulated with IgA for 72 hours were tested for produc-
tion of the chemokines IL-8 and MCP-1. The IL-8 production was significantly high-
er after stimulation of mesangial cells with polymeric IgA than after stimulation with
mIgA (P = 0.010), whereas IL-8 production was undetectable in cultures without IgA
(Figure 2B). Furthermore, IL-8 production tended to be higher upon stimulation with
polymeric IgA from IgAN patients compared with that from controls (P = 0.077). A
significant correlation was observed between binding of pIgA to mesangial cells and
IL-8 production after co-culture (Figure 2C; R = 0.6450, P = 0.0038). Furthermore,
stimulation with IgA also clearly enhanced production of MCP-1, and MCP-1 produc-
tion correlated with IL-8 production after stimulation with different IgA samples (R =
0.59, P = 0.01). These functional data indicate intrinsic differences between
monomeric and polymeric IgA.
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Figure 4. MBL binding to polymeric IgA from IgAN patients and controls.
Monomeric and polymeric IgA were coated in ELISA plates, followed by incubation with purified
MBL-MASP complexes. A) Detection of MBL binding. B) MBL was pre-incubated with MgEGTA (10
mM), D-mannose (100 mM) or L-mannose (100 mM) before incubation on wells coated with IgA as
indicated. MBL binding was detected. The horizontal dashed line represents the negative control C)
Detection of C4 activation after incubation with purified C4. For each IgA sample, blanc values,
obtained after incubation with C4 and/or detection antibodies without MBL, were subtracted. Dashed
lines indicate OD values obtained with coating of HSA. Polymeric IgA versus monomeric IgA (A, C):
P = 0.0001.
Interaction of polymeric IgA with HAA lectin
It has been reported that O-glycans of patients with IgAN contain more Tn anti-
gen (GalNAc-Ser/Thr) compared to controls (18,33). Terminal GalNAc can be
detected by specific lectins, including Helix Aspersa (HAA). We investigated the
binding of HAA to IgA by ELISA (Figure 3).  The binding of HAA to IgA from healthy
individuals and IgAN patients was 4 fold higher for polymeric IgA than for monomer-
ic IgA (P = 0.0003). However, we could not observe a difference in HAA binding
between patients and controls.
MBL exclusively binds to polymeric IgA, resulting in C4 activation
We and others showed that IgAN is associated with complement activation via
the lectin pathway (10,34). Therefore, the binding of MBL to purified IgA from
patients with IgAN and controls was studied, showing that MBL binds to pIgA but not
to mIgA with a high inter-individual variation, both for IgAN patients and controls
(Figure 4A). Using parallel detection of immobilized IgA on plates, we confirmed that
equal amounts of IgA were present in coated wells, indicating that differences in
coating could not explain the observed differences (not shown). Binding of MBL to
IgA was completely inhibitable by D-mannose and MgEGTA but not by L-mannose
(Figure 4B), confirming that the C-type lectin domain of MBL was involved in bind-
ing to IgA.
Binding of MBL to pIgA from IgAN patients and from controls resulted in activa-
tion of purified C4 (Figure 4C), presumably involving C4 cleavage by MBL-associat-
ed MASP-2. This activation of C4 showed a strong correlation with MBL binding (R=
0.98, P < 0.0001 for pIgA). 
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Figure 5: Increased interaction with HAA after treatment of IgA with
neuraminidase.
IgA (5 µg/ml) was coated in ELISA. After treatment with neuraminidase HAA binding (A) and MBL
binding (B) were detected. Depicted is the ratio of non-treated and treated IgA after subtraction of
background values, and the dotted line represents the non-treated IgA. * P < 0.05, ** P <0.01.
Treatment of IgA with neuraminidase enhances its interaction with HAA
To examine whether sialic acids, commonly present on N-linked and O-linked
glycans of IgA, might hamper the interaction of IgA with HAA and/or MBL we treat-
ed immobilized IgA with neuraminidase. After treatment of IgA the interaction with
HAA increased significantly (3.8-fold for control mIgA, 3.1-fold for IgAN mIgA, 3.2-
fold for control pIgA, 3.0-fold for IgAN pIgA; P < 0.004) (Figure 5A), suggesting the
presence of sialylated Tn antigen, as the removal of the sialic acid exposes the
GalNAc (Tn) epitope. In contrast, the binding of MBL to IgA was hardly affected by
neuraminidase, only showing a minor increase after treatment of polymeric IgA (1.1-
fold) (Figure 5B), consistent with the known specificity of MBL for glycans present-
ing 3,4 cis hydroxyls such as mannose to which sialic acids do not attach. 
Molecular composition of monomeric and polymeric IgA from IgAN patients
and controls
The results presented above indicate major functional differences between
monomeric and polymeric IgA. We therefore investigated the molecular composition
of monomeric and polymeric IgA from IgAN patients and controls. The size distribu-
tion of IgA from IgAN patients and controls was similar (mean % polymeric IgA, con-
trols: 18.9 %, patients: 18.8%; P = 0.89). The IgA preparations were assessed for
IgA1 and IgA2 content by ELISA. As described before (35), IgA2 is a minor con-
stituent of human serum IgA. However, the relative amount of IgA2 was significant-
ly higher in polymeric IgA (20 ± 4.1 %) as compared to monomeric IgA (9.2 ± 4.7 %)
(Figure 6A) (P< 0.0001), suggesting that circulating IgA2 is more likely to be pro-
duced as polymeric complexes than circulating IgA1. The relative amount of IgA2
was similar in IgA from patients and controls. 
Subsequently, we measured SIgA in monomeric and polymeric IgA from IgAN
patients and controls. In agreement with the molecular size of SIgA, SIgA is exclu-
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Figure 6. Increased concentration of SIgA and IgA2 in polymeric IgA.
The relative content of IgA2 (A) and SIgA (B) in monomeric and polymeric IgA as assessed by
ELISA. Horizontal lines indicate the median. Polymeric IgA versus monomeric IgA (A, B): P <
0.0001. SIgA content in pIgA of IgAN patients versus controls: * P = 0.0152.
sively present in polymeric IgA (Figure 6B). SIgA comprised less than 1 % of total
polymeric serum IgA. However, the proportion of SIgA present in polymeric IgA from
IgAN patients is 2.5 times higher than in polymeric IgA from controls (P= 0.0152). 
Polymeric IgA shows a different composition of N-linked glycans compared
to monomeric IgA
Recent studies showed that MBL is able to bind to N-linked glycans of IgG (36)
and IgM (37). Based on the known structures of N-linked and O-linked glycans on
IgA, it is more likely that MBL would bind to N-linked glycans than to the O-linked
glycans. Furthermore, information on N-linked glycosylation of IgA in IgAN is not
available. Therefore, we characterized the N-glycans of 6 monomeric and 6 poly-
meric IgA preparations in detail. 
Heavy chains and light chains of monomeric and polymeric IgA were separated
by SDS-PAGE (Figure 7). N-linked glycans were released via an in-gel digestion of
the heavy chain and light chain bands of IgA using PNGase F. Isolated glycan sam-
ples were labeled with 2-aminobenzamide and run on normal phase HPLC.
Consistent with earlier data (32), light chains of IgA were found not to be glycosylat-
ed (not shown). The elution pattern of heavy chains is shown in Figure 8A. The most
prominent peaks, present between glucose units 8 and 10, represent complex gly-
cans that are sialylated, as was demonstrated by a neuraminidase digestion (abs;
Figure 8B). No obvious differences could be observed between N-glycans from
patients and from controls. However, upon comparison of glycans from monomeric
and polymeric IgA, a single peak at GU 6.2 was present in all polymeric IgA sam-
ples but absent in monomeric IgA. Digestion with mannosidase (jbm, Figure 8B)
demonstrated that this is an oligomannose structure (Man 5), as schematically
drawn in Figure 8A. 
Using sequential enzyme digestions (Figure 8B), the glycan structures on these
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Figure 7. SDS-PAGE analysis
of monomeric and polymeric
IgA.
Separation of monomeric and
polymeric IgA with 10% SDS-PAGE
under reducing conditions shows
heavy and light chains after staining
with Coomassie. IgA heavy chains







6 7 8 9 10
GU
6 7 8 9 10
GU



















60 70 80 90 100 110 120 130
4 765 1098 1211 GU
Figure 8. Analysis of N-linked glycans on IgA heavy chains.
A) Analysis of N-glycans of the heavy chain of polymeric IgA from controls and from patients with IgAN
by NP-HPLC. The figures show the individual elution profiles following fluorescence detection.
Retention times are standardized to a glucose oligomer ladder to give glucose units (GU). The boxed
peaks are only present in polymeric IgA and are identified as oligomannose (Man 5), as indicated. B)
Digestion of the N-glycans with A. ureafaciens sialidase (abs), jack bean α-mannosidase (jbm),
bovine testes β-galactosidase (btg), bovine kidney α-fucosidase (bkf) and Streptococcus
pneumoniae N-acetyl β-glucosaminidase (guh), followed by separation with NP-HPLC.










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































samples were identified and quantified (Table 2). Comparison of monomeric and
polymeric IgA revealed that 3.3 % of the total glycan pool contained Man5 in poly-
meric IgA, whereas this structure is absent in monomeric IgA. Furthermore, the dou-
ble sialylated glycans are under-represented in polymeric IgA as compared to
monomeric IgA (29 % and 37 %, respectively, P = 0.001), resulting in a shift to small-
er glycan structures on polymeric IgA. There were no significant differences
between patients and controls. Together, the results indicate that N-linked glycosy-
lation of the IgA heavy chain is significantly different between monomeric and poly-
meric IgA (Table 2). 
DISCUSSION
Deposition of IgA in the renal mesangium is the primary characteristic of IgAN,
responsible for glomerular inflammation and finally the development of renal failure.
Based on earlier observations of mesangial IgA, this IgA is believed to be largely
polymeric IgA1. In the present study we show that polymeric IgA, as opposed to
monomeric IgA, from IgAN patients and from healthy controls shows increased bind-
ing to and activation of mesangial cells, and has a superior capacity to bind the com-
plement-activating lectin MBL. These aspects of polymeric IgA are most likely to be
involved in induction of glomerular deposition and inflammation. Furthermore, we
provide evidence that polymeric IgA is differently glycosylated from monomeric IgA,
as suggested by lectin binding studies and demonstrated by a direct identification of
N-linked glycans. Noteworthy, the only obvious difference that was observed
between IgA from IgAN patients and controls was a substantial increase in the frac-
tion of SIgA in polymeric IgA from IgAN patients. 
Comparisons between IgA isolated from patients and from healthy controls were
reported previously (19,22,28,38-40). Most experiments were performed with either
fractionated total serum without an IgA purification step (28,39,40) or with pooled
serum IgA purified with Jacalin, a lectin that binds Gal 1-3GalNAc (39-41). In our
study we purified IgA from individual patients and controls with an anti-IgA mAb.
With this method we prepared monomeric and polymeric IgA that contains total and
highly pure serum IgA without a preceding selection for certain IgA glycoforms. In
contrast to methods using Jacalin, this method also enabled us to isolate the IgA2
present in serum. 
Previous studies described that the binding of polymeric IgA to mesangial cells
was higher than that of monomeric IgA (23,28) although this could not be repro-
duced by others (24). Moreover, the binding of patient IgA and that of in vitro
degalactosylated IgA was higher than that of control IgA (24). In the present study,
we confirm a prominent increase in mesangial cell binding of polymeric over
monomeric IgA, but we did not detect a difference between patient and control IgA.
Our studies further establish the pro-inflammatory properties of polymeric IgA, and
demonstrate that IgA-induced chemokine production is correlates with the interac-
tion of IgA with the mesangial cell surface. It is most likely that next to the increased
binding of pIgA, also a more efficient receptor crosslinking will contribute to its proin-
flammatory action. In addition, also the observed biochemical properties of pIgA
might contribute to this process. However, unlike previous investigations (27), this
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property could not be specifically attributed to IgA derived from IgAN patients. 
Next to the direct effects of IgA on mesangial cells, activation products of the
complement system, involving both the alternative pathway and the lectin pathway,
are likely to drive the local inflammatory process. Activation of the lectin pathway of
complement via an interaction between MBL and IgA has been shown before (12),
and in the present study we confirm and extend these data by showing that binding
of MBL is a common feature of polymeric but not monomeric IgA isolated from dif-
ferent donors. Since ligand recognition by MBL requires multiply presented carbo-
hydrates, MBL binding could be favored by the structure of polymeric IgA. Binding
of MBL leads to activation of C4 presumably via activation of the C4-cleaving
enzyme MASP-2. In a healthy situation, the binding of MBL to polymeric IgA could
be involved in host defense. However, in IgAN, lectin pathway activation via poly-
meric IgA is unfavorable (10).
Many studies on IgA from IgAN patients focused on glycosylation. IgA is exten-
sively glycosylated, both via N-linkages (IgA1 and IgA2) and O-linkages (IgA1) (21).
It was consistently observed that serum IgA from IgAN patients contains smaller O-
linked glycans, with less sialylation and galactosylation, than IgA from healthy con-
trols (18). Previous investigations suggested that this was predominantly the case
for monomeric IgA (40). Our experiments using HAA, a lectin that is commonly used
to detect terminal GalNAc present on non-galactosylated O-linked glycans, suggest-
ed the presence of terminal GalNAc (Tn antigen) predominantly on polymeric IgA,
both from patients and controls. This is in agreement with a previous study showing
reactivity of HAA with high molecular weight serum proteins (28) and with data pro-
vided by Leung et al. (40). Binding of HAA was strongly increased by neuraminidase
treatment, suggesting a high frequency of non-galactosylated O-linked glycans on
IgA, that expose terminal GalNAc after enzymatic removal of sialic acid. 
A detailed quantitative analysis of N-linked glycans on IgA heavy chains of
monomeric and polymeric IgA revealed several significant differences between
these molecular forms of IgA. In this respect, polymeric IgA consistently contained
an oligomannose structure that was undetectable on all monomeric IgA prepara-
tions, and showed significantly less glycans with two terminal sialic acid residues.
Recent studies showed that MBL can bind to certain glycoforms of human IgM,
involving GlcNAc-terminated glycans and oligomannose structures on the IgM
heavy chains (42). Therefore, the presence of specific glycans on polymeric but not
monomeric IgA might also be involved in its recognition by MBL. At present it is
unknown whether a specific glycosylation pattern of the heavy chain of polymeric
IgA is involved in the polymerization of IgA, and/or whether this merely is related to
the conditions present during production of the different forms of IgA. Earlier stud-
ies from our group indicated that polymeric serum IgA contains dimeric IgA linked
with J chain, as well as complexes of monomeric IgA linked via other mechanisms
(43). In the first case, polymerization takes place in the B cell, and the presence of
oligomannose, which is a premature glycan structure, might suggest the ER as a
possible location for polymerization, which prevents further synthesis of the glycan
structure by steric hindrance. In the latter case, polymerization might take place out-
side the B cell. 
Part of the observed differences in glycosylation between monomeric and poly-
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meric IgA might also be explained by the presence of SIgA in the polymeric fraction
of serum IgA, since the SIgA heavy chain N-glycosylation is very different from that
of monomeric serum IgA (32). SIgA has about 8 % oligomannose structures and 60
% glycans with exposed GlcNAc with less than 15 % for all glycans sialylated (32),
compared to monomeric serum IgA where most of the glycans are sialylated.
However, SIgA comprises only less than 1 % of total polymeric serum IgA. 
We observed that polymeric serum IgA contains more IgA2 than monomeric IgA.
This could be because IgA2 polymerises more easily than IgA1, or that IgA2-pro-
ducing B-cells preferentially secrete polymeric IgA. Bone-marrow-derived IgA as
present in serum is largely monomeric and of the IgA1 subclass, whereas mucosal
IgA is largely polymeric, containing J chain and secretory component (44), and con-
tains a substantial fraction of IgA2 (35). Therefore, an increased fraction of IgA2 and
the presence of SIgA in circulating polymeric IgA may suggest its production by the
mucosal immune system. Quantitative measurement of the presence of SIgA in
polymeric serum IgA suggests that only a minor part of polymeric IgA contains
secretory component. We hypothesize that this SIgA is derived from the mucosal
surface. Circulating dimeric IgA without secretory component could be partially pro-
duced in mucosal lymphoid tissue and directly transported towards the circulation.
Although SIgA requires transepithelial transport for the attachment of secretory
component to dimeric IgA, the presence of low concentrations of circulating SIgA
has been described before (17,45,46). Moreover, increased serum levels of SIgA
have been reported in various diseases (17,47-49). In contrast to previous studies,
we now determined the SIgA concentration in highly purified polymeric serum IgA.
Our data demonstrate a clear relative increase in SIgA in polymeric IgA from patients
with IgAN compared with controls. We recently reported a preferential interaction of
SIgA with mesangial cells, and showed glomerular accumulation of SIgA in IgAN
(17). Therefore, our current results further support a role for SIgA in the pathogene-
sis of IgAN.
Taken together, the presented data suggest that a part of circulating polymeric
IgA has a mucosal origin. There is accumulating evidence that the pathogenesis of
IgAN is related to aberrant production of IgA. In this respect, in vivo studies indicat-
ed that IgAN patients have a disturbed mucosal immune response, which was
restricted to production of antibodies of the IgA1 subclass (50). Our present obser-
vation that secretory IgA is increased in the polymeric IgA fraction of IgAN patients
further supports a role for abnormal mucosal immunity. Since IgAN is a slowly pro-
gressive disease, it is well conceivable that only a minor subfraction of circulating
IgA in IgAN patients is abnormal, and that this IgA gradually accumulates in the
mesangial area. We hypothesize that this abnormal IgA is at least partially derived
from the mucosal immune system. Since our data strongly indicate that large-sized
IgA is especially able to interact with mesangial cells, and to induce complement
activation, the gradual deposition of such pro-inflammatory IgA may eventually lead
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A pathogenic role for Secretory IgA in IgA
Nephropathy.
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Summary
IgA nephropathy (IgAN) is characterized by deposits of IgA in the renal
mesangium. It is thought that deposits of IgA mainly involve high molecular
weight (HMW) IgA1. However there is limited information on the exact compo-
sition of HMW IgA in these deposits. In this study we investigated the presence
of secretory IgA (SIgA) in human serum and in the glomerular deposits of a
patient with IgAN. Furthermore, we analysed the interaction of SIgA with
mesangial cells. With ELISA SIgA concentrations in serum of IgAN patients
and healthy controls was measured. Patients and controls both have circulat-
ing SIgA that was restricted to the HMW fractions. Patients tend to have high-
er levels of SIgA, but this difference was not significant. However, in patients
with IgAN, high serum SIgA concentrations were associated with hematuria.
Binding of size fractionated purified serum IgA and secretory IgA to mesangial
cells was investigated with flow cytometry. These studies with mesangial cells
showed stronger binding of SIgA to primary mesangial cells, compared to bind-
ing of serum IgA. Importantly, after isolation and elution of glomeruli from a
nephrectomized transplanted kidney from a patient with recurrent IgAN, we
demonstrated a 120-fold accumulation of SIgA compared to IgA1 in the eluate.
In conclusion we have demonstrated that SIgA strongly binds to human
mesangial cells, and is present in significant amounts in serum. Furthermore,
we showed that SIgA is accumulated in the glomeruli of an IgAN patient. These
data suggest an important role for SIgA in the pathogenesis of IgA nephropa-
thy.









INTRODUCTION   
Primary IgA nephropathy (IgAN) is the most common form of primary glomeru-
lonephritis. The disease shows a spectrum of clinical presentations, leading to pro-
gressive renal failure in a substantial proportion of patients. The hallmark of this dis-
ease is deposition of IgA in the glomerular mesangium (1-3). It is generally thought
that deposits of IgA mainly involve IgA1 and for a large part consist of high molecu-
lar weight (HMW) IgA (4). The composition of HMW forms of IgA in serum is diverse
and may include dimeric IgA, CD89/IgA complexes, IgA immune complexes and
IgA-fibronectin complexes (5-9).
Several reports have shown that the glycosylation of IgA1 in patients is different
from that in controls. Patient IgA1 contains more terminal GalNAc and this could
play a role in the deposition of IgA1 in the mesangium (10-12). IgA from the
glomeruli of IgAN patients consists at least partly of HMW IgA (13) and is under-O-
glycosylated (10,14). In these studies no data was presented concerning the pres-
ence of secretory IgA (SIgA). When deposited in the kidney, the IgA1-containing
complexes are linked to inflammation. Stimulation of mesangial cells with HMW IgA
leads to enhanced production of cytokines and chemokines, including IL-6, TGF-β,
TNF-α, MCP-1, IL-8 and MIF (15-18).  These cytokines and chemokines might play
a role in the development and progression of renal injury in IgAN patients.
SIgA is the dominant immunoglobulin in external mucosal secretions like in oral,
respiratory, and intestinal cavities, and is often characterized as a component of the
immune systems "first-line defence" against pathogenic micro-organisms (19). The
SIgA molecule is composed of two IgA monomers, linked by a junction peptide
called J chain, and the secretory component (SC) that wraps around the dimer (20).
Next to its presence in mucosal secretions, small amounts of SIgA can also be found
in human serum (21,22). Moreover, increased serum levels of SIgA have been
reported in various diseases (23-25), indicating that SIgA may be a marker of clini-
cal interest. A previous study has suggested that the serum concentrations of SIgA
are not different in IgAN patients compared to healthy controls (23). The physiolog-
ical roles of serum IgA and SIgA are quite different, and the presence of the highly
glycosylated SC can have major effects on the biological functions of SIgA (26,27).
In literature it is still controversial if SIgA is able to bind to mesangial cells (28,29).
One study showed that SIgA is able to bind to mesangial cells (28), however this
could not be confirmed in another study (29). 
In the present study we investigated the presence of SIgA in sera of IgAN
patients and healthy controls, and examined the binding of different molecular forms
of IgA to human mesangial cells with special interest for SIgA. Finally we investigat-
ed the presence of SIgA in the glomerular eluate of an IgAN patient. 
MATERIAL AND METHODS
Human subjects
In this study, we included 19 healthy volunteers and 47 patients with primary IgAN (30).
The latter were defined by mesangial deposits of IgA. None of these patients had clinical or
laboratory evidence of Henoch Schoenlein purpura, systemic lupus erythematosus, liver dis-
ease or received immunosuppressive therapy. Patients were included in the study between
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October 1998 and February 1999. Blood and urine samples were collected, clinical charac-
teristics and laboratory data of the patient group were obtained (Table 1) retrospectively
(observation time 5.9 ± 0.5 years) and prospectively (follow-up time 3.7 ± 0.2 years). 
Renal cortex was obtained from a transplant nephrectomy from a male patient (1977),
with biopsy-proven recurrent IgAN. He was diagnosed with macroscopic hematuria (serum
creatinine 146 µmol/l) in 1993. The renal biopsy of 1996 showed characteristic features of
progressive IgAN, and dialysis was started. In April 2002 he received a cadaveric renal trans-
plantation. Three months later a decline in renal function was observed and a renal biopsy
showed the presence of interstitial nephritis and recurrent IgAN. In a biopsy taken 6 months
following transplantation characteristics of the interstitial nephritis were disappeared, but IgA
was still present. Due to decreased patient compliance there were two episodes of acute
rejection in 2003 and 2004, which eventually led to graft loss. Informed consent was obtained
from all subjects.   
IgA purification
Serum from healthy controls was used for IgA purification, according to methods
described before (9). In brief, serum was applied to an anti-IgA (HisA 43, kindly provided by
dr J. van den Born, Free University Medical Center, Amsterdam) affinity column. IgA was elut-
ed with 0.1 M glycine/ 0.3 M NaCl (pH 2.8). The eluted protein fractions containing IgA, as
assessed by ELISA (31), were pooled and dialysed. The IgA was size-separated with a
HiLoadTM 16/60 HR200 Superdex prep grade gelfiltration column (120 ml, Amersham
Pharmacia, Roosendaal, The Netherlands) into pIgA and mIgA.
Cell culture   
NHMC (normal human mesangial cells, Cambrex, USA) were expanded according to the
protocol provided by the manufacturer. Experiments with NHMC were performed in RPMI with
10 % FCS, 1 % non-essential amino acids, 0.5 % transferrin/insulin/selenium, 1 % sodium
pyruvate, 1 % L-glutamine (all purchased at Gibco/ life Technologies, Paisley, Scotland).
AMC11, a spontaneously growing adult human mesangial cell line (kindly provided by Prof.
Holthofer, Helsinki), was cultured in DMEM with 10 % FCS. Cells were cultured in culture
flasks (Greiner, Frickenhausen, Germany) at 37 ºC in a humidified incubator with 5 % CO2/
95 % air. For passage the cells were harvested by trypsinization (0.02 % (w/v) EDTA/ 0.05 %
(w/v) trypsin in PBS from Sigma (St. Louis, MO)).
Monocyte-derived dendritic cells were generated as described before (32).
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Table 1: Clinical characteristics of the patients with IgAN at the point of serum 
SIgA measurement. 
  Number of patients Median Range 
Male/ female 38/ 9   
ACE-inhibitor/AII antagonist 24/ 3   
Age (years)  47 19-69 
Systolic blood pressure (mmHg)  130 100-160 
Diastolic blood pressure (mmHg)  80 55-100 
Proteinuria (g/day)  0.6 0.1-5.2 
Glomerular filtration rate (ml/min)  71 15-137 




Cells were harvested, washed with FACS buffer (0.5 x PBS containing 1 % BSA/ 2.8 %
glucose/ 0.01 % NaN3) and incubated with monomeric and polymeric serum IgA, and SIgA
(Sigma). Following incubation for 1 hour at 4 ºC, cells were washed and incubated for one
hour at 4 ºC with monoclonal anti-IgA Ab 4E8 (IgG1) (31). IgA binding was visualized using
PE-conjugated goat anti-mouse IgG1 (Southern Biotechnology, Birmingham, AL) and
assessed for fluorescence intensity by flow cytometry (FACSCalibur, Cell quest software; BD
Biosciences). Dead cells, identified by propidium iodide uptake, were excluded from analysis.
For analysing the presence of the mannose receptor, anti-mannose receptor antibody
(D547.3; kindly provided by F. Koning, Leiden University Medical Center, Leiden, The
Netherlands) was used followed by PE-conjugated goat anti-mouse Ig (Dako, Glostrup,
Denmark).  For the detection of the two chains of MAC-1, anti-human CD11b (leu-15-PE, BD
Biosciences) and anti-CD18 (IB4, ATCC) were used. 
For inhibition of the binding of SIgA to mesangial cells, the cells were pre-incubated with
purified free SC (100 µg/ml) (33), 10 mM EDTA or 10 mM CaCl2 for 1 hour at 4 ºC.
Subsequently, without washing, SIgA was added and this binding was visualized as described
above. Inhibition of binding of SIgA was also detected with a pre-incubation of IgA for one
hour at 4 ºC; subsequently Alexa-conjugated SIgA was added. After one hour the binding of
Alexa-conjugated SIgA was measured.
Cytokine analysis
Production of IL-6 was measured in supernatants of mesangial cells after 72 hr stimula-
tion. Prior to stimulation, cells were transferred to 48-wells plates (Costar, Corning, NY) at a
density of 25 x 103 cells per well and cultured overnight in culture medium with 0.5 % serum.
Cells were stimulated with IL-1, serum IgA, or SIgA.  The concentration of IL-6 in culture
supernatants was measured by specific ELISA as described previously (34).
RNA extraction and RT-PCR   
Total RNA was extracted from mesangial cells using RNeasy mini kit (Qiagen, Valencia,
CA). OD260/280 ratio was measured to determine the quantity and purity of RNA prepara-
tions. Fixed amounts of total cellular RNA (1 µg) were reverse transcribed into cDNA by
oligo(dT) priming, using M-MLV reverse transcriptase (Gibco/Life Technologies, Breda, The
Netherlands). PCR to detect the human mannose receptor was performed with specific
primers (sense 5'-TTG AGT GGA GTG ATG GGA CC-3'; antisense 5'-TTT CTG GAC CTT
GGC TTC GT-3') using AmpliTaq DNA polymerase (Applied Biosystems, Roche, Mannheim,
Germany). The PCR reaction was performed under standard conditions (35). The cDNA sam-
ples were also subjected to PCR for GAPDH as an internal control (35), PCR products were
resolved on 1 % agarose gels and bands were visualized by ethidium bromide staining.   
Preparation of glomerular eluate
Glomeruli were isolated from a nephrectomized kidney from a transplanted IgAN patient
with recurrent disease. For this purpose the renal cortex was separated from the medulla.
After slicing the cortex in little pieces, the glomeruli were collected on a 150-mesh sieve and
stored at -70ºC with protease inhibitors (Complete, Mini, and Roche). The glomeruli were
washed with PBS and the final pellet was resuspended in 5 ml of elution buffer (2 M KSCN
in 0.01 M phosphate buffer, pH 7.6) as described before (36). After stirring at room tempera-
ture (RT) for 60 min, the suspension was centrifuged at 8,000 g for 15 min at 4ºC in a high-
speed centrifuge (Beckman, Avanti J25-1). The supernatant was collected and dialysed
overnight against PBS. The precipitate that was formed during dialysis was removed by cen-
trifugation for 15 min at 17,000 g and was negative for immunoglobulins. The remaining
supernatant was concentrated to one-third of the original volume.
ELISA for human SIgA, IgA1, IgA2, IgG and IgM
To test the specificity of the antibodies used for the SIgA ELISA, Ninety-six well Nunc
Maxisorp microtitre plate (Gibco/Invitrogen) was coated with 2 µg/ml IgA and BSA in carbon-
ate buffer (pH 9.6) overnight at RT. After washing, the plate was incubated with monoclonal
antibodies (2 µg/ml) specific for secretory component: NI194-4 (IgG1-k; Nordic Immunology,
Tilburg, The Netherlands) (37) or 3F8 (kindly provided by dr R.M. Goldblum, University of
Texas Medical Branch, Galveston) (38) in PBS/ 1 % BSA/ 0.05 % Tween for one hour at 37
ºC. Bound antibody was detected with goat anti-mouse Ig HRP (Dako). Enzyme activity of
HRP was developed using ABTS (Sigma). The O.D. at 415 nm was measured using a
microplate biokinetics reader (EL312e, Biotek Instruments, Winooski, Vermont, USA).
In order to quantify SIgA levels in isolated IgA and serum, a sandwich ELISA specific for
SIgA was developed. Plates were coated with 2 µg/ml monoclonal antibody specific for secre-
tory component (NI194-4; 3F8) in carbonate buffer (pH 9.6) (100 µl/well) overnight at RT.
Subsequently, the plates were washed with PBS/ 0.05 % Tween. Plates were incubated with
IgA or with serum from patients and controls in PBS/ 1 % BSA/ 0.05 % Tween for one hour
at 37 ºC. After washing, bound IgA was detected using mouse anti-human IgA (4E8) conju-
gated to digoxigenin (Dig), followed by F(ab)2 anti-Dig antibodies conjugated to HRP
(Roche). Enzyme activity of HRP was developed using ABTS (Sigma). The O.D. at 415 nm
was measured. A calibration line was produced using purified SIgA (Sigma).
Concentrations of IgA1, IgA2, IgG and IgM in sera and glomerular eluate were determined
using specific ELISAs (39).
Western blot analysis
IgA preparations were subjected to 10% SDS-PAGE under reducing conditions, followed
by semi-dry blotting to PVDF (immobilin-P, Millipore, Bedford, MA). Blots were blocked for 2
hours at RT in TBS/ 0.1 % Tween/ 5 % skim milk powder (Fluka, Buchs, Switzerland). Blots
were subsequently incubated with 2 µg/ml monoclonal antibody specific for secretory compo-
nent (NI194-4) in TBS/ 0.1 % Tween/ 2.5 % skim milk powder overnight at 4 ºC. After wash-
ing with TBS/ 0.1 % Tween, blots were incubated with HRP conjugated goat anti-mouse
immunoglobulin (Dako) for 2 hours at RT. After washing bands were visualized with
Supersignal (Pierce Chemical Co., Rockford, IL) and exposure to HyperfilmTM films
(Amersham Pharmacia).
Statistical analysis
Statistical analysis was performed using the Mann-Whitney test. Differences were consid-
ered statistically significant when p values are less than 0.05. 
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RESULTS
Specific detection of SIgA in human serum
An ELISA system was developed to specifically measure the amounts of secre-
tory IgA in serum. In this system anti-SC antibodies were coated, samples were
applied and SIgA was detected with anti-IgA antibodies. Purified SIgA was readily
detected by this ELISA with a detection limit of 100 ng/ml (Figure 1A). In contrast,
purified monomeric serum IgA is not recognized in the ELISA, even when applied at
high concentrations (Figure 1A). In accordance with previous publications (23), a
specific signal for SIgA could be detected in serum of healthy individuals (Figure
1B). The specificity of this assay is especially dependent on the specificity of the
anti-SC antibody. Using Western blot, we showed that this monoclonal antibody only
recognized the 75 kDa SC (Figure 2A). Furthermore comparison of the NI194-4 anti-
body with another anti-SC antibody 3F8 (38) showed specificity for SIgA both in a
direct ELISA (Figure 2B) as well as in a sandwich ELISA (Figure 2C). 
To determine the molecular size of SIgA in serum, IgA was isolated from serum
using affinity chromatography. Size-fractionation revealed that SIgA was specifical-
ly present in the HMW fractions (Figure 3A). Using the same procedure, IgA was iso-
lated from 8 healthy controls followed by gel filtration. Pools containing pIgA and
mIgA, respectively, were obtained and assessed for the amount of SIgA (Figure 3B).
In all cases, SIgA was demonstrated exclusively in the pIgA pool. 
Next we assessed concentrations of SIgA in serum of 47 IgAN patients and 19
healthy controls (Figure 4A). Both in controls and in patients significant serum con-
centrations of SIgA were detected.  There was no significant difference (p= 0.159)
in the SIgA concentrations in serum of patients (3.3 ± 3.0 µg/ml) compared to con-
trols (2.2 ± 1.2 µg/ml). After comparison the SIgA concentration in serum of IgAN
patients with different clinical parameters there were no correlations found. However
concentrations of SIgA in IgAN patients were more heterogeneous than in controls.
Therefore we divided the IgAN group in patients with elevated levels of SIgA (> 5













































Figure 1: Specific detection of SIgA in human serum.
A) Purified SIgA and monomeric serum IgA were measured in a sandwich ELISA, as detailed in
the Material and Methods. B) Measurement of SIgA in serum from healthy individuals in different
serum dilutions. NHS, normal human serum.
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Figure 2: Specific detection of SIgA and secretory component.
A) Detection of secretory component in SIgA, 1 and 0.2 µg SIgA were loaded on 10 % SDS-PAGE
gel under reducing conditions after blotting secretory component was detected with 2µg/ml
NI194-4. B) Detection of secretory component with NI194-4 and 3F8 (2 µg/ml) in different forms
of IgA (2 µg/ml) coated on ninety-six well Nunc maxisorp microtitre plate. C) Different forms of
IgA measured with sandwich ELISA using two different coating antibodies (NI194-4 and 3F8).

















































Figure 3: SIgA is present in high molecular weight fractions of serum IgA.
A) IgA was affinity purified and size-fractionated on a HiLoadTM 16/60 HR200 Superdex prep grade
gelfiltration column. All fractions were measured for total protein and the presence of total IgA and
SIgA by ELISA. B) From 8 healthy controls, IgA was purified and size fractionated as above. IgA was
pooled in pIgA fraction (39-47.5ml) and mIgA fraction (47.5-57ml). Both IgA and SIgA concentrations
were determined, and depicted is the amount of SIgA corrected for the amount of total IgA The
horizontal dashed line represents the detection limit. The horizontal solid lines indicate the median.
There were no significant correlations with the degree of proteinuria or creatinine
clearance and the serum concentration of SIgA (Figure 4B). However, there was sig-
nificantly more pronounced hematuria in the group with higher levels of SIgA (p=
0.04) (Figure 4B).  
SIgA binds to mesangial cells and induces cell activation
After demonstrating the presence of SIgA in the circulation, we investigated its
capacity to interact with mesangial cells. After incubation of the mesangial cell-line
AMC11 or normal human mesangial cells (NHMC) with 200 µg/ml of different molec-
ular forms of IgA, the binding was examined by FACS analysis. Binding of
monomeric serum IgA to NHMC is very low (Figure 5A). In contrast, the polymeric
form of serum IgA showed a clear binding to mesangial cells. However the best
binding was observed with similar concentrations of SIgA, which occurred in a dose-
dependent fashion, present over a wide range of concentrations (Figure 5B).






































































Figure 4: Measurement of SIgA in serum of IgAN patients and controls and
relation to clinical parameters.
A) The concentrations of SIgA were determined in serum from patients (n= 47) and controls (n=19).
The horizontal dashed line represents the detection limit and the horizontal solid lines indicate the
median B) Based on SIgA concentrations IgAN patients were divided in two groups: normal SIgA
levels (<5µg/ml; mean ± 2 SD of control sera) and increased SIgA levels (≥ 5µg/ml). These groups
were analyzed for proteinuria, creatinin clearance (700* creatinin in urine (mmol/ 24 hours)/ creatinin
in serum (µmol/l) and erythrocyturia at the time of sampling. The horizontal solid lines indicate the
median. Statistics were performed using the Mann-Whitney test (ns= not significant)
AMC11, was overall higher for all forms of IgA, the relative differences between the
different forms of IgA were the same.
The different molecular forms of IgA were compared for their capacity to induce
IL-6 production by mesangial cells. Stimulation of NHMC for 72 hours with IgA
resulted in an increased IL-6 production. This increase was most prominent follow-
ing stimulation with SIgA (Figure 6A). The induction of IL-6 production by mesangial
cells was dose dependent: a 17-fold increase was observed compared to the nega-
tive control upon stimulation with 200 µg/ml SIgA (Figure 6B).  
Mesangial cells do not express the mannose receptor (CD206) or MAC-1
(CD11b/CD18)
Recently we showed that dendritic cells are able to bind SIgA via the mannose
receptor (CD206) (40). Therefore we investigated the presence of the mannose
receptor as a potential SIgA receptor on mesangium cells. However both using
FACS analysis (Figure 7A) and RT-PCR (Figure 7B) we were not able to demon-
strate the presence of the mannose receptor on mesangial cells. In both cases, DC
served as a positive control. Similarly, we were not able to demonstrate the pres-
ence of CD11b/CD18 (Figure 7C), recently identified as a co-receptor for SIgA bind-
ing (41). 
Binding of SIgA to mesangial cells is not inhibited by secretory component,
EDTA and calcium
To investigate in more detail the mechanism of binding of SIgA to mesangial
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Figure 5: Binding of SIgA to mesangial cells.
A) Normal human mesangial cells (NHMC) were
incubated with different molecular forms of IgA
(200µg/ml) and assessed for IgA binding by flow
cytometry. Filled histograms represent the binding of
IgA, the open histograms represent the control staining
with secondary antibodies B) FACS analysis with
AMC11 was performed using increasing doses of SIgA
(Sigma) and pIgA (isolated from a healthy individual).

















cells, the cells were pre-incubated with free SC. After pre-incubation with SC the
binding of SIgA to mesangial cells was not affected (Figure 8A). Binding of SIgA was
slightly inhibited with SIgA and pIgA but not with mIgA (Figure 8A), suggesting inter-
action with the IgA part of the molecule. 
To investigate the potential contribution of C-type lectins, a family of cell surface
molecules including the mannose receptor, the role of calcium in SIgA binding to
human mesangial cells was examined. However, neither the addition of extra calci-
um, nor the removal of calcium using EDTA showed a significant effect on the bind-
ing of SIgA to mesangial cells (Figure 8B). 
SIgA is present in glomerular eluate from a kidney of an IgAN patient.
To determine the potential role of SIgA in the pathogenesis of IgAN, we had the
unique opportunity to analyse the glomerular eluate of a nephrectomized specimen
derived from a patient with recurrent IgAN. After elution, concentrations of specific
immunoglobulin isotypes were determined. In the glomerular eluate, all
immunoglobulin classes measured were detectable (Table 2), including SIgA in a
concentration of 2 µg/ml. To exclude that the immunoglobulins in the eluate were the
result of aspecific trapping from the circulation, serum immunoglobulin levels were
determined in the serum of this patient at the time of nephrectomy (Table 2). The
ratio of the immunoglobulin concentrations in the eluate and the serum can be used
as a measure of the specific accumulation in the glomerular deposit (Figure 9). In
this analysis we observed a ratio for SIgA which was 120 fold higher that the ratio
for IgA1. 
DISCUSSION  
This is the first study to support a role for SIgA in the pathogenesis of IgAN. We
show that SIgA is present in low concentrations in serum of healthy individuals as
well as in IgAN patients. In patients with higher SIgA serum concentrations hema-
turia is more pronounced. Furthermore we show that SIgA exhibits the strongest
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Figure 6: SIgA increase IL-6 production by mesangial cells.
A) Normal human mesangial cells (NHMC) (25x103 cells/well) were stimulated with different
molecular forms of IgA (200µg/ml). After 72 hours supernatants were harvested and tested for
IL-6 using ELISA. Depicted is the mean ± SD B) NHMC was stimulated with different
concentrations of SIgA (Sigma) as described above and IL-6 production was assessed.
binding to mesangial cells compared to serum IgA. Finally, in the eluate of glomeruli
from a kidney of an IgAN patient a strong accumulation of SIgA was detected. Taken
together these data suggest an important role for SIgA in the pathogenesis of IgAN.
The high incidence of IgAN recurrence after renal transplantation, and the disap-
pearance of deposits of IgA from accidentally transplanted kidneys clearly suggests
that intrinsic alterations and/or structural characteristics of IgA contribute to the
process of deposition (42,43). The predominance of IgA1 deposits and the specific
hinge region of IgA1 with potential O-linked glycosylation sites, has initiated a direct-
ed search for alterations in glycosylation. Indeed, both in serum but, more important-
ly, also in the eluate of renal deposits (14), a specific reduction of O-linked galacto-
sylation has been observed (10,12,14). Furthermore, with size fractionation of elut-
ed proteins from kidney sections, it was shown that deposited IgA was mostly HMW
of nature (13). In addition based on different staining methods, it has been proposed
that a large part of the deposited IgA is high molecular weight of nature (44-46). 
The results from all these methods provide indirect indications for the composi-
tion of the IgA1 deposits. We now show by eluting glomeruli, that glomeruli show a
strong and specific accumulation of SIgA compared to other serum immunoglobu-
lins. However, this technique can only be applied in limited cases of situations. We
have tried to demonstrate the presence of SIgA deposits using traditional immuno-
fluorescense on cryosections. Until now, we were not able to show SIgA in renal































































Figure 7: Mannose receptor and MAC-1 are not present on mesangial cells.
A) FACS analysis of mannose receptor on DC and AMC11. Filled histograms represent expression
of mannose receptor; open histograms represent the control staining with secondary antibodies B)
Mannose receptor mRNA expression was analyzed by RT-PCR as described in the material and
methods C) Presence of MAC-1 on mesangial cells and DC was tested with FACS analysis. Filled
histograms represent expression of MAC-1. Open histograms represent the control staining with
secondary antibodies.
sections, even not in cryosections of the kidney used for our elution study. This
might be due to inappropriate reagents or conformational changes of the deposited
SIgA, thereby masking the SC epitope. Therefore it will be necessary to generate
other reagents for the detection of deposited SIgA, and a more thorough analysis of
renal biopsies.
As described above, it is assumed that glycosylation of IgA is an important fac-
tor in IgAN. Previous studies have shown the role of the glycosylation of IgA on the
activation of mesangial cells (47,48), which could be partially explained by altered
interaction with mesangial cells (49). The glycosylation of SIgA is different compared
to that of serum IgA in several aspects. First, SIgA is a tetra molecular complex con-
sisting of two IgA molecules, a J chain and the SC wrapped around the H chain.
Modelling of SIgA suggests that the N-glycans on the heavy chain can be masked
by the SC (50). This may also result in a different exposure of the O-glycans.
Moreover, specific analysis of the glycosylation of the IgA heavy chain present in
SIgA, demonstrated different N-glycan structures compared to that of serum IgA,
with terminal GlcNAc residues on the majority of the N-glycans (50). The O-glycans
on the hinge region of the heavy chain of SIgA1 presented a wide range of glycan
structures, of which the major part is now characterized (50).  Finally, also the SC
itself is heavily glycosylated. However we were not able to inhibit the binding of SIgA
to mesangial cells with SC, suggesting that the SC part is not important for interac-
tion with mesangial cells.  It will be a major challenge to isolate SIgA from serum of
IgAN patients and to determine specific alterations in glycosylation.
Having shown that SIgA strongly binds to mesangial cells, an important question
is which receptor is involved in this binding and whether this receptor is different
from that of serum IgA. Several IgA receptors have been described in the literature.
The best known receptors, the polymeric Ig receptor (pIgR), the asialoglycoprotein
receptor and CD89, have already been described to be absent on mesangial cells
(28,51,52). The transferrin receptor is described as an IgA receptor present on
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Figure 8: Binding of SIgA to mesangial cells is not affect by free secretory
component or calcium but is affected by IgA.
A) Mesangial cells were pre-incubated with mIgA, pIgA, SIgA (400 µg/ml) or free secretory
component (SC) (100 µg/ml). After one hour SIgA (200 µg/ml) was added and the binding of SIgA
to mesangial cells was examined with flow cytometry. Depicted is the percentage of SIgA binding
of a representative experiment of 2 experiments. B) Cells were incubated with SIgA (200 µg/ml)
in the presence of absence of EDTA (10 mM) or calcium (10 mM) followed by detection of SIgA
binding as described in the Material and Methods.
mesangial cells but it has been reported that this receptor is not able to bind SIgA
(29). We have previously reported the binding of SIgA to the mannose receptor on
dendritic cells (40), but we were not able to demonstrate the presence of the man-
nose receptor on mesangial cells. Similarly we were not able to demonstrate the
presence of CD11b/CD18 (MAC1), a co-receptor for CD89 specifically involved in
recognizing SIgA or free SC (41). Therefore until now we have no indication for the
mesangial IgA receptor involved in SIgA binding. Our inhibition experiments suggest
that IgA rather than SC is recognized and that no C-type lectin is involved.
Importantly we found that the putative receptor is able to transmit proinflammatory
signals, since SIgA induced a strong dose-dependent increase in IL-6 production by
mesangial cells. This seems in contrast with the proposed anti-inflammatory role of
SIgA (53).
Generation of SIgA, i.e. production of dIgA followed by transcytosis using the
pIgR, is a specific process taking place at mucosal surfaces (54). Interestingly, IgAN
patients often present macroscopic hematuria following upper respiratory tract infec-
tions. Mucosal challenge also leads to an increased production of IgA in the sys-
temic compartment, probably based on the migration of B cells (the mucosa-bone
marrow axis) (55). This mucosa-bone marrow traffic has been confirmed by chal-
lenging healthy individuals intranasally with the neoantigen cholera toxin subunit B
(CTB) (56). In patients with IgAN we observed a reduced mucosal IgA response to
mucosal immunization with CTB (56). At present it is not clear whether a mucosal
challenge also regulates levels of circulating SIgA. Still our finding of glomerular
accumulation of SIgA provides a link between the mucosal immune system and
renal deposits.  
In summary, we have shown that SIgA is able to bind to mesangial cells in a
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Table 2: Immunoglobulin concentrations in serum and glomerular eluate of 
IgAN patient. 
  IgA1 IgA2 SIgA IgM IgG 
Serum (mg/ml) 5.9 0.59 0.016 0.74 10 
Glomerular eluate (µg/ml) 6.1 0.65 2 2.2 6.8 
            
 














Figure 9: SIgA is accumulated in the glomerular eluate of an IgAN kidney
To make an estimate for the specific accumulation in the glomerular deposit,
immunoglobulin concentrations in the eluate and serum were compared. Depicted is the ratio
of concentration of different immunoglobulins in the eluate and the serum.
dose-dependent manner and that this binding is calcium-independent and cannot be
inhibited with free SC. Furthermore low concentrations of SIgA can be detected in
serum. Further research is needed to determine to which receptor SIgA can bind
and what the mechanism of cell activation induced by SIgA is. SIgA is strongly accu-
mulated in the glomeruli of a kidney from an IgAN patient. Therefore we conclude
that our data support a role for SIgA in the pathogenesis of IgAN, and further
research to define such a pathogenic role is warranted.
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Summary
Recently we reported a possible role for secretory IgA (SIgA) in IgA nephropa-
thy (IgAN), as suggested by increased serum levels in patients with active dis-
ease and accumulation of SIgA in a glomerular eluate. Therefore, we attempt-
ed to find support for these findings by analysis of the presence of SIgA in
biopsies of IgAN patients. Renal biopsies of 26 patients with biopsy-proven
IgAN were analyzed for the presence of SIgA. In 15 % clear deposition of SIgA
was demonstrable. The presence of SIgA in these biopsies showed a strong
correlation with deposition of MBL and C4d. It has been previously document-
ed that patients with MBL deposits have more severe renal injury. Therefore,











Primary IgA nephropathy (IgAN) is the most common form of primary glomeru-
lonephritis worldwide. The hallmark of this disease is deposition of IgA in the
glomerular mesangium, together with markers of complement activation (1-3). It is
generally thought that deposits of IgA consist of IgA1 which is mostly polymeric (4).
The composition of polymeric IgA in serum is highly diverse and may include
CD89/IgA complexes, dimeric IgA, IgA immune complexes and secretory IgA (SIgA)
(5-7).
SIgA is the dominant immunoglobulin in external mucosal secretions like oral,
respiratory and intestinal cavities, and is often characterized as a component of the
immune systems' first line defense against pathogens (8). Next to its presence in
mucosal secretions, small amounts of SIgA can also be found in human serum
(7,9,10). Noteworthy, increased serum levels of SIgA have been reported in various
diseases (11-13), and are associated with more hematuria in IgAN patients (7).
Moreover, polymeric serum IgA of patients with IgAN contains higher SIgA concen-
trations as compared to healthy controls (14).
Glomerular IgA deposition is associated with activation of the complement sys-
tem (15), involving the alternative pathway and the lectin pathway of complement
(16). Recent studies indicate that deposition of MBL, one of the recognition mole-
cules of the lectin pathway of complement, in a subpopulation of IgAN patients is
associated with a more severe renal injury (16,17), compatible with the observation
that MBL bind to polymeric IgA (18). 
The aim of the present study was to investigate whether SIgA can be demon-
strated in biopsies from patients with IgA nephropathy. The results show that SIgA
can be found in a subpopulation of IgAN patients, and that presence of SIgA is asso-
ciated with the presence of MBL and C4d.  
MATERIAL AND METHODS
Patients and biopsies 
Renal biopsies were selected from patients with IgA nephropathy of whom a renal biopsy
was taken between January 2001 and December 2003. Patients were selected when ade-
quate tissue was obtained for diagnostics (at least 8 glomeruli in light microscopy sections;
complete immunohistology and electron microscopy examination), and when sufficient frozen
material was available for additional staining after immunodiagnosis (at least 6 glomeruli in at
least 15 (5µm thick) tissue sections). Cases with Henoch-Schönlein purpura, systemic lupus
erythematosus, liver cirrhosis or other systemic diseases were excluded. In total, 26 biopsies
were selected for evaluation. 
Among selected patients, 77 % were male and 23 % females. Creatinine clearance was
calculated according to the Cockroft formula (range 16-130 ml/min). 
Immunofluorescence
For immunofluorescence stainings, unfixed renal tissue was embedded in OCT com-
pound (Sakura Tissue-tek, Bayer), snap-frozen in a mixture of isopentane and dry-ice and




We used mouse monoclonal antibodies directed against the following molecules: MBL
(mAb 3E7, kindly provided by Prof. Fujita, Fukushima, Japan (27)), and secretory component
(SC) (mAb NI194-4 from Nordic (7)). Rabbit polyclonal antibodies were applied for detection
of IgA (FITC-labeled anti-human IgA, Dako), C3 (FITC-labeled anti-human C3c, Dako) and
C4d (Biomedica (28)). For indirect immunofluorescence, after fixation in cold acetone, tissues
were incubated sequentially with the primary antibody and the proper fluorescently labeled
secondary antibody (Alexa Fluor 488-conjugated goat anti-mouse Ig or Alexa Fluor 546-con-
jugated goat anti-mouse Ig, Molecular probes). Slides were finally mounted with anti-fading
aqueous mounting medium (Fluorsave, Calbiochem). 
Statistical analysis
Data were compared between IgAN patients showing positive and negative glomerular
staining of SIgA, respectively. Frequency analysis was performed using the Fisher exact test.
Other comparisons were evaluated using the Mann Whitney U test. Differences were consid-
ered statistically significant when P was below 0.05.
RESULTS  
Immunofluorescence staining for SIgA was performed in renal biopsies from 26
IgAN patients. Glomerular SIgA positivity was observed in a mesangial pattern in 4
biopsies (15 %, Figure 1), whereas glomeruli in 22 biopsies were negative. 
Next we examined the presence of molecules of the complement system (Table
1). In line with our previous study we observed that 19 % were positive for MBL and
C4d (16). We observed a strong association between the presence of SIgA and the
presence of MBL (P = 0.0003) and C4d, respectively (P = 0.0003). 
Based on the presence (15 %) or absence (85 %) of glomerular SIgA Two IgAN
SIgA present in kidney
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(N= 4) P 
Intense mesangial proliferation (% of cases) 32 75 0.264 
Extracapillary proliferation present (% of cases) 27 50 0.543 
Global sclerosis (% of glomeruli ; median) 13 23 0.943 
Segmental sclerosis (% of glomeruli ; median) 3.5 8 0.972 
Interstitial infiltration (0-3 scale scoring: median) 1 2 0.319 
Interstitial fibrosis (0-3 scale scoring: median) 1 1 0.831 
Vessel lesions present (% of cases) 45 25 0.614 
C3 present (% of cases) 91 50 0.0987 
C4d present (% of cases) 4.5 100 0.0003 
Glomerular MBL staining present (% of cases) 4.5 100 0.0003 
    
SIgA-negative cases and SIgA-positive cases are defined on basis of glomerular 
staining.  
 
patient groups were defined and further characterized. SIgA-positive and negative
cases had a similar male/female distribution and no difference in renal function
(Table 2). There was a clear trend towards a younger age at time of renal biopsy for
patients with positive glomerular SIgA staining as compared to negative SIgA stain-
ing (p= 0.0596, Table 2). There was also a trend towards more severe mesangial
proliferation in SIgA- positive biopsies as compared to SIgA-negative biopsies
(Table 1). This is in line with our previous observation that deposition of MBL is asso-
ciated with more severe renal injury, characterized by more intense mesangial and
extracapillary proliferation, glomerular sclerosis and interstitial damage (16). 
DISCUSSION
The present study provides further evidence for a possible pathogenic role for
SIgA in IgAN. We demonstrate glomerular deposition of SIgA in biopsies of a sub-
population of IgAN patients. Furthermore, there was a strong association between
glomerular SIgA staining and the presence of MBL and C4d, suggesting activation
of the lectin pathway of complement in cases with SIgA deposition. 
Deposition of IgA in the mesangial area is the hallmark of patients with IgAN and
it is generally thought that this deposition drives a local inflammatory response.
Previous research has concentrated on quantitative and qualitative differences of
IgA deposited in the kidney. It has been proposed that IgA in renal deposits is most-
ly high MW of nature and might contain differences in glycosylation which might
affect receptor interaction or effector functions. We now show that in a subset of
patients SIgA can be demonstrated in the renal biopsies, in line with our previous
investigation of a renal eluate (7). Deposition of SIgA in patients with IgAN has not
been widely documented, although it was observed in a recent study (19).
Generation of secretory IgA (SIgA) is a specific process taking place at mucosal
surfaces (20). It has been reported that SIgA adheres selectively to microfold (M)
cells irrespective of their antigen-binding specificity (21,22), followed by its transport
across the epithelium and targeting of dendritic cells (DC) (23,24). In vitro it has
been demonstrated that DC can bind and endocytose SIgA (25). Probably not all
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(N= 4) P 
Age at renal biopsy (Years; median)(range) 33 (21-57) 26.5 (24-31) 
Female gender (%) 27 0 0.5425 
Proteinuria (gram/24hr; median) 1.4 2.1 0.2864 
Macroscopic hematuria present (% of cases) 37 25 0.6603 
Serum creatinine (ì mol/l; median) 1.3 1.4 0.4553 
Creatinine clearance (ml/min; median) 53 71.5 0.9151 
Serum IgA (mg/ml) 2.4 2.49 0.6698 
SIgA-negative cases and SIgA-positive cases are defined on basis of glomerular 
staining. All data were obtained at the time of renal biopsy 
 
SIgA is internalized by DC and this SIgA may end up in the circulation. Indeed, small
amounts of SIgA have also been found in human serum (9,10). Moreover, increased
serum levels of SIgA have been reported in various diseases (11-13) indicating that
SIgA may be a marker of clinical interest.  We hypothesize that after mucosal chal-
lenge the production of SIgA at mucosal sites is increased. This could potentially
lead to increased serum SIgA concentrations (7) and thereby, via a presently unde-
fined mechanism, lead to glomerular deposition of SIgA. 
Earlier studies have shown that the carbohydrate moieties on SIgA are different
as compared to serum IgA (26). Furthermore, it was shown that MBL can interact
with SIgA upon conformational change under acid conditions. This suggests that
disruption of the non-covalent interactions between secretory component and the
IgA heavy chain can lead to MBL binding and subsequently complement activation
via the lectin pathway. The data from the present study suggest that in the glomeruli
of a subpopulation of IgAN patients, the deposition of SIgA may lead to unmasking
SIgA present in kidney
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Figure 1. Glomerular SIgA deposition in IgAN patients.
Renal tissue from patients with IgAN was stained for the presence of SIgA (A, B and C), MBL (D, E
and F), IgA (G), C4d (H) and C3 (I). Representative images are shown. Renal tissues are derived
from different patients who showed positive (A and B) and negative staining (C) for SIgA and
positive (D and E) and negative staining (F) for MBL. All patients were positive for IgA (G). A
subpopulation of patients was positive for C4d (H) and C3 (I).
the heavy chain of IgA of SIgA leading to MBL binding and complement activation.
Recently, it has been described that MBL deposition in glomeruli is associated
with more severe renal disease (16). In the present study we show a strong co-dep-
osition of SIgA and MBL, suggesting SIgA as a strong cofactor. Furthermore, more
hematuria was observed in patients with higher concentrations of SIgA in serum (7).
Moreover, after elution of isolated glomeruli from a patient with IgAN a 120-fold
accumulation of SIgA in the glomeruli was observed. In the present study we pro-
vide additional evidence for a pathogenic role of SIgA in a subpopulation of patients
with IgA nephropathy.
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Primary IgA nephropathy (IgAN) is the most common form of primary glomeru-
lonephritis. The disease is characterized by mesangial deposits of IgA (1-3). These
deposits are thought to be composed mostly of high molecular weight IgA1, some-
times together with IgM or complement components like C3 (4,5). The disease
shows a broad spectrum of clinical presentations, leading to progressive renal fail-
ure in a substantial proportion of patients. Case reports have shown that IgA
deposits disappear after transplantation of a kidney with IgA deposits into a non-
IgAN patient (6). Furthermore, after renal transplantation recurrent mesangial IgA
deposition is observed in about 50 % of the patients (7). These results strongly sug-
gest that the basic abnormality of the disease lies within the IgA immune system
rather than in the kidney.
In serum of IgAN patients, elevated levels of IgA and IgA immune complexes
were observed (8,9). Furthermore, aberrantly glycosylated IgA, due to a reduced
activity of the β1-3 galactosyltransferase, has been described in patients with IgAN.
This aberrantly glycosylated IgA is also demonstrated in glomerular IgA deposits,
suggesting a better binding of this IgA as compared to normal glycosylated IgA. 
Another important factor is the binding of IgA to mesangial cells. Several findings
point to an IgA receptor on mesangial cells (10,11). For most of the IgA receptors it
has already been demonstrated that they are not present on mesangial cells
(12,13). There are some new candidates like Fcα/µR (14) or transferrin receptor
(15) but, there is only limited information available about these receptors and further
research has to confirm their possible role in IgAN. 
The present thesis focuses on different aspects of IgAN, namely IgA and the
binding of IgA to its receptors. In the first part of this thesis (chapter 2,3) we focused
on possible receptor-mediated mechanisms underlying mesangial IgA deposition. In
the second part of the thesis (chapter 4 to 7) we focused our attention on the char-
acterization of IgA and associated molecules present in the mesangium of IgAN
patients and on the characterization of serum IgA from patients and controls.
Binding of IgA to IgA receptors 
Several IgA receptors have been identified and characterized. One of these
receptors is FcαRI/CD89. A number of studies already showed that CD89 is not
present on mesangial cells. Still, there are suggestions for a role of this receptor in
IgAN. Human CD89 transgenic mice spontaneously develop at old age renal dis-
ease with characteristics of IgAN (16). On the other hand, our group showed that
injection of soluble human CD89 into mice does not induce deposition of IgA in kid-
neys (17). It remains unclear how human CD89 could affect IgA deposition, since
we and others showed that human CD89 cannot react with murine IgA (17,18). 
Complexes of CD89 with monomeric IgA are present in the circulation (19).
However, it is also shown that especially high molecular weight IgA can interact with
CD89 (20-22). Therefore, we investigated the binding of different molecular forms of
IgA with CD89 with different methods. In chapter 2 we confirm data from literature
(20-22), that high molecular weight IgA can interact with CD89. We however, using
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surface plasmon resonance (SPR), a method in which the interaction in time can be
measured, found that the initial interaction of monomeric IgA and CD89 is compara-
ble to polymeric IgA-CD89 interactions. However, the interaction of polymeric IgA
with CD89 is more stable as compared to monomeric IgA ultimately resulting in a
higher final binding of polymeric IgA to CD89 than monomeric IgA. A recently pub-
lished crystal structure of the IgA1Fc-CD89 complex showed that one IgA molecule
is in complex with two CD89 molecules, confirming interactions of mIgA with CD89
(23). Furthermore, the initial interaction of mIgA with CD89 might also be sufficient
for internalization of mIgA via CD89, thereby creating intracellular CD89-IgA com-
plexes which then can be secreted in the circulation (19). 
After cleavage of the N-glycans present on IgA we demonstrated enhanced
association of IgA to CD89, suggesting an important role for the N-glycans on IgA in
the initial interaction. In literature, it is still controversial whether N-glycans present
on IgA do influence the interaction with CD89 (24,25). In the crystal structure of the
IgA1Fc-CD89 complexes the observed N-glycans are close but do not directly con-
tact the receptor (23). Some amino acid mutations in the CD89 molecule, which are
not in direct contact with IgA, also hamper the binding of IgA-CD89. Because of the
presence of the N-glycans close to the contact sites it could be that the N-glycans
hamper the IgA/CD89 interaction.
Another recently identified IgA receptor is Fcα/µR. This receptor has been
described to be present on B cells and macrophages (26). Furthermore, high
expression in the kidney is observed (26). The Fcα/µR is also suggested to be pres-
ent on mesangial cells, and thereby could play a role in IgAN. However there are no
suitable reagents available to study this receptor. Therefore we made chimeric pro-
teins to study IgA and IgM binding to this receptor. We demonstrated that IgA binds
to Fcα/µR, likely through the proximal immunoglobulin like domain. The binding of
IgA to Fcα/µR was equal for monomeric and polymeric IgA and was glycan depend-
ent. Therefore these findings do not fit in the observations that it is mostly pIgA that
is present in the renal mesangium of IgAN patients (27). Moreover, the glycan com-
position of IgA described in patients with IgAN (28-30), does not have any effect on
the interaction of IgA with Fcα/µR. After removing the N-glycans and the sialic acids
from the IgA molecule, the interaction with the Fcα/µR is hampered, whereas deg-
lycosylation of IgA leads to an increase in binding to mesangial cells (31). We con-
firmed the presence of the Fcα/µR on mesangial cells. Furthermore, we showed an
upregulation of Fcα/µR transcript in mesangial cells after IL-1 stimulation. However,
high molecular weight IgA binds better to mesangial cells as compared to monomer-
ic IgA and we could not detect differences in IgA binding to IL-1 stimulated mesan-
gial cells. In conclusion, the Fcα/µR could play a role in the clearance of IgA in IgAN,
but its in vitro characteristics do not favor a significant role for this receptor in IgAN.
Complement in IgA nephropathy
In IgAN deposits of IgA are commonly associated with complement components,
most often C3, the membrane attack complex (C5b-9) and properdin (32,33).
Furthermore, increased levels of split products of activated C3 have been observed
in the circulation of IgAN patients (34-36). These findings suggest involvement of the
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alternative pathway in IgAN. Indeed, in vitro as well as in vivo studies, have indicat-
ed that IgA can directly activate the alternative pathway of complement (37-39).
Recently, the lectin pathway of complement, with their recognition molecules
MBL, H-ficolin and L-ficolin, has been described (40-43). MBL is able to bind direct-
ly to a number of microorganisms, via carbohydrates expressed on their surface
(44,45). Upon binding, MBL activates the complement cascade via the lectin path-
way, which plays a critical role in the first line of host defense against these
pathogens. Furthermore, genetic mutations in the MBL gene, leading to low serum
MBL levels and non functional MBL, have a negative impact on several chronic dis-
eases (46-48). However evidence is increasing that MBL and the lectin pathway of
complement can also be unfavorable for disease progression. This is proposed for
rheumatoid arthritis, and is suggested by the presence of MBL in renal biopsies from
patients with IgAN (49-51). Furthermore, it was shown that MBL is able to bind to
polymeric IgA which leads to the activation of the lectin pathway in vitro (52).
In chapter 4 we investigated the presence of MBL in glomerular IgA deposits of
IgA nephropathy patients. We showed that in 25 % of the cases co-deposition of IgA
with MBL was present (Figure 1). Furthermore, patients with MBL deposition suf-
fered from more severe renal injury as compared to the MBL negative cases, sug-
gesting an important role for MBL in disease progression. In a recent Japanese
study it has been suggested that MBL deposition was restricted to biopsies with
IgA2 deposition (53). However, in the biopsies that we investigated we were not able
to detect any IgA2. The difference with an earlier report might be due to ethnical dif-
ferences of the patients. 
In chapter 5 we investigated the differences between monomeric and polymeric
IgA purified from patient and control. We confirmed that specifically polymeric IgA is
able to bind to MBL and induce C4 activation. However, no differences between
patients and controls were observed. Furthermore, we showed that on the heavy
chain of polymeric IgA oligomannose structures are present which are absent on
monomeric IgA. The carbohydrate recognition domain of MBL is able to bind in a
calcium-dependent way to a number of saccharides, such as D-mannose, L-fucose,
and N-acetylglucosamine (GlcNAc) (44). Therefore, the oligomannose structure
present on the heavy chain of IgA could be a likely candidate to bind MBL, but this
needs further confirmation 
Serum IgA in IgA nephropathy
In IgAN, the glycosylation of the IgA1 molecule plays an important role. It has
been described that the IgA1 molecule is aberrantly glycosylated leading to
increased Tn antigen (GalNAcα1-Ser/Thr) residues (28,30). Allen et al. have report-
ed that the β1-3 galactosyltransferase synthesis activity was remarkably lower in
peripheral B lymphocytes of IgAN patients as compared to healthy controls (54). The
β1-3 galactosyltransferase activity is dependent on the coexistence of a specific
chaperone, Cosmc (core 1 β1-3-Gal-T-specific molecular chaperone) (55), and in
IgAN patients it is suggested that downregulation of Cosmc is important for the aber-
rant O-glycosylation of IgA1 (56). 
Serum IgA from IgAN patients was shown to have an increased binding to
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mesangial cells (57), however this could not be confirmed by others (58).
Furthermore, increased production of cytokines and chemokines was shown after
stimulation of mesangial cells with serum IgA from IgAN patients (59-61). To mimic
this aberrantly glycosylated IgA, IgA was treated with enzymes. In vitro studies with
deglycosylated IgA suggested that the undergalactosylated IgA in IgAN patients
might be involved in increased interaction with mesangial cells (31).  Noteworthy,
these in vitro studies made use of the lectin Jacalin (which specifically recognizes
Galβ1-3GalNAc) for IgA purification, possibly leading to a selection of only a sub-
population of serum IgA1. 
In chapter 5 we purified IgA from serum of patients and controls with an anti-
human IgA affinity column and separated these IgA preparations in monomeric and
polymeric IgA. With this method we did not select for typical IgA glycosylation struc-
tures. With these highly purified monomeric and polymeric IgA preparations we stud-
ied the interaction with mesangial cells and lectins. The interaction with mesangial
cells, and the induction of IL-8 production was better for polymeric IgA than for
monomeric IgA, but there was no difference between patients and controls.
Stimulation of mesangial cells with IgA and IgA binding to mesangial cells has been
studied before (31,60,62,63), but this is one of the first studies that a correlation
between binding of IgA to mesangial cells and chemokine production after stimula-
tion of mesangial cells with the same IgA preparations shows. 
Another interesting finding in this chapter is the binding of Helix aspersa (HAA)
to the IgA preparations. HAA is a lectin which recognizes terminal GalNAc. In an ear-
lier report, size fractionation of total serum of an IgAN patient showed HAA reactiv-
ity in the high molecular weight fractions suggesting interaction with high molecular
weight IgA (31). In our study, we confirmed this better binding of polymeric IgA to
HAA as compared to monomeric IgA. Binding of HAA was strongly increased by
neuraminidase treatment, suggesting a high frequency of non-galactosylated O-
linked glycans on IgA, that expose terminal GalNAc after enzymatic removal of sial-
ic acid. 
Polymeric serum IgA contains more IgA2 as compared to monomeric serum IgA
(chapter 5). Mucosal IgA is largely polymeric IgA whereas serum IgA contains main-
ly monomeric IgA. Furthermore, the IgA subclass distribution varies with different
mucosal locations (5) depending on the site, the total IgA amount consists of 15 to
65 % IgA2. Therefore, an increased polymeric IgA2 fraction may suggest its produc-
tion at the mucosal sites. Another explanation could be the glycosylation of the IgA
molecule. IgA2 contains additional N-glycans as compared to IgA1. At present it is
unknown whether the glycans present on IgA are important for the polymerization
process. The observation of a difference in N-glycosylation of polymeric IgA versus
monomeric IgA, together with the presence of two to three additional N-glycans on
IgA2 as compared to IgA1, may suggest a more efficient polymerization of IgA2, and
therefore could explain that more IgA2 is found in the polymeric IgA fraction. 
Secretory IgA in IgA nephropathy
About 40% of patients with IgAN have recurrent episodes of macroscopic hema-
turia frequently preceded one or two days earlier by infections. Upper respiratory
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tract infections occur most frequently (64), but also occasionally other infections
have been implicated, including gastrointestinal and urinary tract infections (65,66).
Furthermore, mucosal immunization with a neo-antigen in healthy individuals leads
to an antigen-specific immune response in plasma, suggesting a relation between
mucosa and bone marrow. However, this response is reduced after immunization of
patients with IgAN (67). SIgA is the major immunoglobulin responsible for protecting
the mucosal surfaces. However, at present it is not clear whether a mucosal chal-
lenge also regulates levels of circulating SIgA.
Generation of secretory IgA (SIgA) is a specific process taking place at mucosal
surfaces (68), after binding of dimeric IgA (dIgA) to the polymeric Ig receptor (pIgR)
followed by a process of transcytosis. In addition also a process of transepithelial
transport has been described in which SIgA adheres selectively to microfold (M)
cells irrespective of their antigen-binding specificity (69,70), and that SIgA is subse-
quently transported across the epithelium and targeted to dendritic cells (DC)
(71,72). In vitro it has been demonstrated that DC can bind and endocytose SIgA
(73). It could be hypothesized that not all SIgA is internalized by DC and this SIgA
may end up in the circulation. Indeed, small amounts of SIgA can also be found in
human serum (74,75). Moreover, increased serum levels of SIgA have been report-
ed in various diseases (76-78) indicating that SIgA may be a marker of clinical inter-
est. 
In the final section of this thesis we addressed the role of SIgA in IgA nephropa-
thy (Figure 1). First, we investigated the presence of SIgA in serum (chapter 6) and
in purified IgA preparations (chapter 5). We showed that in purified IgA preparations
SIgA is restricted to the polymeric IgA fractions and that the relative concentration of
SIgA is higher in patients with IgAN as compared to controls. In serum we measured
low concentrations of SIgA, but we could not observe differences in SIgA concen-
trations between patients and controls. However, we did find a relation between
hematuria in patients with IgAN and the SIgA concentration in serum. 
Tonsils in IgA nephropathy
Tonsils are located at the gateway of the respiratory and alimentary tract and
belong to the mucosa-associated lymphoid tissue. The major function of the tonsils
is a first line of defence against viral, bacterial and food antigens. Tonsils of IgAN
patients contain more IgA secreting B cells as compared to other diseases (79). This
increase is paralleled by an increase of the number of dimeric IgA secreting cells
(79). Furthermore, SIgA can adhere to M cells and transported into the lymphoid tis-
sues. Stimulation, by ultra short wave, of the tonsils of IgAN patients leads to dete-
rioration in renal function as compared to patients with other kidney diseases (80).
In addition, previous episodes of gross hematuria following upper respiratory tract
infections and the level of serum secretory IgA were higher in IgAN patients with
deterioration of renal function after tonsil stimulation that those without deterioration
(80). Tonsillar IgA1 from IgAN patients contains more asialo IgA1 as compared to
serum IgA1 (81,82), suggesting that underglycosylated tonsillar IgA is produced in
this lymphoid organ. This abnormally produced IgA reach the peripheral blood, and
because of their size or composition, fails to be properly filtered by the kidneys but
rather accumulate in the mesangium. In this respect the role of SIgA in this process
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was not studied. Tonsillectomy can improve the renal function and keep the renal
function stable in some IgAN patients (83,84). Tonsillectomy had a favorable effect
on long term renal survival in IgAN patients (85).
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Figure 1: Hypothetical overview of different factors involved in IgA Nephropathy.
In IgAN three compartments are important, the mucosa, the circulation and the kidney. After upper
respiratory tract infection 40 % of the IgAN patients have recurrent episodes of hematuria, suggesting
a role for the mucosal compartment, whereby may be some SIgA is leaking in the circulation.
Furthermore, the B lymphocytes present at the mucosal surface will produce dIgA which will be present
in the circulation and via transcytosis in the epithelial cells secreted as SIgA in the mucosa. Via the
circulation the SIgA is in contact with the mesangial cells to which it can bind. At the same time, the
bone marrow is producing increasing amounts and aberrantly glycosylated IgA which is also present in
the circulation.  The binding of IgA to mesangial cells will lead to activation of the mesangial cells and
the complement pathways. This mesangial cell activation will attract immune cells, and thereby




























SIgA and mesangial cells
The activation of mesangial cells by IgA1 immune complexes is considered as
an initiating event in the pathogenesis of IgA nephropathy (Figure 1). Therefore, we
analyzed the interaction of serum IgA and SIgA with mesangial cells (chapter 6). We
demonstrated a higher binding of SIgA to mesangial cells as compared to the bind-
ing of serum IgA. Passive protection by SIgA, secreted by the mucosal immune sys-
tem, plays a central role in the protection of mucosal surfaces in general. However,
after stimulation of mesangial cells with SIgA, the mesangial cells start to produce
even more IL-6 than after exposure to serum IgA. Finally, we demonstrate in chap-
ter 6 that immunoglobulins eluted from glomeruli of a patient show a strong accumu-
lation of SIgA in the renal mesangium as compared to other immunoglobulins.
These data suggest a pathogenic role for SIgA in IgA nephropathy. 
SIgA glycosylation in IgAN
As mentioned before, it is assumed that glycosylation of IgA is an important fac-
tor in IgAN (Figure 1). Previous studies have shown a role for glycosylation of IgA
and its subsequent interaction with mesangial cells (31,60,62,63). The glycosylation
of SIgA is different as compared to serum IgA. Secretory IgA consists of two IgA mol-
ecules together with the J chain and the secretory component. Modeling SIgA has
shown that secretory component masks the heavy chain of IgA and thereby pre-
vents interaction with glycan structures (86). Furthermore, it was shown that N-gly-
cans present on SIgA contain other structures as compared to serum IgA (86). In
IgAN, especially the O-glycosylation of IgA was studied. The O-glycan structure on
the hinge region of SIgA1 contains many different carbohydrate structures. These
structures might be differently exposed because of the presence of secretory com-
ponent. Taken together, this may lead to increased interaction of SIgA with mesan-
gial cells. In this respect, the specific alterations in glycosylation of SIgA from IgAN
patients would be very interesting to study.   
SIgA in IgAN biopsies
To confirm the presence of SIgA in glomeruli of a patient with IgAN, we stained
kidney biopsies from IgA nephropathy patients for SIgA (chapter 7). In 15 % of the
cases positive staining of SIgA in biopsies was observed. In a Japanese study all
IgAN biopsies studied were positive for secretory component, whereas normal kid-
neys were negative (87). However, the relation with the presence of secretory com-
ponent and other molecules in the glomeruli or clinical parameters of the patients
were not studied. Interestingly, this study (87) showed an association with single
nucleotide polymorphisms (SNPs) in the pIgR and the presence of IgAN. 
In chapter 7 we demonstrate a clear correlation between the presence of SIgA
and MBL in renal biopsies. Earlier studies had already demonstrated an interaction
of SIgA with MBL (86). Royle et al. suggested that disruption of the non-covalent
interactions between secretory component and the IgA heavy chain may, for
instance at low pH, lead to MBL binding and subsequent complement activation via
the lectin pathway (86). The presence of SIgA with MBL in glomeruli of a subpopu-
lation of IgAN patients suggests unmasking of the IgA heavy chain leading to MBL
deposition. However, MBL was found in 20 % of the cases in the glomeruli, where-
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as glomerular SIgA is detected in 15 % of the cases. This indicates that MBL most
probably is not only binding to deposited SIgA but also to other high molecular
weight forms of IgA. 
Immunization studies in IgAN patients
Several immunization studies, both after systemic and oral secondary immuniza-
tion, showed conflicting results with respect to the specific serum and mucosal IgA
concentrations in IgAN patients (88-94). After mucosal immunization with CTB, IgAN
patients exhibit a decreased mucosal and systemic antigen specific IgA response,
whereas simultaneous systemic immunization with KLH did not lead to a difference
in antigen specific IgA response between patients and controls (67). Unpublished
results from our group showed the size distribution of the antigen specific IgA
response in serum and nasal washes after immunization with CTB and KLH. The
nasal washes contain mainly SIgA whereas serum IgA showed a typical serum IgA
profile (mainly mIgA). Furthermore, SIgA is restricted to fractions containing high
molecular weight IgA. The antigen specific IgA response is mostly of high molecular
weight. Unfortunately, with the available reagents, we were not able to detect anti-
gen specific SIgA. However, the partly overlapping profile would be in line with a role
for antigen specific SIgA.
The systemic antigen specific IgA response we found was mainly associated with
high molecular weight IgA. We hypothesize that this IgA may be partly derived from
mucosal sites via production of dimeric IgA by mucosal B cells and leakage of SIgA
from the mucosa (Figure 1). However, also in the bone marrow antigen specific IgA1
antibody producing cells were demonstrated (67). IgA from the circulation is mainly
produced in the bone marrow and is monomeric, whereas the response we tested
was mainly high molecular weight IgA. Therefore it would be very interesting to
investigate the size distribution of bone marrow synthesized antigen specific IgA. In
literature, up-regulation of pIgA synthesis in the bone marrow and an increase of
pIgA-producing plasma cells have been described in IgAN patients (79,95).
However, after intramuscular immunization with inactivated influenza virus mainly a
monomeric IgA response is observed (88). It seems that the route of immunization
is important for the size distribution of the antigen specific IgA response. Therefore,
it would be very interesting to investigate the size of the antigen specific IgA after
different immunization routes.  
Conclusion
In summary, we have demonstrated in the first part of this thesis that monomer-
ic IgA is able to interact with different IgA receptors and that this interaction is glyco-
sylation dependent. Furthermore, we investigated the binding of IgA to a recently
identified IgA receptor, thereby showing clear IgA binding to this receptor. However,
the binding of monomeric and polymeric IgA were similar, suggesting that this recep-
tor is probably not the mesangial receptor responsible for the deposition of IgA in the
mesangium of IgAN patients.
In the second part of this thesis we showed clear differences between polymer-
ic and monomeric IgA, which could finally lead to deposition of IgA (Figure 1). We
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demonstrated a better interaction of polymeric IgA with mesangial cells than that of
monomeric IgA. Furthermore, polymeric IgA is able to interact with MBL and there-
by activates the lectin pathway of complement, in addition to the alternative path-
way. We also showed that binding of MBL to IgA can lead to MBL deposition in the
glomeruli of a subpopulation of IgAN patients. Moreover, we showed that this depo-
sition of MBL is associated with more severe renal injury (Figure 1).  
IgAN patients often have macroscopic hematuria following upper respiratory tract
infections. Although, we could not observe differences in SIgA concentrations in
serum of IgAN patients and controls, we showed a clear relation with the SIgA con-
centration in serum and hematuria. Furthermore, significantly more SIgA was pres-
ent in affinity purified IgA preparations from IgAN patients as compared to controls.
Moreover, we showed a strong accumulation of SIgA, as compared to other
immunoglobulins, in the glomeruli, and this was in agreement with the positive SIgA
staining in kidney biopsies of a subpopulation of IgAN patients (Figure 1). Altogether,
the data presented in this thesis support a role for SIgA in the pathogenesis of a sub-
population of IgAN patients. Further research to define such a pathogenic role is
warranted. 
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Primaire IgA nefropathie (IgAN) is een veel voorkomende nierziekte, waarbij IgA
neerslaat in het mesangium van de glomeruli (zeeflichaampjes) van de nier. Door
de binding van IgA aan mesangium cellen kan dit leiden tot een lokale ontstek-
ingsreactie. Deze ontsteking veroorzaakt schade met als gevolg uitscheiding van
bloed en eiwit in de urine en uiteindelijk, in een groot deel van de patiënten tot nier-
functieverlies. De mechanismen die IgAN veroorzaken zijn nog onduidelijk. Er zijn
aanwijzingen dat het primaire probleem niet de nier is, maar het IgA. Bijvoorbeeld;
na transplantatie van een nier in een IgAN patiënt is er 50 % kans dat er opnieuw
IgA neerslaat in de nier. Ook is er aangetoond dat als een nier van een IgAN patiënt
in een niet IgAN patiënt wordt geplaatst de IgA neerslag verdwijnt. Deze data sug-
gereren dat in IgAN niet alleen de nier belangrijk is maar dat de circulatie ook een
rol speelt.
Immunoglobuline A (IgA) is een van de moleculen van het afweersysteem. Zodra
er vreemde eiwitten (antigenen) in het lichaam aanwezig zijn, zullen er verschillende
eiwitten binden aan deze antigenen waardoor de antigenen worden opgeruimd. In
eerste instantie zullen dat niet specifieke eiwitten zijn waaronder eiwitten van het
complement systeem. Daarnaast worden er specifieke antistoffen gemaakt en
zullen er verschillende antistoffen aan deze antigenen binden, waaronder IgA. IgA
is in hoge concentraties aanwezig in de slijmvliezen van bijvoorbeeld longen en dar-
men, maar is ook aanwezig in het bloed. 
Er zijn verschillende vormen van IgA beschreven, waaronder monomeer IgA
(mIgA)(1 IgA molecuul) en dimeer IgA (dIgA)(twee IgA moleculen die bij elkaar wor-
den gehouden door een ander eiwit (J chain)). Polymeer IgA (pIgA) bestaat uit ver-
schillende IgA moleculen aan elkaar, maar ook bijvoorbeeld complexen van IgA met
andere moleculen. In het menselijke lichaam is vooral monomeer IgA aanwezig in
het bloed terwijl in de slijmvliezen voornamelijk SIgA aanwezig is. Om SIgA te
genereren, wordt dIgA door cellen van het weefsel dicht bij de slijmvliezen getrans-
porteerd. Tijdens dit transport blijft het extracellulaire deel van de receptor (secretoir
component) dat het dIgA bindt, aan het dIgA zitten. Het complex van dIgA met
secretoir component, wordt SIgA genoemd. 
Verder zijn er ook twee verschillende isotypen beschreven, IgA1 en IgA2. Een
belangrijk verschil tussen IgA1 en IgA2 zijn de suikergroepen (glycosylering) die
aanwezig zijn op het eiwit. IgA1 bevat namelijk O-glycanen die niet aanwezig zijn op
IgA2, terwijl IgA2 meer N-glycanen bevat dan IgA1. In de literatuur is beschreven
dat in patiënten met IgAN de O-glycosylering van IgA1 veranderd is en dat dit IgA
een belangrijke rol in IgAN speelt.
Het mechanisme van IgA binding aan mesangiumcellen en welke IgA vormen
een belangrijke rol spelen in IgAN is nog onduidelijk. Daarom hebben we in dit
proefschrift gekeken naar IgA receptoren die een rol zouden kunnen spelen in IgAN
en hebben we vervolgens de verschillende vormen van IgA bestudeerd in relatie
met IgAN.
Binding van IgA aan IgA receptoren
In IgAN bindt IgA aan een IgA receptor op de mesangiumcellen, waardoor het
IgA neerslaat in de nier. Verschillende IgA receptoren zijn beschreven, maar van de
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meest beschreven IgA receptoren is al aangetoond dat deze niet aanwezig zijn op
de mesangiumcellen. In hoofdstuk 2 is de binding van verschillende vormen van IgA
aan een bekende IgA receptor (FcαRI/CD89) met verschillende methodes
bestudeerd. CD89 is een IgA receptor dat beschreven is op myeloide cellen en
waarvan onze groep al eerder heeft aangetoond dat deze receptor niet aanwezig is
op mesangiumcellen. Toch kan deze receptor wel belangrijk zijn in IgAN, doordat de
klaring van het IgA via de IgA receptor verminderd kan zijn. Dit zou een hogere con-
centratie van het IgA in de circulatie tot gevolg kunnen hebben wat kan leiden tot
binding van IgA aan mesangiumcellen. In dit hoofdstuk worden de binding ver-
schillen, zoals beschreven in de literatuur, tussen monomeer IgA en polymeer IgA
aan CD89 bevestigd. In dit hoofdstuk is gebruikt gemaakt van twee verschillende
methodes om de binding van IgA aan CD89 te meten. Met deze methodes laten we
zien dat er geen verschillen waren in de initiële fase van de binding van monomeer
en polymeer IgA aan CD89, maar dat de uiteindelijke binding van polymeer IgA aan
CD89 sterker was dan de binding van monomeer IgA aan CD89. Verder werd
aangetoond dat de N-glycanen aanwezig op IgA van belang waren voor de binding
van IgA met CD89, terwijl de O-glycosylering van IgA geen rol lijkt te spelen.
Recent is een nieuwe IgA receptor beschreven (Fcα/µR) die wel aanwezig zou
zijn op mesangium cellen en ook verhoogd tot expressie wordt gebracht na stimu-
latie van de mesangiumcellen. Omdat er nog geen reagentia aanwezig zijn om deze
receptor in detail te bestuderen hebben we een recombinante vorm van de recep-
tor gemaakt (hoofdstuk 3). Deze recombinante receptor was in staat om IgA en IgM
dosis afhankelijk te binden. De binding van monomeer en polymeer IgA aan Fcα/µR
waren gelijk terwijl de binding van IgM aan Fcα/µR lager dan de binding van
monomeer en polymeer IgA was. Ook hier waren de N-glycanen van belang voor de
binding aan de receptor. Een ander aspect van de receptor, bestudeerd in dit hoofd-
stuk, was de expressie van de receptor in mesangiumcellen in relatie met de IgA
binding aan mesangiumcellen. De receptor expressie was hoger na stimulatie van
mesangium cellen terwijl er geen verschil in binding van IgA aan de mesangium-
cellen was na stimulatie. Deze resultaten suggereren dat de Fcα/µR op mesangium-
cellen geen directe rol speelt in IgAN.
Serum IgA in IgA nefropathie
Er zijn aanwijzingen in de literatuur dat er verschillen zijn tussen IgA van IgAN
patiënten en controles, voornamelijk met betrekking tot de glycosylering van IgA. De
neerslag van IgA in de nier van patiënten is door verschillende onderzoeksgroepen
bestudeerd. De resultaten laten zien dat het IgA in de nier voornamelijk bestaat uit
hoog moleculair IgA met een abnormale glycosylering. Verder is al aangetoond dat
IgA in de nier het complement systeem kan activeren. In hoofdstuk 4 is de neerslag
van IgA met moleculen van het complementsysteem in de nier bestudeerd. Hierin
werd duidelijk aangetoond dat de aanwezigheid van MBL, een molecuul van de lec-
tine route van het complement systeem, in de nierneerslag leidt tot ernstigere
nierontsteking. 
In de literatuur zijn er ook glycosylerings verschillen beschreven tussen het
serum IgA van patiënten en controles, In hoofdstuk 5 hebben we IgA geïsoleerd uit





interactie met lectines en mesangiumcellen. Verder hebben we ook gekeken of er
verschillen in IgA2 en SIgA concentratie tussen IgA van patiënten en controles
waren te detecteren. Het opvallende van deze studie was dat er grote functionele
en moleculaire verschillen zijn tussen monomeer en polymeer IgA maar niet tussen
patiënten en controles. Het enige verschil tussen patiënten en controles was een
verhoogde concentratie SIgA in patiënten. 
SIgA in IgA nefropathie
Naast allerlei andere functionele en moleculaire veranderingen is de SIgA con-
centratie in de gezuiverde IgA preparaten van patiënten en controles ook gemeten.
Zoals verwacht was SIgA alleen aanwezig in polymeer IgA, daarbij was er een sig-
nificante verhoging van de SIgA concentratie in de patiënten ten opzichte van de
controles. Deze verhoging van SIgA in patiënten was niet te meten in serum van
patiënten en controles (hoofdstuk 6), hoewel patiënten met een hogere SIgA con-
centratie in het serum ook meer hematurie (bloed in urine) hadden. Verder is er in
hoofdstuk 6 ook aangetoond dat SIgA kan binden aan mesangiumcellen en dat
deze binding in vergelijking met serum IgA superieur is. Voor SIgA is beschreven dat
het in de slijmvliezen een bescherming biedt tegen antigenen zonder een ontstek-
ingsreactie te initiëren. Na stimulatie van mesangiumcellen met SIgA een verhoging
van de IL-6 productie (een cytokine dat belangrijk is voor een ontstekingsreactie)
was gemeten, suggererend dat er na binding van SIgA aan mesangiumcellen wel
een ontstekingsreactie kan ontstaan. Om aan te tonen dat SIgA ook daadwerkelijk
aanwezig is in een nier van een IgAN patiënt hebben we de glomeruli uit de nier van
deze patiënt geïsoleerd. Na elutie van de eiwitten uit deze glomeruli was er een
duidelijke accumulatie van SIgA in de neerslag aanwezig. Dit suggereert dat SIgA
aanwezig kan zijn in de IgA neerslag van patiënten met IgAN. Deze neerslag is in
hoofdstuk 7 bevestigd met kleuringen van nierweefsel van IgAN patiënten en con-
troles. In 15% van de patiënten was SIgA aanwezig terwijl alle controles negatief
voor SIgA waren. 
Conclusie
Bij IgAN patiënten is er vaak een verergering van de ziekte, met bloed in de
urine, na een ontsteking van de bovenste luchtwegen. Een activatie op de sli-
jmvliezen zal resulteren in een verhoogde IgA productie en met name het genereren
van SIgA. In dit proefschrift laten we zien dat als patiënten bloed in de urine hebben
er ook meer SIgA in het bloed aanwezig is. Verder laten we zien dat SIgA in staat is
aan mesangiumcellen te binden en er dan voor te zorgen dat er IL-6 door de
mesangiumcellen wordt geproduceerd. Uiteindelijk laten we zien dat er een accu-
mulatie van SIgA in de nier is en dit wordt bevestigd met een kleuring van SIgA in
nierweefsel. Alles bij elkaar suggereren bovenstaande data dat SIgA een rol speelt
in de pathogenese bij een subpopulatie van de IgAN patiënten. Verder onderzoek is
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Chapter 3, Figure 1B, page 46
Fcα/µRIg fusion proteins.
B) IgG staining of transfected cells after cytospin centrifugation.
Chapter 4, Figure 1, page 60
Glomerular MBL deposition in IgAN patients.
Biopsies from patients with IgAN were stained with mAb 1C10 (A), mAb 3E7 (C,
D) or an isotype control mAb (B). Figures A, C, and D are derived from different
patients who showed positive (A, C) or negative (D) staining for MBL. Figures A
and B are from the same patient. Please note tubular and vascular staining for
MBL in C, in addition to glomerular staining. 
Chapter 4, Figure 2, page 61
Lectin pathway activation in IgAN.
Renal tissue from IgAN patients was stained for the presence of MBL (mAb 3E7),
L-ficolin (mAb GN4), MASP-1/3 (mAb 1E2), MASP-2, C4d, C4 binding protein,
C5b-9, IgA1 and IgA2 (mAb NI512), as indicated. Representative images are
shown. 
Chapter 4, Figure 4, page 63
Renal histological damage in IgAN patients.
Renal histology from three patients without glomerular MBL deposition (A-C)
shows glomeruli affected by mild mesangial proliferation and mild mesangial
matrix expansion. No major tubulo-interstitial lesions are visible. Images D-F rep-
resent patients with glomerular MBL deposition (N = 3). Glomerular injury is char-
acterized by intense mesangial proliferation and mesangial matrix expansion (D),
segmental and global sclerosis (E), and extracapillary proliferation (F), whereas
tubular dilations, interstitial infiltration and fibrosis are evident in the interstitium (D-
F).  Sections were stained with PAS (A, B), PASM (C, F) or trichrome (D, E) tech-
niques. 
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Chapter 7, Figure 1, page 113
Glomerular SIgA deposition in IgAN patients.
Renal tissue from patients with IgAN was stained for the presence of SIgA (A, B
and C), MBL (D, E and F), IgA (G), C4d (H) and C3 (I). Representative images are
shown. Renal tissues are derived from different patients who showed positive (A
and B) and negative staining (C) for SIgA and positive (D and E) and negative
staining (F) for MBL. All patients were positive for IgA (G). A subpopulation of
patients was positive for C4d (H) and C3 (I).
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